



Canadian Patents Database


(12) Patent Application:

(11) CA 2303526

(54) HEPATITIS C VIRUS CELL CULTURE SYSTEM

(54) SYSTEME DE CULTURE DU VIRUS DE L'HEPATITE C

Representative Drawing:



[View or Download Images](#)

[View Administrative Status](#)

ABSTRACT:

The hepatitis C virus (HCV) cell culture system according to the invention consists of human hepatoma cells, which are transfected with a HCV-RNA construct, that comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR as well as a minimum of one marker gene for selection (selection gene).

CLAIMS: Show all claims

*** Note: Data on abstracts and claims is shown in the official language in which it was submitted.

(72) Inventors (Country): **BARTENSCHLAGER, RALF** (Germany (Federal Republic of))

(73) Owners (Country): **BARTENSCHLAGER, RALF** (Germany (Federal Republic of))

(71) Applicants (Country): **BARTENSCHLAGER, RALF** (Germany (Federal Republic of))

(74) Agent: **BORDEN LADNER GERVAIS LLP**

(45) Issued:

(22) Filed: **Mar. 31, 2000**

(41) Open to Public Inspection: **Oct. 3, 2000**

Examination requested: **Jan. 11, 2002**

(51) International Class (IPC): **C12N 7/02**
C12N 5/10
C12N 15/51

Patent Cooperation Treaty (PCT): **No**

(30) Application priority data:

| Application No. | Country | Date |
|------------------------|-------------------------------|--------------|
| 199 15 178.4 | Germany (Federal Republic of) | Apr. 3, 1999 |

Availability of licence: **N/A**

Language of filing: **English**

View or Download Images :

- Cover Page Image**
- Abstract Image**
- Claims Image**
- Disclosures Image**
- Drawings Image**
- Representative Drawing Image**

[View the Image](#)


[Download in Adobe PDF](#)

MicroPatent® Family Lookup

| Stage 1 Patent Family - "Complex" | | Priorities and Applications | |
|--|-------------|-----------------------------|-------------|
| CC DocNum | KD PubDate | CC AppNum | KD AppDate |
| <input type="checkbox"/> AT 236988 | E 20030415 | AT 105929 | EP 20000323 |
| | | DE 19915178 | A 19990403 |
| <input type="checkbox"/> AU 200025180 | A5 20001019 | AU 25180 | A 20000331 |
| | | DE 19915178 | A 19990403 |
| <input type="checkbox"/> CA 2303526 | AA 20001003 | CA 2303526 | A 20000331 |
| | | DE 19915178 | A 19990403 |
| <input type="checkbox"/> DE 19915178 | A1 20001005 | DE 19915178 | A 19990403 |
| | | DE 19915178 | A 19990403 |
| <input type="checkbox"/> DE 50001673 | C0 20030515 | DE 19915178 | A 19990403 |
| | | DE 50001673 | A 20000323 |
| | | DE 50001673 | A 20000323 |
| <input type="checkbox"/> DK 1043399 | T3 20030728 | DE 19915178 | A 19990403 |
| | | DK 105929 | A 20000323 |
| <input type="checkbox"/> EP 1043399 | A2 20001011 | DE 19915178 | A 19990403 |
| | | EP 105929 | A 20000323 |
| <input type="checkbox"/> EP 1043399 | B1 20030409 | DE 19915178 | A 19990403 |
| | | EP 105929 | A 20000323 |
| <input type="checkbox"/> EP 1043399 | A3 20020508 | DE 19915178 | A 19990403 |
| | | EP 105929 | A 20000323 |
| <input type="checkbox"/> JP 2001017187 | A2 20010123 | DE 19915178 | A 19990403 |
| | | JP 2000101615 | A 20000403 |


10 Publications found.

[Add Selected Documents to Order](#)[Display the Extended Patent Family](#)



(21) (A1) 2,303,526
(22) 2000/03/31
(43) 2000/10/03

(72) BARTENSCHLAGER, RALF, DE
(71) BARTENSCHLAGER, RALF, DE
(51) Int.Cl. ⁷ C12N 7/02, C12N 15/51, C12N 5/10
(30) 1999/04/03 (199 15 178.4) DE
(54) **SYSTÈME DE CULTURE DU VIRUS DE L'HEPATITE C**
(54) **HEPATITIS C VIRUS CELL CULTURE SYSTEM**



(57) The hepatitis C virus (HCV) cell culture system according to the invention consists of human hepatoma cells, which are transfected with a HCV-RNA construct, that comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR as well as a minimum of one marker gene for selection (selection gene).



Hepatitis C Virus Cell Culture System

5

ABSTRACT

The hepatitis C virus (HCV) cell culture system according to the invention consists of human hepatoma cells, which are transfected with a HCV-RNA construct, that comprises 10 the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR as well as a minimum of one marker gene for selection (selection gene).

CLAIMS

1. A hepatitis C virus (HCV) cell culture system, which comprises mainly eukaryotic cells containing transfected HCV specific genetic material, characterized in that, the eukaryotic cells are human hepatoma cells and the transfected HCV specific genetic material is a HCV-RNA construct, which comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR as well as an additional marker gene for selection (selection gene).
2. A cell culture system according to Claim 1, characterized in that, the hepatoma cells are derived from a usual hepatoma cell line.
3. A cell culture system according to Claim 1, characterized in that, the hepatoma cells are extracted from a primary hepatoma cell culture.
4. A HCV-RNA construct, characterized in that, it comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR as well as an additional marker gene for selection (selection gene).
5. A HCV-RNA construct according to Claim 4, characterized in that, it comprises one of the nucleotide sequences illustrated in the sequence protocols SEQ ID NO: 1 to SEQ ID NO: 11.
- 35 6. A HCV-RNA construct according to Claim 4, characterized in that,

the 3' NTR has a nucleotide sequence, which has been selected from the group of nucleotide sequences (a) to (i) listed in the following:

5 (a) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTA
GCTTTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGCC
CAGACTGGAGT

10 (b) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTA
GTCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGCCA
GACTGGAGC

15 (c) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTAAT
CTTTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGCCA
GACTGCAGC

20 (d) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTT
AGTCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGC
CCAGACTGGAGT

(e) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTA
GTCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGC
CCAGACTGGAGT

25 (f) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTA
GTCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTG
CCCAGACTGGAGT

(g) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTA
GTCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGTTGCC
CAGACTGGAGT

30 (h) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTT
TAATCTTTTTTTCTTTTTGAGAGAGAGAGTCTCACTCTGT
TGCCCAGACTGGAGT

35

(i) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTTTTT
AATCTTTTTTTTTTTCTTTTTTGAGAGAGAGTCTCACTCTG
TTGCCAGACTGGAGT

5 7. A HCV-RNA construct according to one of the Claims 4 to 6, characterized in that,
the marker gene for selection is a resistance gene and
preferably an antibiotic resistance gene.

10 8. A HCV-RNA construct according to one of the Claims 4 to 6, characterized in that,
the marker gene for selection is a neomycin
phosphotransferase gene.

15 9. A HCV-RNA construct according to one of the Claims 4 to 8, characterized in that,
the marker gene for selection is integrated in the
HCV-RNA downstream from the 5' NTR.

20 10. A HCV-RNA construct according to one of the Claims 4 to 83, characterized in that,
the marker gene for selection is linked to the HCV-RNA
via a ribozyme or a recognition sequence for a
ribozyme.

25 11. A HCV-RNA construct according to one of the Claims 4 to 10, characterized in that,
it has an integrated reporter gene.

30 12. A HCV-RNA construct according to Claim 11,
characterized in that,
the reporter gene is a gene from the group of the
luciferase genes, the CAT gene (chloramphenicol acetyl
transferase gene), the lacZ gene (beta galactosidase
gene), the GFP gene (green fluorescence protein gene),
the GUS gene (glucuronidase gene) and the SEAP gene
(secreted alkaline phosphatase gene).

13. A HCV-RNA construct according to one of the Claims 4 to 11, characterized in that, their replication has an influence on the expression of a (cellular) surrogate marker gene.
14. A HCV-RNA construct according to one of the Claims 11 to 13, characterized in that, the resistance gene is cloned into the open reading frame of the HCV-RNA in such a way that it will only be transferred to an active form after proteolytic processing.
15. A HCV-RNA construct according to one of the Claims 11 to 14, characterized in that, the reporter gene and the marker gene for selection are arranged in the construct in such a way, that they are expressed as a fusion protein.
16. A cell culture system according to one of the Claims 1 to 3, characterized in that, the HCV-RNA construct is a construct according to at least one of the Claims 4 to 15.
17. A cell culture system according to Claim 1, characterized in that, the cells containing the HCV-RNA construct are lodged at the DSMZ, Braunschweig, Germany under the deposit number DSM ACC2394 (laboratory name HuBl 9-13).
18. A use of a cell culture system according to one of the Claims 1 to 3 or 16 to 17 and/or a HCV-RNA construct according to one of the Claims 4 to 15 for the production and/or evaluation and/or testing of treatments and/or diagnostics for the treatment of HCV infections in particular.

19. A use of a cell culture system according to one of the Claims 1 to 3 or 16 to 17 and/or a HCV-RNA construct according to one of the Claims 4 to 15 for the production of a vaccine against HCV infections.
5
20. A use a HCV-RNA construct according to one of the Claims 4 to 15 for the production of a liver cell specific vector in gene therapy.
- 10 21. A HCV-RNA construct according to one of the Claims 4 to 15, characterized in that, it has an integrated foreign gene and can be used to transfect this foreign gene in a target cell, which can be used to express this foreign gene.
15
- 20 22. A process for the production of cell culture adapted mutants of a HCV-RNA construct according to one of the claims 4 to 15, in which the mutants have increased replication efficiency compared to the HCV-RNA construct,
characterized in that,
a cell culture system according to claim 1, in which the transfected HCV specific genetic material is a HCV-RNA construct with a selection gene according to one of the claims 4 to 15, is cultivated on/in the selection medium corresponding to the selection gene, that the cell clones created are collected, and that the HCV-RNA constructs or parts thereof are isolated from these cell clones.
25
- 30 23. A process according to claim 22, characterized in that,
the isolated HCV-RNA constructs are passaged at least one more time. That is, they are transfected in cells of a cell culture system according to claim 1. The cell culture system of claim 1 thereby obtained, in which the transfected HCV specific genetic material is
35

the isolated HCV-RNA construct with a selection gene, is cultivated on/in the selection medium corresponding to the selection gene, the cell clones created are collected, and the HCV-RNA constructs are isolated from these cell clones.

24. A process for the production of mutants of a HCV full-length genome or of a HCV subgenome or any HCV construct with increased replication efficiency in comparison to the original HCV full-length genome or subgenome or HCV-RNA construct, characterized in that, a cell culture adapted mutant of a HCV-RNA construct is produced and isolated by a process according to claim 22 or 23, the nucleotide and amino acid sequence of these mutants is determined and the type, number and positions of the nucleotide and amino acid mutations is determined by comparison with the nucleotide and amino acid sequence of the original HCV-RNA construct, and these mutations are introduced in an (isolated) HCV full-length genome or a HCV subgenome or any HCV-RNA construct, either by site-directed mutagenesis or by exchange of fragments containing the relevant mutations

25. A cell culture adapted HCV-RNA construct with high replication efficiency, characterized in that, it is derivable from a HCV-RNA construct according to one of the claims 4 to 15 through nucleotide and/or amino acid mutations and that it is obtainable with a process according to one of the claims 22 to 24.

30 26. A cell culture adapted HCV-RNA construct according to claim 25, characterized in that,




5 it carries one or several of the following amino acid exchanges: 1283 arg -> gly and/or 1383 glu -> ala and/or 1577 lys -> arg and/or 1609 lys -> glu and/or 1936 pro -> ser and/or 2163 glu -> gly and/or 2330 lys -> glu and/or 2442 ile -> val.


10 27. A cell culture adapted HCV-RNA construct according to claim 25 or 26, characterized in that, it displays one or several of the nucleotide and/or amino acid exchanges shown in Table 3, where Table 3 is an integral part of this claim.

15 28. Cell culture adapted mutant of a HCV-RNA construct or of a HCV full-length genome with increased replication efficiency in comparison to the original HCV-RNA construct or original HCV full-length genome, characterized in that, it is obtainable with a process in which the number and type of mutations in a cell culture adapted HCV-RNA construct according to claim 24 are determined through sequence analysis and sequence comparison, and these mutations are introduced in a HCV-RNA construct, particularly in a HCV-RNA construct according to one of the claims 4 to 15, or in an (isolated) HCV-RNA full-length genome, either by targeted mutagenesis or by exchange of sequence sections containing the relevant mutations.

20 29. Hepatitis C virus particles or virus-like particles, characterized in that, they are obtainable by a process according to one of the claims 22 - 24.

25 30. Cells infected with Hepatitis C virus particles or virus-like particles, according to claim 29.

A**B****C****Fig. 1**



A

| Condition | 8-13 (wt) | 8-1 (Δ) | Transf. |
|-----------|-------------|-----------|-----------|
| IP | Strong band | Weak band | Weak band |
| 5B | Strong band | Weak band | Weak band |
| 5A | Strong band | Weak band | Weak band |
| 5B/5A | Strong band | Weak band | Weak band |
| 3/4 | Strong band | Weak band | Weak band |
| 3 | Strong band | Weak band | Weak band |

B

| Condition | 8-13 (wt) | 8-1 (Δ) | Transf. |
|-----------|-------------|-----------|-----------|
| IP | Strong band | Weak band | Weak band |
| 5B | Strong band | Weak band | Weak band |
| 5A | Strong band | Weak band | Weak band |
| 5B/5A | Strong band | Weak band | Weak band |
| 3/4 | Strong band | Weak band | Weak band |
| 3 | Strong band | Weak band | Weak band |

Panel A: NS3 bands. Panel B: NS5A bands. Molecular weight markers (kDa) are indicated on the right: 69, 43, 29, 19, 64.

3
Fig.






Fig. 4

A



B








Fig. 5

A**B****C****D****Fig. 6**




Fig. 7




Fig. 8




Fig. 9






Fig. 10

A**B****Fig. 11**




Fig. 12




Fig. 12




Fig. 14




Fig. 15



CA 02303518 2000-03-31

Hepatitis C Virus Cell Culture System**DESCRIPTION**

5 The invention relates to a hepatitis C virus (HCV) cell culture system, which comprises mainly eukaryotic cells containing transfected HCV specific genetic material, which means they are transfected with HCV specific genetic material.

10

The hepatitis C virus (HCV) is one of the main causes worldwide of chronic and sporadic liver diseases. The history of most HCV infections does not involve any obvious clinical signs, but 80 - 90 % of the infected people become 15 chronic carriers of the virus and 50 % of these chronic carriers of the virus develop chronic hepatitis with different degrees of severity. Approx. 20 % of the chronically infected develop a cirrhosis of the liver over 10 to 20 years, based on what a primary hepatocellular 20 carcinoma can develop. Nowadays chronic hepatitis C is the main indication for liver transplantation. A specific therapy does not exist until now. The only therapy currently available is high-dose administration of Interferon alpha or a combination of Interferon alpha and 25 the purine nucleoside analogue Ribavirin. However, only approx. 60 % of all treated persons respond to this therapy and with these, a new viraemia occurs in more than half of all cases after the discontinuation of the treatment.

30 Due to the high prevalence, especially in industrialized countries, the serious effects of chronic infections and the non-existence of a specific therapy, the development of a HCV specific chemotherapy is an important goal of pharmaceutical research and development. The main problem 35 lies in the previous lack of a suitable cell culture system, which enables the study of virus replication and pathogenesis in eukaryotic cells.



Hepatitis C Virus Cell Culture System**DESCRIPTION**

5 The invention relates to a hepatitis C virus (HCV) cell culture system, which comprises mainly eukaryotic cells containing transfected HCV specific genetic material, which means they are transfected with HCV specific genetic material.

10

The hepatitis C virus (HCV) is one of the main causes worldwide of chronic and sporadic liver diseases. The history of most HCV infections does not involve any obvious clinical signs, but 80 - 90 % of the infected people become 15 chronic carriers of the virus and 50 % of these chronic carriers of the virus develop chronic hepatitis with different degrees of severity. Approx. 20 % of the chronically infected develop a cirrhosis of the liver over 10 to 20 years, based on what a primary hepatocellular 20 carcinoma can develop. Nowadays chronic hepatitis C is the main indication for liver transplantation. A specific therapy does not exist until now. The only therapy currently available is high-dose administration of Interferon alpha or a combination of Interferon alpha and 25 the purine nucleoside analogue Ribavirin. However, only approx. 60 % of all treated persons respond to this therapy and with these, a new viraemia occurs in more than half of all cases after the discontinuation of the treatment.

30 Due to the high prevalence, especially in industrialized countries, the serious effects of chronic infections and the non-existence of a specific therapy, the development of a HCV specific chemotherapy is an important goal of pharmaceutical research and development. The main problem 35 lies in the previous lack of a suitable cell culture system, which enables the study of virus replication and pathogenesis in eukaryotic cells.

Due to the small amount of virus in blood or tissue, the lack of suitable cell culture systems or animal models (the chimpanzee is still the only possible experimental animal) as well as the lack of efficient systems for producing virus-like particles, it was not possible up to now, to analyze the molecular composition of the HCV particle in-depth and to solve it. The information currently available can be summarized as follows: HCV is an enveloped plus-strand RNA virus with a particle diameter of 50 - 60 nm and a medium density of 1.03 - 1.1 g/ml. It was molecularly cloned and characterized for the first time in 1989 (Choo et al., 1989, *Science*, 244, 359 - 362). The HCV-RNA has a length of approx. 9.6 kb (= 9600 nucleotides), a positive polarity and comprises one open reading frame (ORF), which encodes a linear polyprotein of approx. 3010 amino acids (see Rice 1996, in *Virology*, B. N. Fields, D. M. Knipe, P. M. Howley, Eds. (Lippincott-Raven, Philadelphia, PA, 1996), vol. 1, pp. 931 - 960; Clarke 1997, *J. Gen. Virol.* 78, 2397; and Bartenschlager 1997, *Intervirology* 40, 378 and see Fig. 1 A). During the replication of the virus the polyprotein is cleaved into the mature and functionally active proteins by cellular and viral proteases.

Within the polyprotein the proteins are arranged as follows (from the amino- to the carboxy terminus): Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B. The core protein is the main component of the nucleocapsid. The glycoproteins E1 and E2 are transmembrane proteins and the main components of the viral envelope. They probably play an important role during the attachment of the virus to the host cell. These three proteins core, E1, and E2 constitute the viral particle and are therefore called structural proteins. The function of the protein p7 is still not clear. The protein NS2 is probably the catalytic domain of the NS2-3 protease, which is responsible for the processing between the proteins NS2 and NS3. The protein NS3 has two functions, one is a

protease activity in the amino terminal domain, which is essential for the polyprotein processing, and the other a NTPase/helicase function in the carboxy terminal domain, which is probably important during the replication of the 5 viral RNA. The protein NS4A is a co-factor of the NS3 protease. The function of the protein NS4B is unknown.

The open reading frame is flanked on its 5' end by a non-translated region (NTR) approx. 340 nucleotides in length, 10 which functions as the internal ribosome entry site (IRES), and on its 3' end by a NTR approx. 230 nucleotides in length, which is most likely important for the genome replication. A 3' NTR such as this is the object of patent application PCT/US 96/14033. The structural proteins in the 15 amino terminal quarter of the polyprotein are cleaved by host cell signal peptidase. The non-structural proteins (NS) 2 to (NS) 5B are processed by two viral enzymes, namely the NS2-3 and the NS3/4A protease. The NS3/4A protease is required for all cleavages beyond the carboxy 20 terminus of NS3. The function of NS4B is unknown. NS5A, a highly phosphorylated protein, seems to be responsible for the Interferon resistance of various HCV genotypes (see Enomoto et al. 1995, *J. Clin. Invest.* 96, 224; Enomoto et al. 1996, *N. Engl. J. Med.* 334, 77; Gale Jr. et al. 1997, 25 *Virology* 230, 217; Kaneko et al. 1994, *Biochem. Biophys. Res. Commun.* 205, 320; Reed et al., 1997, *J. Virol.* 71, 7187), and NS5B has been identified as the RNA-dependent RNA polymerase.

30 First diagnostic systems have been developed from these findings, which are either based on the detection of HCV specific antibodies in patient serum or the detection of HCV specific RNA using the reverse transcription polymerase chain reaction (RT-PCR), and which are (must be) routinely 35 used with all blood and blood products and/or according to the regulations.

Since the first description of the genome in 1989 several partial and complete sequences of the HCV have been cloned and characterized using the PCR method. A comparison of these sequences shows a high variability of the viral genome in particular in the area of the NS5B gene, which eventually resulted in the classification of 6 genotypes, which are again subdivided into the subtypes a, b, and c.

The genomic variance is not evenly distributed over the genome. The 5'NTR and parts of the 3'NTR are highly conserved, while certain encoded sequences vary a lot, in particular the envelope proteins E1 and E2.

The cloned and characterized partial and complete sequences of the HCV genome have also been analyzed with regard to appropriate targets for a prospective antiviral therapy. In the course of this, three viral enzymes have been discovered, which may provide a possible target. These include (1) the NS3/4A protease complex, (2) the NS3 Helicase and (3) the NS5B RNA-dependent RNA polymerase. The NS3/4A protease complex and the NS3 Helicase have already been crystallized and their three-dimensional structure determined (Kim et al., 1996, Cell, 87, 343; Yen et al., 1998, Protein Science, 7, 837; Love et al., 1996, Cell, 87, 311; Kim et al., 1998, Structure, 6, 89; Yao et al., 1997, Nature Structural Biology, 4, 463, Cho et al., 1998, J. Biol. Chem., 273, 15045). It has not been successful until now with the NS5B RNA-dependent RNA polymerase.

Even though important targets for the development of a therapy for chronic HCV infection have been defined with these enzymes and even though a worldwide intensive search for suitable inhibitors is ongoing with the aid of rational drug design as well as high throughput screening, the development of a therapy has one major deficiency, namely the lack of cell culture systems or simple animal models, which allow direct, reliable identification of HCV-RNA or

HCV antigens with simple methods which are common in the laboratory. The lack of these cell culture systems is also the main reason that to date the comprehension of HCV replication is still incomplete and mainly hypothetical.

5 Although according to the experts, a close evolutionary relationship exists between HCV and the flavivirus and pestiviruses, and self-replicating RNAs have been described for these, which can be used for the replication in 10 different cell lines with a relatively high yield, (see Khromykh et al., 1997, *J. Virol.* 71, 1497; Behrens et al., 1998, *J. Virol.* 72, 2364; Moser et al., 1998, *J. Virol.* 72, 5318), similar experiments with HCV have not been successful to date.

15

Although it is known from different publications that cell lines or primary cell cultures can be infected with high titre patient serum containing HCV, (Lanford et al. 1994, *Virology* 202, 606; Shimizu et al. 1993, *Proceedings of the 20 National Academy of Sciences, USA*, 90, 6037 - 6041; Mizutani et al. 1996, *Journal of Virology*, 70, 7219 - 7223; M. Ikeda et al. 1998, *Virus Res.* 56, 157; Fournier et al. 1998, *J. Gen. Virol.* 79, 2376 and bibliographical references quoted in here; Ito et al. 1996, *Journal of 25 General Virology*, 77, 1043 - 1054), these virus-infected cell lines or cell cultures do not allow the direct detection of HCV-RNA or HCV antigens. The viral RNA in these cells can not be detected in a Northern Blot (a standard method for the quantitative detection of RNA) or the viral protein in a Western Blot or with 30 immunoprecipitation. It has only been possible to detect HCV replication with very costly and indirect methods. These disadvantageous facts show that obviously the replication in these known virus-infected cell lines or 35 cell cultures is completely insufficient.

Furthermore it is known from the publications of Yoo et al. (1995, *Journal of Virology*, 69, 32 - 38) and of Dash et al., (1997, *American Journal of Pathology*, 151, 363 - 373) that hepatoma cell lines can be transfected with synthetic HCV-RNA, which are obtained through in vitro transcription of the cloned HCV genome. In both publications the authors started from the basic idea that the viral HCV genome is a plus-strand RNA functioning directly as mRNA after being transfected into the cell, permitting the synthesis of viral proteins in the course of the translation process, and so new HCV particles are (could be) formed. This viral replication, which means these newly formed HCV viruses and their RNA, have been detected through RT-PCR. However the published results of the RT-PCR carried out indicate, that the HCV replication in the described HCV transfected hepatoma cells is not particularly efficient and is not sufficient to measure the quality, let alone the quantity of the fluctuations in the replication rate after an targeted action with prospective antiviral treatments.

Furthermore it is prior art (Yanagi et al., Proc. Natl. Acad. Sci. USA, 96, 2291-95, 1999), that the highly conserved 3' NTR is essential for the virus replication. This knowledge strictly contradicts the statements of Yoo et al. and Dash et al., who used for their experiments only HCV genomes with shorter 3' NTRs since they did not know the authentic 3' end of the HCV genome.

The object of the present invention is to provide a HCV cell culture system, where the viral RNA self-replicates in the transfected cells with such a high efficiency that the quality and quantity of the fluctuations in the replication rate can be measured with common methodologies usually found in the laboratory after a targeted action with virus and prospective HCV specific antivirals in particular.

35

The solution to this problem is to provide a cell culture system of the prior mentioned type, where the eukaryotic

cells are human cells, in particular hepatoma cells, which are preferably derived from a normal hepatoma cell line, but can also be obtained from an appropriate primary cell culture, and where the transfected HCV specific genetic material is a HCV-RNA construct, which essentially comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR preferably in the order mentioned as well as a minimum of one marker gene for selection (selection gene).

10

Here and in the following "NTR" stands for "non-translated region" and is a known and familiar term or abbreviation to the relevant expert.

15

Here and in the following the term "HCV-RNA construct" comprises constructs, which include the complete HCV genome, as well as those, which only include a part of it, which means a HCV subgenome.

20

A preferred variation of the cell culture system according to the invention, which had proven to be worthwhile in practice, is lodged at the DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German collection of Microorganisms and Cell Cultures) in Braunschweig, Germany under the number DSM ACC2394 (laboratory name HuBl 9-13).

25

With the cell culture system according to the invention an in vitro system is provided for the first time, where HCV-RNA is self-replicated and expressed intracellularly and in a sufficient amount, so that the quantity of the amounts of HCV-RNA as well as the HCV specific proteins can be determined with conventional and reliably precise biochemical measuring methods. This means an almost authentic cell-based HCV replication system is available for the first time, which is urgently needed for the development and testing of antiviral drugs. This test system provides the possibility of identifying potential

targets for an effective HCV specific therapy and developing and evaluating HCV specific chemotherapeutics.

The invention is based on the surprising finding that efficient replication of the HCV-RNA only occurs in cells if they have been transfected with an HCV-RNA construct, which comprises at least the 5' and the 3' non-translated regions (NTR) and the non-structural proteins (NS) 3 to 5B and additionally a marker gene for selection (selection gene). The structural genes are obviously without great importance for replication, whereas efficient replication of the HCV-RNA apparently only occurs if the transfected cells are subject to permanent selection pressure, which is imparted by the marker gene for selection (selection gene) linked to the HCV-RNA. Consequently the marker gene (selection gene) seems on one hand to provoke the selection of those cells, where the HCV-RNA replicates productively, and it seems on the other hand to considerably increase the efficiency of the RNA replication.

An object of the invention is also a cell-free HCV-RNA construct, characterized in that it comprises the HCV specific RNA segments 5' NTR, NS3, NS4A, NS4B, NS5A, NS5B, and 3' NTR, preferably in the order mentioned, as well as a marker gene for selection (selection gene).

In the present context the terms 5' NTR and NS3 and NS4A and NS4B and NS5A and NS5B and 3' NTR comprise each nucleotide sequence, which is described in the state of the art as the nucleotide sequence for each functional segment of the HCV genome.

By providing a HCV-RNA construct such as this, a detailed analysis of the HCV replication, pathogenesis and evolution in cell culture is possible for the first time. The HCV specific viral RNA can specifically be created as a complete genome or subgenome in any amount, and it is

possible, to manipulate the RNA construct and consequently to examine and identify the HCV functions on a genetic level.

5 Because all HCV enzymes identified as a main target for a therapy at the moment, namely the NS3/4A protease, the NS3 helicase and the NS5B polymerase, are included in the HCV-RNA construct according to the invention, it can be used for all relevant analyses.

10

An embodiment of the HCV-RNA construct, which has proven to be worthwhile in practical use, stands out by the fact that it comprises the nucleotide sequence according to the sequence protocol SEQ ID NO:1.

15

Further embodiments with similar good properties for practical use are characterized in that they comprise a nucleotide sequence either according to sequence protocol SEQ ID NO:2 or according to sequence protocol SEQ ID NO:3 or according to sequence protocol SEQ ID NO:4 or according to sequence protocol SEQ ID NO:5 or according to sequence protocol SEQ ID NO:6 or according to sequence protocol SEQ ID NO:7 or according to sequence protocol SEQ ID NO:8 or according to sequence protocol SEQ ID NO:9 or according to sequence protocol SEQ ID NO:10 or according to sequence protocol SEQ ID NO:11.

30 It is possible to provide the HCV subgenomic construct with a 3' NTR, which has a nucleotide sequence so far unknown in the state of art, a nucleotide sequence, which has been selected from the group of nucleotide sequences (a) to (i) listed in the following:

(a) ACGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTTTAGCTTT
35 TTTTTTTTCTTTTTGAGAGAGAGTCTCACTCTGTTGCCAGACTGGAG
T

(b) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTAGTCT
TTTTTTTTTC TTTTTTTGA GAGAGAGAGT CTCACTCTGT TGCCCAGACT
GGAGC

5 (c) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTAATCTTT
TTTTTTTTCT TTTTTTTGA GAGAGAGAGT CTCACTCTGT TGCCCAGACT
GCAGC

10 (d) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTAGTC
TTTTTTTTT TCTTTTTTT TGAGAGAGAG AGTCTCACTC TGTTGCCAG
ACTGGAGT

15 (e) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTAGTCT
TTTTTTTTT TCTTTTTTT TGAGAGAGAG AGTCTCACTC TGTTGCCAG
ACTGGAGT

(f) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTAGTCT
TTTTTTTTT TCTTTTTTT TGAGAGAGAGA GAGTCTCACT CTGTTGCCAG
GACTGGAGT

20 (g) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTAGTCT
TTTTTTTTT CTTTTTTTT GAGAGAGAGA GTCTCACTCT GTTGCCAGA
CTGGAGT

25 (h) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTTAAT
CTTTTTTTT TTTTCCTTT TTTTGAGAGA GAGAGTCTCA CTCTGTTGCC
CAGACTGGAG T

30 (i) ACAGGGGAGCTAACACTCCAGGCCAATAGGCCATCCTGTTTTT TTTTTTAATC
TTTTTTTTT TTTCTTTTT TTTTGAGAG AGAGAGTCTC ACTCTGTTGC
CCAGACTGGA GT

35 The marker gene for selection (selection gene) included in
the HCV-RNA constructs according to the invention is
preferably a resistance gene, in particular an antibiotic
resistance gene.

5 This has the advantage that the cells transfected with this construct can easily be selected from the non-transfected cells by adding for example the appropriate antibiotic to the cell culture medium in the case of an antibiotic resistance gene.

In the present context 'antibiotic' means any substance, which impedes the non-transfected host cells or the cells, where the HCV-RNA is not replicating efficiently,
10 continuing to live or grow, especially the cell poison Puromycin, Hygromycin, Zeocin, Bleomycin or Blasticidin.

15 A preferred marker gene for selection (selection gene) and resistance gene, which has proven to be worthwhile in practice, is the neomycin phosphotransferase gene.

An alternative for the antibiotic resistance genes is for example the thymidine kinase gene, which can be used to carry out a HAT selection.

20

The marker gene for selection (selection gene), the preferred resistance gene and the most preferred antibiotic resistance gene is preferably positioned in the HCV-RNA construct after the HCV 5' NTR, which means downstream from the 5' NTR and upstream from the HCV reading frame.
25 However, an insertion in the area of the 3' NTR or another site of the HCV genome or subgenome, for example within the polyprotein, is also conceivable.

30 In another embodiment of the HCV-RNA construct according to the invention the marker gene for selection (selection gene), in particular an antibiotic resistance gene, is linked to the HCV-RNA or HCV genomic or subgenomic sequence via a ribozyme or a recognition site for a ribozyme.

35

This has the advantage, that after the selection of the cells, in which the HCV-RNA is replicating productively,

the resistance gene in the obtained cell clones can be separated from the HCV subgenomic sequence through a ribozyme-dependent cleavage, namely by activating the inserted ribozyme or in the case of a construct with a 5 recognition site for a ribozyme, by transfecting the ribozyme into the cells (for example through the transfection of a ribozyme construct or infection with a viral expression vector, into which the appropriate ribozyme has been inserted). By this means an authentic HCV 10 genomic construct can be obtained without a resistance gene, which can then form authentic infectious virus particles.

Another preferred embodiment of the HCV-RNA construct 15 is according to the invention is characterized in that the construct has at least one integrated reporter gene.

In the following a reporter gene means any gene, whose presence can be easily detected with, in general, simple 20 biochemical or also histochemical methods after being transferred into a target organism, which means a gene, that encodes for a protein, which can be easily and reliably detected and quantified in small amounts with the common measuring methods in the laboratory.

25

This variation of the HCV-RNA construct has the advantage that the extent of the replication of this construct can be easily and quickly measured with the methods common in the laboratory using the reporter gene product.

30

The reporter gene is preferably a gene from the group of the luciferase genes, the CAT gene (chloramphenicol acetyl transferase gene), the lacZ gene (beta galactosidase gene), the GFP gene (green fluorescence protein gene), the GUS 35 gene (glucuronidase gene) or the SEAP gene (secreted alkaline phosphatase gene). This reporter gene and its products, namely the relevant reporter proteins, can be

detected for example using fluorescence, chemiluminescence, colorimetric measurements or by means of immunological methods (for example ELISA).

5 A surrogate marker gene can also be considered as a reporter gene. In this context it includes those genes, which encode for cellular proteins, nucleic acids or generally for those functions, which are subject to variation depending on the replication of the virus, and
10 which consequently are either suppressed or activated in the cells, in which the HCV or the HCV-RNA construct multiplies. This means, the suppression or activation of this function is a surrogate marker for the replication of the virus or the replication of the HCV-RNA construct.

15

The positions of the reporter genes and the marker gene for selection (selection gene) can be selected in such a way, that a fusion protein made from both genetic products will be expressed. This has the advantage that these two genes
20 can be arranged in such a way in the HCV-RNA construct that their two expressed proteins are fused via a recognition sequence for a protease (for example ubiquitin) or via a self-cleaving peptide (for example the 2A protein of the Picornaviruses) at first and will be separated
25 proteolytically later.

These two positions might as well lie apart from each other in such way, that both genetic products are separately expressed (for example in the order: marker or resistance
30 gene - internal ribosome binding site - reporter gene).

In the case of the reporter gene one embodiment has proven to be particularly worthwhile, where the reporter gene is cloned into the open reading frame of the HCV genome or
35 subgenome in such a way that it will only be transferred to an active form after proteolytic processing.

The cell culture system according to the invention can be used for various purposes in each of its embodiments. These comprise:

- 5 • The detection of antiviral substances. This can include for example: organic compounds, which interfere directly or indirectly with viral growth (for example inhibitors of the viral proteases, the NS3 helicase, the NS5B RNA-dependent RNA polymerase), antisense oligonucleotides, 10 which will hybridize to any target sequence in the HCV-RNA construct (for example the 5' NTR) and will have an direct or indirect influence on the virus growth for example due to a reduction of translation of the HCV polyprotein or ribozymes, which cleave any HCV-RNA sequence and consequently impair virus replication.
- 15 • The evaluation of any type of antiviral substances in the cell culture. These substances can be detected on the isolated purified enzyme for example with 'rational drug design' or 'high-throughput screening'. Evaluation means mainly the determination of the inhibitory features of the respective substance as well as its mode of action.
- 20 • The identification of new targets of viral or cellular origin for a HCV specific antiviral therapy. If for example a cellular protein is essential for viral replication, the viral replication can also be influenced by inhibiting this cellular protein. The system according to the invention also enables the 25 detection of these auxiliary factors.
- 30 • The determination of drug resistance. It can be assumed that resistance to therapy occurs due to the high mutation rate of the HCV genome. This resistance, which is very important for the clinical approval of a substance, can be detected with the cell culture system.

according to the invention. Cell lines, in which the HCV-RNA construct or the HCV genome or subgenome replicates, are incubated with increasing concentrations of the relevant substance and the replication of the viral RNA is either determined by means of an introduced reporter gene or through the qualitative or quantitative detection of the viral nucleic acids or proteins. Resistance is given if no or a reduced inhibition of the replication can be observed with the normal concentration of the active substance. The nucleotide and amino acid replacements responsible for the therapy resistance can be determined by recloning the HCV-RNA (for example by the means of RT-PCR) and sequence analysis. By cloning the relevant replacement/s into the original construct its causality for the resistance to therapy can be proven.

- The production of authentic virus proteins (antigens) for the development and/or evaluation of diagnostics.
- The cell culture system according to the invention also allows the expression of HCV antigens in cell cultures. In principle these antigens can be used as the basis for diagnostic detection methods.
- The production of HCV viruses and virus-like particles, in particular for the development or production of therapeutics and vaccines as well as for diagnostic purposes. Especially cell culture adapted complete HCV genomes, which could be produced by using the cell culture system according to the invention, are able to replicate in cell culture with high efficiency. These genomes have the complete functions of HCV and in consequence they are able to produce infectious viruses.
- The HCV-RNA construct according to the invention by itself can also be used for various purposes in all its embodiments. This includes first of all:

• The construction of attenuated hepatitis C viruses or HCV-like particles and their production in cell cultures:

5

10

20

25

30

35

Attenuated HCV or HCV-like particles can be created by accidental or purposefully introduced mutations, such as point mutations, deletions or insertions, which means viruses or virus-like particles with complete ability to replicate, but reduced or missing pathogenicity. These attenuated HCV or HCV-like particles can be used in particular as vaccine.

• The construction of HCV-RNA constructs with integrated foreign genes, used for example as liver cell specific vector in gene therapy. Due to the distinctive liver cell tropism of the HCV and the possibility of replacing parts of the genome by heterologous sequences, HCV-RNA constructs can be produced, where for example the structural proteins can be replaced by a therapeutically effective gene. The HCV-RNA construct obtained in this way is introduced into cells preferably by means of transfection, which express the missing HCV functions, for example the structural proteins, in a constitutive or inducible way. Virus particles, carrying the HCV-RNA construct, can be created by means of this method known to the expert under the term 'transcomplementation'. The particles obtained can preferably be used for the infection of liver cells. Within these the therapeutically effective foreign gene will be expressed and will consequently develop its therapeutic effect.

• The detection of permissive cells, which means cells, in which a productive virus growth occurs. For this purpose either one of the HCV-RNA genomic constructs previously mentioned, which is able to form complete infectious viruses, or one of the HCV subgenomes previously

mentioned, which according to the previously mentioned example will be transfected in a cell line first, which expresses the missing functions in a constitutive or inducible way, is used. In each case virus particles are created, which carry a resistance and/or reporter gene apart from the HCV sequence. In order to detect cells, where the HCV is able to replicate, these cells are infected with viruses generated in this way and subject to an antibiotic selection or they are examined depending on the HCV-RNA construct by means of determining the presence of the expression of the reporter gene. Because an antibiotic resistance or reporter gene expression can only be established, when HCV-RNA construct replicates, the cells detected in this way must be permissive. Almost any cell line or primary cell culture can be tested in regard to the permissivity and detected in this way.

The cell culture system according to the invention also permits targeted discovery of HCV-RNA constructs for which there is an increase in the efficiency of replication due to mutations. This occurs either by chance, in the context of HCV-RNA replication, or by targeted introduction into the construct. These mutations, leading to a change in the replication of the HCV-RNA construct, are known to experts as adaptive mutations. The invention therefore also includes a method for obtaining cell culture adapted mutants of a HCV-RNA construct according to the invention following the above description, in which the mutants have increased replication efficiency compared to the original HCV-RNA construct. It further includes a method for the production of mutants of a HCV-RNA full-length genome or of a HCV-RNA subgenome or of any HCV-RNA construct with increased replication efficiency compared to the original HCV-RNA full-length genome or subgenome or HCV-RNA construct, as well as cell culture adapted mutants of HCV-

RNA constructs, HCV-RNA full-length genomes and HCV subgenomes with increased replication efficiency compared to the original constructs, subgenomes or full-length genomes.

5

The method according to the invention for the production of cell culture adapted mutants of a HCV-RNA construct according to the invention, in which the mutants have increased replication efficiency compared to the HCV-RNA construct, is characterised in that a cell culture system according to claim 1, in which the transfected HCV specific genetic material is a HCV-RNA construct with a selection gene according to claims 4 to 19, is cultivated on/in the selection medium corresponding to the selection gene, that the cultivated cell clones are collected and that the HCV-RNA construct is isolated from these cell clones.

In an advantageous extension of this production method, the isolated HCV-RNA constructs are passaged at least one more time, that is they are transfected in cells of a cell culture system according to claim 1, the thus obtained cell culture system according to claim 1, in which the transfected HCV specific genetic material is the isolated HCV-RNA construct with a selection gene, is cultivated on/in the selection medium corresponding to the selection gene, the cultivated cell clones are collected and the HCV-RNA constructs are thus isolated.

30

Using this process variation, the quantity of adaptive mutations and hence the degree of replication efficiency in the relevant HCV-RNA constructs can be increased even further.

35

The method according to the invention for the production of mutants of a HCV-RNA full-length genome or of a HCV-RNA subgenome or of any HCV-RNA construct with increased replication efficiency compared to the original HCV-RNA

full-length genome or subgenome or HCV-RNA construct, has the following features. Using one of the two production methods presented above, a cell culture adapted mutant of a HCV-RNA construct is produced, isolated from the cells, 5 cloned using state of the art known methods and sequenced. By comparing with the nucleotide and amino acid sequence of the original HCV-RNA construct, the type, number and position of the mutations is determined. These mutations are then introduced into an (isolated) HCV subgenome or 10 full-length genome or any HCV-RNA construct, either by site-directed mutagenesis, or by exchange of DNA fragments containing the relevant mutations.

A test can be carried out to determine or verify which 15 mutations actually are responsible for an alteration of replication efficiency, particularly an increase in replication. In this test the corresponding nucleotide and/or amino acid changes are introduced into the original HCV-RNA construct and the modified construct is then 20 transfected in cell culture. If the introduced mutation actually leads to an increase in replication, then for a HCV-RNA construct with a selectable marker gene, the number of resistant cell clones in the artificially mutated construct should be noticeably higher compared to the 25 untreated construct.

In the case of a construct with a reporter gene, the activity or quantity of the reporter should be noticeably higher for the artificially mutated construct compared to 30 the untreated one.

The cell culture adapted HCV-RNA constructs with high replication efficiency according to the invention are characterized in that, through nucleotide or amino acid 35 exchanges, they are derivable from a HCV-RNA construct according to one of the claims 4 to 19, and that they are

obtainable using one of the two production processes presented above.

5 These cell culture adapted HCV-RNA constructs can be used to produce any HCV-RNA constructs or HCV full-length or subgenomes with increased replication efficiency. Both constructs with a selectable resistance gene and constructs without one or with a non-selectable reporter gene (e.g. 10 luciferase) can be produced in this way, since replication 10 of cell culture adapted HCV-RNA constructs can also be demonstrated in non-selected cells due to their high replication efficiency.

15 The cell culture adapted mutants of a HCV-RNA construct or HCV-RNA full-length genome or HCV subgenome with high replication efficiency compared to the original HCV-RNA construct or the original HCV full-length genome are characterized in that they are obtainable by a method in which the type and number of mutations in a cell culture 20 adapted HCV-RNA construct are determined through sequence analysis and sequence comparison and these mutations are introduced into a HCV-RNA construct, particularly a HCV-RNA construct according to one of the claims 4 to 19, or into an (isolated) HCV-RNA full-length genome, either by site- 25 directed mutagenesis, or by exchange of DNA fragments containing the relevant mutations.

30 A group of preferred HCV-RNA constructs, HCV full-length genomes and HCV subgenomes with high and very high replication efficiency, which are consequently highly suitable for practical use is characterised in that it contains one, several or all of the amino acid or nucleic acid exchanges listed in table 3 and/or one or several of the following amino acid exchanges: 1283 arg -> gly , 1383 35 glu -> ala , 1577 lys -> arg , 1609 lys -> glu , 1936 pro -> ser , 2163 glu -> gly , 2330 lys -> glu , 2442 ile

-> val. (The numbers refer to the amino acid positions of the polyprotein of the HCV isolate con1, see Table 1).

5 Special features of the nucleotid sequences according to the sequence listings:

SEQ ID-NO: 1

Name: I389/Core-3'/wt

Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

10 2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker

3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame

15 4.1813-10842: HCV Polyprotein from Core up to nonstructural protein 5B

5. 1813-2385: HCV Core Protein; structural protein

6. 2386-2961: envelope protein 1 (E1); structural protein

20 7. 2962-4050: envelope protein 2 (E2); structural protein

8. 4051-4239: Protein p7

9. 4240-4890: nonstructural protein 2 (NS2); HCV NS2-3 Protease

25 10.4891-6783: nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase

11.6784-6945: nonstructural protein 4A (NS4A); NS3 Protease cofactor

12.6946-7728: nonstructural protein 4B (NS4B)

30 13.7729-9069: nonstructural protein 5A (NS5A)

14.9070-10842: nonstructural protein 5B (NS5B); RNA-dependent RNA-polymerase

15.10846-11076: HCV 3' non-translated region

SEQ ID-NO: 2

Name: I337/NS2-3'/wt

Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

5 2.342-1181: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker

3.1190-1800: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame

10 4.1801-8403: HCV Polyprotein from nonstructural protein 2 up to nonstructural protein 5B

5. 1801-2451: nonstructural protein 2 (NS2); HCV NS2-3 Protease

6. 2452-4344: nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase

7. 4345-4506: nonstructural protein 4A (NS4A); NS3 Protease cofactor

8. 4507-5289: nonstructural protein 4B (NS4B)

9. 5290-6630: nonstructural protein 5A (NS5A)

20 10.6631-8403: nonstructural protein 5B (NS5B); RNA-dependent RNA-polymerase

11.8407-8637: HCV 3' non-translated region

SEQ ID-NO: 3

25 Name: I389/NS3-3'/wt

Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker

30 3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame

4.1813-7767: HCV Polyprotein from nonstructural protein 3 up to nonstructural protein 5B

- 23 -

5. 1813-3708: nonstructural protein 3 (NS3); HCV NS3
Protease/Helicase
6. 3709-3870: Nonstructural protein 4A (NS4A); NS3
Protease Cofactor
- 5 7. 3871-4653: Nonstructural protein 4B (NS4B)
8. 4654-5994: Nonstructural protein 5A (NS5A)
9. 5995-7767: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
10. 7771-8001: HCV 3' non-translated Region

10

SEQ ID-NO: 4

Name: I337/NS3-3'/wt

Composition (Nucleotide positions):

- 1.1-341: HCV 5' non-translated region
- 15 2.342-1181: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker
- 3.1190-1800: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame
- 20 4.1801-7758: HCV Polyprotein from Nonstructural protein 3 up to Nonstructural protein 5B
5. 1801-3696: Nonstructural protein 3 (NS3); HCV NS3
Protease/Helicase
6. 3697-3858: Nonstructural protein 4A (NS4A); NS3
25 Protease Cofactor
7. 3859-4641: Nonstructural protein 4B (NS4B)
8. 4642-5982: Nonstructural protein 5A (NS5A)
9. 5983-7755: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
- 30 10. 7759-7989: HCV 3' non-translated Region

SEQ ID-NO: 5

Name: I389/NS2-3'/wt

Composition (Nucleotide positions):

- 24 -

- 1.1-341: HCV 5' non-translated region
- 2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker
- 3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame
- 4.1813-8418: HCV Polyprotein from Nonstructural protein 2 up to Nonstructural protein 5B
5. 1813-2463: Nonstructural protein 2 (NS2); HCV NS2-3 Protease
6. 2464-4356: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase
7. 4357-4518: Nonstructural protein 4A (NS4A); NS3 Protease Cofactor
8. 4519-5301: Nonstructural protein 4B (NS4B)
9. 5302-6642: Nonstructural protein 5A (NS5A)
10. 6643-8415: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
11. 8419-8649: HCV 3' non-translated Region

20

SEQ ID-NO: 6

Name: I389/NS3-3'/9-13F

Composition (Nucleotide positions):

- 1.1-341: HCV 5' non-translated region
- 2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker
- 3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame
- 4.1813-7767: HCV Polyprotein from Nonstructural protein 3 up to Nonstructural protein 5B of the cell culture-adapted mutant 9-13F
 5. 1813-3708: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase
 6. 3709-3870: Nonstructural protein 4A (NS4A); NS3

Protease Cofactor

7. 3871-4653: Nonstructural protein 4B (NS4B)
8. 4654-5994: Nonstructural protein 5A (NS5A)
9. 5995-7767: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
- 5 10. 7771-8001: HCV 3' non-translated Region

SEQ ID-NO: 7

Name: I389/Core-3'/9-13F

10. 1. 1-341: HCV 5' non-translated region
2. 342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker
3. 1202-1812: internal ribosome entry site from
- 15 15. encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame
4. 1813-10842: HCV Polyprotein from Core up to Nonstructural protein 5B of the cell culture-adapted mutant 9-13F
5. 1813-2385: HCV Core Protein; structural protein
- 20 6. 2386-2961: envelope protein 1 (E1); structural protein
7. 2962-4050: envelope protein 2 (E2); structural protein
8. 4051-4239: Protein p7
- 25 9. 4240-4890: Nonstructural protein 2 (NS2); HCV NS2-3 Protease
10. 4891-6783: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase
11. 6784-6945: Nonstructural protein 4A (NS4A); NS3
- 30 30. Protease Cofactor
12. 6946-7728: Nonstructural protein 4B (NS4B)
13. 7729-9069: Nonstructural protein 5A (NS5A)
14. 9070-10842: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
- 35 15. 10846-11076: HCV 3' non-translated Region

SEQ ID-NO: 8

Name: I389/NS3-3'/5.1

Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

5 2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker

3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame

10 4.1813-7767: HCV Polyprotein from Nonstructural protein 3 up to Nonstructural protein 5B of the cell culture-adapted mutant 5.1

5. 1813-3708: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase

15 6. 3709-3870: Nonstructural protein 4A (NS4A); NS3 Protease Cofactor

7. 3871-4653: Nonstructural protein 4B (NS4B)

8. 4654-5994: Nonstructural protein 5A (NS5A)

9. 5995-7767: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase

20 7771-8001: HCV 3' non-translated Region

SEQ ID-NO: 9

Name: I389/Core-3'/5.1

25 Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker

3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame

30 4.1813-10842: HCV Polyprotein from Core up to Nonstructural protein 5B of the cell culture-adapted mutant 5.1

5. 1813-2385: HCV Core Protein; structural protein

- 27 -

6. 2386-2961: envelope protein 1 (E1); structural protein
7. 2962-4050: envelope protein 2 (E2); structural protein
8. 4051-4239: Protein p7
9. 4240-4890: Nonstructural protein 2 (NS2); HCV NS2-3 Protease
10. 4891-6783: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase
11. 6784-6945: Nonstructural protein 4A (NS4A); NS3 Protease Cofactor
12. 6946-7728: Nonstructural protein 4B (NS4B)
13. 7729-9069: Nonstructural protein 5A (NS5A)
14. 9070-10842: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
15. 10846-11076: HCV 3' non-translated Region

SEQ ID-NO: 10

Name: I389/NS3-3'/19

20. Composition (Nucleotide positions):
 - 1.1-341: HCV 5' non-translated region
 - 2.342-1193: HCV Core Protein-Neomycin Phosphotransferase fusion protein; selectable Marker
 - 3.1202-1812: internal ribosome entry site from encephalomyokarditis virus; directs translation of the downstream located HCV open reading frame
 - 4.1813-7767: HCV Polyprotein from Nonstructural protein 3 up to Nonstructural protein 5B of the cell culture-adapted mutant 19
30. 5. 1813-3708: Nonstructural protein 3 (NS3); HCV NS3 Protease/Helicase
6. 3709-3870: Nonstructural protein 4A (NS4A); NS3 Protease Cofactor
7. 3871-4653: Nonstructural protein 4B (NS4B)
35. 8. 4654-5994: Nonstructural protein 5A (NS5A)

9. 5995-7767: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase
7771-8001: HCV 3' non-translated Region

5 SEQ ID-NO: 11

Name: I389/Core-3'/19

Composition (Nucleotide positions):

1.1-341: HCV 5' non-translated region

2.342-1193: HCV Core Protein-Neomycin Phosphotransferase

10 fusion protein; selectable Marker

3.1202-1812: internal ribosome entry site from
encephalomyokarditis virus; directs translation of the
downstream located HCV open reading frame

4.1813-10842: HCV Polyprotein from Core up to Nonstructural
15 protein 5B of the cell culture-adapted mutant 19

5. 1813-2385: HCV Core Protein; structural protein

6. 2386-2961: envelope protein 1 (E1); structural
protein

7. 2962-4050: envelope protein 2 (E2); structural
protein

20 8. 4051-4239: Protein p7

9. 4240-4890: Nonstructural protein 2 (NS2); HCV NS2-3
Protease

10.4891-6783: Nonstructural protein 3 (NS3); HCV NS3
25 Protease/Helicase

11.6784-6945: Nonstructural protein 4A (NS4A); NS3
Protease Cofactor

12.6946-7728: Nonstructural protein 4B (NS4B)

13.7729-9069: Nonstructural protein 5A (NS5A)

30 14.9070-10842: Nonstructural protein 5B (NS5B); RNA-dependent RNA-Polymerase

15.10846-11076: HCV 3' non-translated Region

The invention is described in detail in the following by way of examples of embodiments and respective diagrams. These are as follows.

5 **Fig. 1 A:** The structure of a HCV-RNA construct according to the invention

10 On the top a diagram of the structure of the complete parental HCV genome is given with the positions of the genes for the cleavage products core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B within the polyprotein, and the 5' and 3' non-translated regions (5' NTR and 3' NTR) shown as a thick horizontal line -, and with the two positions selected for the creation of the 15 subgenomic constructs, namely the position of the 'GDD catalytic domain' of the NS5B RNA polymerase (GDD) and the position of the 3' end of the HCV-IRES (nucleotide positions 1 to 377 and 1 to 389) - drawn above the diagram of the genome. The 20 numbers below the diagram of the genome indicate the respective nucleotide positions.

25 Diagrams of the structure of two modified HCV-RNA constructs (subgenome) according to the invention are shown below, consisting of the 5' HCV-IRES, the neomycin phosphotransferase gene (Neo^R), the EMCV-IRES (E-I) and the HCV sequences of NS2 or 30 NS3 up to the authentic 3' end. The position of the 10-amino acid deletion comprising the NS5B polymerase GDD motive is marked with a triangle (Δ).

35 **Fig. 1 B:** The result of a denaturing formaldehyde-agarose gel electrophoresis for the detection of replicating plus-strand RNA in transfected subpassaged Huh 7 cell clones.

5 The positions of HCV specific RNAs (arrows) and the 28S rRNA are specified to the right of lane 12, the size (number of nucleotides) of the RNA marker (M) is specified to the left of lane 1.

10 **Fig. 1 C:** The result of a PCR test with subsequent Southern Blot to demonstrate the absence of integrated replicon DNA in most of the selected cell clones.

15 The lanes 1 and 2 show the positive control, lane 13 the negative control. The figures to the left of lane 1 indicate the size of the nucleotide marker molecules.

20 **Fig. 2 A:** The result of a PCR test with subsequent Southern Blot for the detection of the sensitive exclusion of integrated replicon DNA (plasmid molecule I₃₇₇/NS3-3'/wt) in a cell clone containing a HCV-RNA construct (9-13).

25 The lanes 7 to 11 represent the result of a titration of DNA molecules of the construct I₃₇₇/NS3-3'/wt without addition of total DNA of the cell clone 9-13, and the lanes 2 - 6 represent the result obtained with the same plasmid molecules with the addition of 1 μ g 9-13 DNA each prior to the PCR (for the purpose of excluding an inhibitor of the PCR in the DNA preparation). Lane 13 represents the negative control (PCR without DNA template). Lane 1 shows the result, which was achieved with one μ g total DNA of the cell clone 9-13.

30 **Fig. 2 B:** The result of a Northern Blot test to quantify the amounts of HCV plus- and minus-strand RNA.

The arrows mark the positions of replicon RNA.

The "plus" and "minus" details indicate the positive (plus) and negative (minus) polarity of the RNA controls, which have been applied to the gel. "Minus-strand" and "Plus-strand" indicate the specificity of the radioactive RNA probes.

Fig. 2 C: The result of a formaldehyde-agarose gel electrophoresis after radioactive labeling of the intracellular replicated HCV-RNA to demonstrate the resistance of HCV-RNA replication to dactinomycin.

Fig. 3 A: The detection of HCV specific antigens in the selected cell clones by means of immunoprecipitation after metabolic radioactive labeling.

The lanes 7 - 9 represent authentic size marker (which have been obtained in Huh 7 cells after the transient expression of a HCV-RNA construct); identified HCV proteins are labeled on the left edge of lane 1, the molecular weights (in Kilodalton) are specified to the right of lane 9.

Fig. 3 B: Results of an immunofluorescence test to establish the subcellular localisation of HCV antigens.

Fig. 4 : Diagram of the structure of a selectable HCV-RNA construct according to the invention (complete genome) consisting of the 5' HCV-IRES, the neomycin phosphotransferase gene (NeoR), a heterologous IRES element, for example from the encephalomyocarditis virus (E-I), the complete HCV open reading frame and the authentic 3' NTR.

5 **Fig. 5:** Diagram of the structure of HCV-RNA constructs with inserted antibiotic resistance gene (A) within the nucleotide sequence encoding the polyprotein (monocistronic RNA construct), and (B) within the 3' NTR (bicistronic RNA construct).

10 **Fig. 6:** Diagram of the structure of HCV-RNA constructs with inserted reporter genes (A) as part of a HCV replicon from NS3 to NS5B, - in the end the reporter protein is cleaved by viral or cellular proteases out of the polyprotein or the marker gene for selection (selection gene) or the resistance gene are transfected into the cells through co-transfection -, (B) as part of a fusion gene composed of a resistance and reporter gene (for example for the neomycin phosphotransferase and green fluorescent protein), (C) as part of a replicon composed of a resistance and reporter gene (for example the neomycin phosphotransferase and green fluorescent protein) bound via a nucleotide sequence, which encodes for an amino acid sequence (area with hatches), which can be cleaved by a protease or has a self-cleaving (autocatalytic) activity, (D) as independent gene (in this case the green fluorescent protein), which is expressed from its own internal ribosome binding site (IRES); - the resistance gene (in this case the neomycin phosphotransferase gene) is also expressed from its own internal ribosome binding site (IRES) (polycistronic construct).

15

20

25

30

35 **Fig. 7:** Diagram of the structure of a HCV-RNA construct, where the resistance gene is linked to the HCV-

RNA sequence via a ribozyme or a recognition site for a ribozyme.

The thick lines illustrate the HCV 5' and 3' NTRs, E-I is a heterologous internal ribosome binding site, which is required for the expression of the resistance gene, and the grey square illustrates the ribozyme or a recognition site for a ribozyme.

Fig. 8: Diagram of the structure of a HCV-RNA construct with resistance gene and integrated foreign gene.

Fig. 9: Method for comparing the specific infectivity (expressed as number of cell colonies obtained) of total RNA against in vitro transcripts. HCV-RNA is generated by in vitro transcription of a corresponding RNA construct and quantified by measurement of the optical density at 260 nm (OD 260 nm). A defined number of these molecules is mixed with a specified amount of total RNA from naive Huh-7 cells and this mixture is transfected into naive Huh-7 cells with the aid of electroporation. At the same time the total RNA of a cell clone, produced by the method described in Figure 1, is isolated using a known state of the art method and the amount of HCV-RNA contained therein is determined by means of Northern Blot using a HCV specific RNA probe and subsequent quantification via phosphoimaging. A defined amount of this total RNA is analogously transfected in naïve Huh-7 cells. These cells from both the cultures are then subjected to a G418 selection and the number of colonies created is determined by counting after fixing and staining with Coomassie Brilliant Blue. For the determination of transfection efficiency 1 μ g of a

5 plasmid allowing the expression of luciferase is added to each transfection culture. An aliquot of the transfected cells is collected after 24 hours and the luciferase activity determined in the respective cell lysates. The number of colonies is always normed to the luciferase expression.

10 **Fig. 10:** Sequence analysis of the 9-13 clone. Total RNA of the 9-13 cell clone, resulting from transfection of HCV-RNA construct I377/NS3-3', was isolated using a known state of the art method and the HCV-RNA construct amplified from nucleotide position 59 to 9386 with the aid of 'long-distance RT-PCR' using primer S59 and A9413. The 15 PCR fragments were cloned and 11 clones (9-13 A - K) completely sequenced. Clones D and I, E and G as well as H and J turned out to be identical, respectively. The positions of the amino acid differences in the NS3-5B region between the recloned HCV-RNAs and the parental construct are marked with a thick vertical mark for each clone. Each clone was digested with restriction enzyme 20 SfiI and the respective fragment inserted in the parental construct. These clones were each transfected in Huh-7 cells and the cells subjected to selection as described in Figure 1. The 25 number of cell clones obtained with each construct is noted next to the respective construct on the right.

30 **Fig.11 A:** Principle of determination of replication with the aid of a reporter gene. In the upper part of the figure, the HCV-DNA construct I₃₈₉/Luc/NS3-3' is shown. It consists of the HCV 5' NTR (nucleotide positions 1-389), the luciferase gene (luc), the IRES of the encephalomyocarditis 35 virus, the HCV NS3-5B and the 3' NTR. The

position of the active centre of the NS5B RNA polymerase, into which a deactivating amino acid exchange was introduced, is indicated by 'GND'. The plasmids, which code for the HCV-⁵RNA construct which is able to replicate or is defective, are digested with the restriction enzyme *Sca*I and added to an in vitro transcription reaction with T7 RNA polymerase. After removal of the template DNA, the respective HCV-¹⁰RNA constructs were transfected in naive Huh-7 cells by means of electroporation and the latter collected at regular intervals.

Fig.11 B: Comparison of luciferase activity in cells transfected with the parental HCV-¹⁵RNA construct $I_{389}/Luc/NS3-3'$ /wt (wt) or the following variants: inactive RNA (318 DN), variants 9-13F or variant 5.1. The cells were collected 6 (not shown), 24, 48, 72, 96, 120, 144 and 168 hours after transfection and luciferase activities determined by luminometric measurement.

Fig. 12: Selectable HCV full-length genomes (constructs $I_{389}/core$ 3'/5.1 and $I_{389}/core$ 3'/9-13F). (A) Diagram of the full-length construct. The region between both indicated recognition sites for the restriction enzyme *Sfi*I corresponds to the sequences of the highly adapted RNA variants 5.1. or 9-13F. (B) Number of colonies which were obtained after transfection of 0.1 μ g in vitro transcribed RNA of the construct $I_{389}/core-3'$ /5.1. described under A into HUH7-cells. The result of a representative experiment is given. (C) Demonstration of autonomously replicating HCV full-length RNAs in G418 resistant cell clones which were obtained after transfection of the

corresponding in vitro transcript. The illustration shows the autoradiogram of a Northern Blot, which was hybridised with a probe against the neo-resistance gene and the HCV 5' NTR. The controls shown in lanes 1 and 2 each correspond to 10^8 molecules of the indicated in vitro transcripts, mixed with total RNA from naive Huh-7 cells. The negative control contains only total RNA from naive Huh-7 cells (lane 3). Lanes 4-9 contain 3-10 μ g total RNA from G418 resistant cell clones, which were obtained after transfection by in vitro transcribed I_{389} /core 3'/5.1 RNA or I_{389} /core 3'/9-13F RNA. The G418 concentration used for the selection is indicated in each case. Five of the cell clones shown contain the highly adapted RNA variant 5.1 (lanes 4-8), one contains the adapted RNA variant 9-13F (lane 9).

20 **Fig. 13:** HCV-RNA constructs with a reporter gene. (A) Bicistronic HCV-RNA constructs. The reporter gene is translated with the aid of a separate IRES. (B) Monocistronic HCV-RNA constructs. The reporter gene product is expressed as fusion protein with a HCV protein. Both portions are linked via a recognition sequence for a viral or cellular protease, which permits a proteolytic separation of the two fused protein portions. In the example shown the reporter gene product and respective HCV protein was fused through a recognition sequence for ubiquitin (Ub).

25 30 35 **Fig. 14:** Tricistronic full-length HCV-RNA construct, that in addition to the resistance gene possesses an inserted foreign gene (ther. gene).

Fig. 15: Monocistronic HCV-RNA constructs, for which the resistance gene product is expressed as a fusion protein with HCV portion. The resistance gene (RG) is either active as a fusion protein or it is fused with the HCV portion via a proteolytically cleavable sequence in such a way that the resistance gene product is split from the HCV portion by a cellular or viral protease. In the example shown the resistance gene was fused with the respective HCV portion through the sequence coding for ubiquitin (Ub).

15 Example 1: Production of HCV-RNA constructs

(A) Synthesis and cloning of a complete HCV consensus genome by means of RT-PCR

20 The HCV genome, which means the HCV-RNA, was isolated from
the liver of a chronically infected patient as described in
the following:

The total RNA was isolated from approx. 100 mg of liver
25 according to the method described by Chomczynski and Sacchi
(1987, Anal. Biochem. 162, 156). Using 1 µg of this
isolated RNA a reverse transcription was carried out with
the primers A6103 (GCTATCAGCCGGTTCATCCACTGC) or A9413
(CAGGATGGCCTATTGG CCTGGAG) and the expand reverse
30 transcriptase system (Boehringer Mannheim, Germany)
according to the manufacturer's recommendations. A
polymerase chain reaction (PCR) was carried out with the
products of this reverse transcription using the expand
long template system (Boehringer Mannheim, Germany), in
35 which the buffer containing 2 % of dimethyl sulfoxide was
used. After one hour at 42 °C, 1/8 of the reaction mixture
was used for a first PCR with primers A6103 and S59

(TGTCTTCACGCAGAAAGCGTCTAG) or A9413 and S4542 (GATGAGCT CGCCCGCGAAGCTGTCC). After 40 cycles, 1/10 of this reaction mixture was used for a second PCR with primers S59 and A4919 (AGCACAGCCCGCGTCATAGCACTCG) or S4542 and A9386 (TTAGCTCCCCG TTCATCGGTTGG. After 30 cycles the PCR products were purified by means of preparative agarose gel electrophoresis and the eluted fragments were ligated into the vector pCR2.1 (Invitrogen) or pBSK II (Stratagene). Four clones of each fragment were analyzed and sequenced, and a consensus sequence was established. For this purpose the DNA sequences were compared to each other. The positions, where the sequence of one fragment was different from the others, were considered as undesired mutations. In the case of ambiguities of the sequence, shorter overlapping PCR fragments of the respective region were amplified and several clones sequenced. By this means several potential mutations could be identified in each fragment and consequently an isolate specific consensus sequence could be established. This established consensus sequence or genome belongs to the worldwide spread genotype 1b. The non-translated region at the 3' end (=3' NTR) was obtained by means of a conventional PCR, whereby an antisense primer, which covers the last 24 nucleotides of the 'X-tail' known from the state of the art was used (Tanaka et al., 1995, Biochem. Biophys. Res. Commun. 215, 744; und Rice, PCT/US 96/14033). The authentic non-translated region on the 5' end (=5' NTR) downstream of the T7 promoter was created by means of PCR, whereby an oligonucleotide, which corresponds to a shortened T7 promoter (TAA TAC GAC TCA CTA TAG) and the first 88 nucleotides of HCV, was used on one hand and one of the previously mentioned plasmids, which carries one of the 5' fragments of the genome, was used on the other hand. A complete HCV consensus genome was assembled from the subgenomic fragments with the smallest number of non-consensus replacements and inserted into a modified pBR322 vector. Deviations from the consensus sequence were

eliminated by means of site-directed mutagenesis. In order to produce run-off transcripts with an authentic 3' end, the 3' NTR of the isolates (with the end TGT) was modified to AGT (according to the sequence of the genotype 3' = clone 5 'WS' according to Kolykhlov et al., 1996, J. Virol. 70, 3363) and an additional nucleotide replacement was carried out at position 9562, to preserve the A:T pairing in the hairpin structure at the 3' end of the 3' NTR (Kolyhalov et al. ibid.). In order to eliminate an internal restriction 10 site for the Scal enzyme, a silent nucleotide replacement was further carried out. After joining the full-length genome with the appropriate 5' and 3' NTRs the complete HCV sequence was analyzed. No undesired nucleotide replacement was detected.

15

The HCV genome produced in this way should be hepatotropic according to the definition.

(B) Synthesis of selectable HCV subgenomic constructs

20

By means of the consensus genome described under (A), HCV subgenomic constructs were created, which include the antibiotic resistance gene neomycin phosphotransferase (NPT) and two sequences of internal ribosome entry sites (IRES). The biochemical procedures used for this are known and familiar to the expert (see: Sambrook, J., E.F. Fritsch, T. Maniatis, 1989, Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbour Laboratory, Cold Spring Harbor, N.Y.; Ausubel et al. (eds.), 1994, Current Protocols in Molecular Biology, Vol. 1-3, John Wiley & Sons Inc., New York). The antibiotic resistance gene was inserted immediately after the 5' NTR, obtaining a bicistronic RNA as a result (see Fig. 1 A). However, the antibiotic resistance gene might as well be inserted at 25 another site of the HCV subgenomic construct, for example within the nucleotide sequence encoding for the polyprotein, obtaining a monocistronic RNA as a result (see

Fig. 5 A), or in the 3' NTR (see Fig. 5 B). The IRES elements are one of the two HCV-IRES variants from nucleotides 1-377 or nucleotides 1-389 as well as the IRES of the encephalomyocarditis virus, which controls the 5 translation of the HCV sequence downstream from the genes for NS2 or NS3 up to the authentic 3' end of the genome.

The two HCV-IRES variants mentioned were determined in the following way:

10

Based on deletion analyses of the 3' end of the HCV-IRES (Reynolds et al. 1995, *EMBO J.* 14, 6010) various segments of the 5' NTR were fused with the NPT gene and analyzed with regard to the maximum number of colonies formed by means of 15 co-transfection with a plasmid containing the T7 RNA polymerase gene. The best results were achieved with the HCV sequences from 1-377 to 1-389. Due to the fact that the AUG start codon of the HCV polyprotein is located at position 342 and is consequently included in the IRES sequence, 12 or 16 amino acids of the HCV core protein ("core protein") were fused with the neomycin phosphotransferase (see Fig. 1 A).

25 Accordingly, these modified HCV subgenomic constructs were given the designations $I_{377}/NS2-3'$ (or $I_{377}/NS3-3'$) and $I_{389}/NS2-3'$ (or $I_{389}/NS3-3'$). They are illustrated in a diagram in Fig. 1A.

30 Different cell lines and primary cell cultures of human hepatocytes were transfected with *in vitro* transcripts of these modified parental HCV subgenomic constructs $I_{377}/NS2-3'$ (or $I_{377}/NS3-3'$) and $I_{389}/NS2-3'$ (or $I_{389}/NS3-3'$).

35 As a parallel negative control for all transfection experiments, an appropriately modified, but defective subgenome was constructed for every modified parental HCV subgenomic construct, which differs from the parental

construct due to the fact, that it has a deletion of 10 amino acids within the reading frame comprising the active site of the NS5B RNA polymerase (Behrens et al., 1996, *EMBO J.* 15, 12; and Lohmann et al., 1997, *J. Virol.* 71, 8416).

5 (C) Synthesis of selectable HCV genomic constructs

A NS2-3' subgenomic construct, linked at its 5' end to a fragment of the luciferase gene and the complete EMCV-IRES, 10 was restricted with NcoI and SpeI and purified using preparative agarose gel electrophoresis. The vector obtained in this way was ligated with a NcoI/NotI-HCV fragment corresponding to the nucleotide positions 342 to 1968 of the HCV genome and a NotI/SpeI fragment 15 corresponding to the nucleotide positions 1968-9605 in a 3-factor-ligation. The resulting construct, where the complete HCV open reading frame and the 3' NTR lie downstream from the luciferase gene fragment and the EMCV-IRES, was then restricted with PmeI and SpeI and ligated 20 with the analogously restricted I₃₈₉/NS3-3'/wt subgenomic construct vector. This selectable HCV genomic construct is illustrated in Fig. 4.

25 (D) Production of in vitro transcripts corresponding to the HCV-RNA constructs

The previously described purified plasmid DNAs were linearized with ScaI and used for an in vitro transcription reaction after phenol/chloroform extraction and isopropanol precipitation using the following components: 80 mM HEPES, 30 pH 7.5, 12.5 mM MgCl₂, 2 mM Spermidine, 40 mM Dithiothreitol, 2 mM of each NTP, 1 unit RNasin/ μ l, 50 μ g/ml restricted DNA and approx. 2 units/ μ l T7 RNA polymerase. After 2 hrs. at 37 °C half of the amount of T7 35 polymerase was added and the reaction mixture was incubated for two further hours. In order to remove DNA the mixture was extracted with acid phenole (U. Kedzierski, J.C. Porte,

1991, Bio Techniques 10, 210), precipitated with isopropanol, the pellet was dissolved in water and incubated with DNase (2 units per μ g DNA) for 60 min. at 37 °C. After subsequent extraction with acid phenole, acid phenole/chloroform and chloroform as well as isopropanol precipitation the dissolved RNA was quantified using optical density measurement and its integrity was checked using formaldehyde-agarose gel electrophoresis.

10

Example 2: Transfection experiments with the hepatoma cell line Huh 7

With all transfection experiments it was carefully ensured that any template DNA had been removed beforehand so as to avoid the possibility of this DNA integrating in transfected cells and conferring a neomycin resistance to them independent from HCV replication. The reaction mixture was therefore treated with 2 units of DNase per μ g DNA for 60 min. at 37 °C after the in vitro transcription and extracted with acid phenole, acid phenole/chloroform and chloroform. Prior to being used for the transfection the precipitated RNA was analyzed using formaldehyde-agarose gel electrophoresis.

25

Three separate transfection experiments were carried out with the highly differentiated human hepatoma cell line Huh 7 (according to Nakabayashi et al. 1982, Cancer Res. 42, 3858). Each time 15 μ g RNA were introduced into 8×10^6 Huh 7 cells by electroporation and the cells were seeded in culture dishes with a diameter of 10 cm. 24 hours after seeding, neomycin (= G418) was added in a final concentration of 1 mg/ml. The culture medium was changed twice a week. After 3 - 5 weeks small colonies were visible, which were isolated and grown under the same culture conditions.

The cell clones obtained during the first experiment were isolated and subpassaged. Most of the clones died during this procedure, and the final yield was only 9 clones from cells, which had been transfected with the parental HCV subgenomic constructs and 1 clone (clone 8-1) from cells, which had been transfected with a defective HCV genomic construct, namely a defective NS2-3' HCV-RNA. Apart from an extended doubling time and the occasional occurrence of irregularly shaped cells, no consistent morphological differences were found between these 9 cell clones and the single cell clone (clone 8-1) or the parental Huh 7 cells.

The main criteria for functioning HCV genomic constructs are the formation of viral RNA with the correct size and the absence of (integrated) plasmid DNA, which could transfer or mediate on a G418 resistance.

To determine the HCV-RNA in the Huh 7 cells, the total RNA was isolated and analyzed by means of the common Northern Blot method using a plus-strand specific ribo probe (RNA probe). For this purpose the total RNA was isolated from the respective cell clones according to the method described by Chomczynski and Sacchi 1987, *Anal. Biochem.* 162, 156 and 10 µg RNA, which is equivalent to the total RNA content of 0,5 - 1 x 10⁶ cells, are separated using denatured formaldehyde-agarose gel electrophoresis (lanes 3 to 12 of Fig. 1 B). At the same time 10⁹ in vitro transcripts (ivtr.), which correspond to the I₃₈₉/NS2-3'/wt or the I₃₈₉/NS3-3'/wt replicon RNAs, are separated as well as size markers with authentic sequence (lane 1 or lane 2). The separated RNA was transferred onto nylon-based membranes and hybridized with a radioactively labeled plus-strand specific RNA probe, which was complementary to the complete NPT gene and the HCV-IRES of nucleotide 377 to nucleotide 1. The positions of the HCV specific RNAs (arrows) and the 28S rRNA are specified to the right of lane 12, the size (amount of nucleotides) of the RNA marker

is specified to left of lane 1. The RNA marker fragments contain HCV sequences and therefore hybridize with the ribo probe (= RNA probe). The results of this analysis are illustrated in Fig. 1 B.

With the exception of clone 8-1 transfected with the defective HCV genomic construct, all cell clones produced homogenous HCV-RNAs of correct lengths (approx. 8640 nucleotides in the case of the NS2-3' and approx. 7970 nucleotides in the case of NS3-3' replicon). This result is an indication of the fact, that the functional replicons or the functional HCV genomic constructs transfer the G418 resistance. In order to exclude, that the G418 resistance is caused by a plasmid DNA, which is integrated in the genome of the Huh 7 host cell and transcribed under control of a cellular promoter, the DNA of each clone was analyzed by means of a NPT gene specific PCR. Consequently the DNA was isolated from the selected Huh 7 cell clones by means of digestion with proteinase K (40µg/ml, 1h, 37 °C) in 10mMTris, pH7,5, 1mM EDTA, 0,5 % SDS and subsequent extraction with phenol, phenol/chloroform and isopropanol precipitation. The DNA precipitate was dissolved in 10 mM Tris (pH 7,5) and 1 mM EDTA and incubated with Rnase A for 1 hour. Following a phenol/chloroform extraction and ethanol precipitation, 1 µg DNA, equivalent to 4 - 8 x 10⁴ cells, was analyzed by means of PCR using NPT gene specific primers (5'-TCAAGACCGACCTG TCCGGTGCC-3' and 5'-CTTGAGCCTGGCGAACAGTTCGGC-3'), and a DNA fragment consisting of 379 nucleotides was generated. The specificity of the PCR product was established by means of the Southern Blot method, in which a DNA fragment labeled by digoxigenin was used, which corresponds to the NPT gene. As positive controls (for the detection of possibly contaminating nucleic acids) the PCR method was carried out with 10⁷ plasmid molecules or 1 µg DNA from a BHK cell line, which was stably transfected with a neomycin resistance gene, and

as negative control, the PCR was carried out with the same reagents but without added DNA.

5 The results of this analysis are illustrated in Fig. 1 C. The lanes 1 and 2 represent the positive controls, lane 13 represents the negative control. The numbers to the left of lane 1 indicate the sizes of the nucleotide marker molecules.

10 A NPT-DNA could not be detected in any cell clone, apart from clone 7-3 (Fig.1C, lane 3), which was obtained from cells after transfection with a NS2-3' replicon/NS2-3'HCV genomic construct, and clone 8-1 (Fig.1C, lane 12), which was obtained from cells after transfection with a defective HCV genomic construct. This result was another indication of the fact, that the G418 resistance of most clones was passed on by the replicating HCV-RNA. But even regardless of these results, it is unlikely, that integrated plasmid DNA produces HCV-RNAs of correct sizes, because the 15 plasmids used for the in vitro transcription contain neither an eukaryotic promoter nor a polyadenylation signal. In the case of clone 7-3 the resistance is therefore very probably passed on by the HCV-RNA construct or the replicating HCV-RNA as well as by an integrated NPT 20 DNA sequence, whereas the resistance of the cells of clone 8-1 is only caused by the integrated plasmid DNA.

30 Clone 9-13 (Fig. 1 B, lane 11) was subject to further tests, to confirm that the G418 resistance was passed on by a self-replicating HCV-RNA. Clone 8-1, which carries the integrated copies of the NPT gene, was used throughout as negative control. A PCR was carried out, which allows the detection of < 1000 NPT gene copies in ~ 40.000 cells, with the aim to rigorously exclude the presence of NPT-DNA in 35 clone 9-13. The result of this PCR is illustrated in Fig. 2A. The PCR proceeded in detail as follows:

During the test, 10^6 - 10^2 plasmid molecules (I_{377} /NS3-3'/wt) were used either directly (lanes 7 - 11) or after adding each 1 μ g 9-13 DNA (lanes 2 - 6). The specificity of the amplified DNA fragment was determined by Southern Blot using a NPT specific probe. A PCR without DNA probe was carried out as negative control (lane 12).

Even with this sensitive method, no plasmid DNA could be detected in one μ g DNA of the cell clone 9-13 (lane 1). To estimate the amount of HCV plus- and minus-strand RNAs in these cells, a dilution series of total RNA was analyzed with the Northern Blot method using a plus- or minus-strand specific radioactively labeled ribo probe (= RNA probe). For this purpose, 8, 4 or 2 μ g of total RNA, which have been isolated from the cell clones 9-13 and 8-1, were analyzed in parallel to known amounts of in vitro transcripts with plus- or minus-strand polarity (control RNAs) in the Northern Blot method and were then subjected to a hybridization. The hybridization was carried out with a plus-strand specific ribo probe, which covered the complete NPT gene and the HCV-IRES ('plus-strand', top panel), or with a minus-strand specific RNA probe, which was complementary to the NS3 sequence ('minus-strand', bottom panel). The arrows mark the positions of replicon RNA. The results of this analysis are illustrated in Fig. 2.B.

Approx. 10^6 copies/ μ g total RNA were detected in the case of the plus-strand, which is equivalent to 1000 - 5000 HCV-RNA molecules per cell, whereas the amount of minus-strand RNA was 5- to 10-times less. This result corresponds to the assumption, that the minus-strand RNA is the replicative intermediate form or intermediate copy, which is used as a template for the synthesis of the plus-strand molecules.

35

Due to the fact that the reaction is mainly catalyzed by the viral RNA-dependent RNA polymerase, the synthesis of

the HCV-RNAs should be resistant to dactinomycin, an antibiotic, which selectively inhibits the RNA synthesis of DNA templates, but not the RNA synthesis from RNA templates. To confirm this assumption, cells were incubated with [³H] uridine in the presence of dactinomycin, the radioactively labeled RNAs were extracted, separated by means of denaturing agarose gel electrophoresis and analyzed with the aid of a common Bio-Imager using a [³H]-sensitive screen. For this purpose approx. 5 x 10⁵ cells of the clones 9-13 and 8-1 were incubated at a time with 100 μ Ci [³H] uridine for 16 hrs. in the absence (-) or presence (+) of 4 μ g/ml of dactinomycin (Dact). Following this labeling reaction the total RNA was prepared and analyzed by means of formaldehyde-agarose gel electrophoresis. Only 1/10 of the total RNA is illustrated in the first two lanes. The radioactively labeled RNA was visualized using a BAS-2500 Bio-Imager (Fuji).

The results of this analysis are illustrated in Fig. 2 C. In accordance with the inhibitor profile of the NS5B polymerase (Behrens et al., 1996, *EMBOJ.* 15, 12 and Lohmann et al., 1997, *J. Virol.* 71, 8416), dactinomycin had no influence on the replication of the HCV RNA, whereas the synthesis of cellular RNA was inhibited. A RT-PCR was carried out for recloning the replicating sequences, to confirm the identity of the viral RNA. The sequence analysis of the recloned RNA showed that the RNA in clone 9-13 is HCV specific and corresponds to the transfected transcript of the HCV construct I₃₇₇/NS3-3'/wt.

For the analysis of the viral proteins, at first the respective cells were metabolically radioactively labeled with [³⁵S] methionine/cysteine, then lysed and afterwards the HCV specific proteins were isolated from the cell lysates by means of immunoprecipitation. The results of these analyses are illustrated in Fig. 3 A. The detailed procedure was as follows: Cells of the cell clones 9-13

(wt) and 8-1 (Δ) were metabolically radioactively labeled by treating them with a protein labeling mixture familiar to the expert and available on the market (for example. NEN Life Science). The HCV specific proteins were separated 5 from the cell lysate by immunoprecipitation (IP) under non-denaturing conditions (for example according to Bartenschlager et al., 1995, J. Virol. 69, 7519) using three different antisera (3/4, 5A, 5B, according to the labeling on the top end of the lanes 1 to 12). The immune 10 complexes were analyzed by means of tricine SDS-PAGE and made visible by means of autoradiography. To obtain authentic size markers, the homologous replicon construct I₃₇₇/NS3-3'/wt was subject to a transient expression by the vaccinia virus-T7 hybrid system in the Huh 7 cells. The 15 resulting products were used as size markers (lanes 7 - 9) parallel to the cells of the clones 9-13 and 8-1. Identified HCV proteins are labeled on the left edge of lane 1, the molecular weights (in Kilodalton) are specified on the right edge of lane 9. It should be noted that the 20 NS3/4 specific antiserum ('3/4') used preferably reacts with NS4A and NS4B causing an underrepresentation of NS3.

All viral antigens could unambiguously be detected, and their apparent molecular weights did not show any 25 difference to those being detected after transient expression of the same bicistronic HCV-RNA construct in the original Huh 7 cells. An immunofluorescence detection reaction was carried out using NS3 and NS5A specific 30 antisera, to determine the subcellular distribution of the viral antigens (for example according to Bartenschlager et al., 1995, J. Virol. 69, 7519). For this purpose cells of the clones 9-13 (wt) and 8-1 (Δ) were fixed with methanol/acetone 24 hrs. after incubating on coverslips and incubated with polyclonal NS3 or NS5A specific antisera. 35 The bound antibodies were made visible with a commercially available FITC conjugated anti-rabbit antiserum. The cells

were counterstained with the 'Evans Blue' stain to suppress unspecific fluorescence signals.

The results of this detection test are illustrated in Fig. 5 3 B. A strong fluorescence in the cytoplasm could be detected with both antisera. The NS5A specific antiserum also caused a slight nuclear fluorescence, which indicates that at least small amounts of this antigen also reach the nucleus. But the generally dominating presence of the viral 10 antigens in the cytoplasm are a strong indication that HCV-RNA replication occurs in the cytoplasm, as is the case with most RNA viruses.

These results prove clearly that the establishment of a 15 cell culture system for the HCV could be accomplished with the test arrangement described, the efficiency of which surpasses everything known up until now by far and for the first time allows the detection of viral nucleic acids and 20 proteins with conventional and approved biochemical methods. This efficiency actually allows detailed examination of HCV pathogenesis, genetic analyses of different HCV functions and a precise study of the virus/host cell interaction, through which new starting 25 points for the development of a antiviral therapy can be defined.

Example 3: Transfection of Huh 7 cells with HCV total constructs

30

Huh7 cells are transfected and selected as described in example 2, whereby in this case selectable constructs are used, which contain the complete virus genome. Corresponding to Example 2, the resulting cell clones are 35 tested for the absence of HCV-DNA by means of PCR and the productive replication of HCV-RNA is then established by means of Northern Blot, [³H]uridine labeling in the

presence of dactinomycin, detection of the viral proteins or antigens preferably with the aid of the Western Blot, the immunoprecipitation or immunofluorescence. In contrast to the arrangements described in Example 2, the construct described here makes it possible to obtain more complete and very likely infectious viruses, which has not been the case in the subgenomic constructs described in Example 2. These viruses existing in the cell and the cell culture supernatant are concentrated for example by means of ultracentrifugation, immunoprecipitation or precipitation with polyethyleneglycol, and all exogenous nucleic acids, which means those that are not incorporated into the virus particle, are digested by incubation with nucleases (RNase, DNase, micrococcal nuclease). In this way all contaminating nucleic acids, which are not included in the protecting virus particle, can be removed. After inactivation of the nucleases, the protected viral RNA is isolated for example by means of incubation with proteinase K in a buffer containing SDS, by extracting with phenol and phenol/chloroform and detected by means of Northern Blot or RT-PCR using HCV specific primers. Also in this test arrangement, the combination of the HCV consensus genome described with a selection marker was crucial for the efficient production of viral RNA, viral protein and therefore HCV particles.

Example 4: Production and application of a HCV-RNA construct, whereby the resistance gene is linked to the HCV subgenomic sequence via a ribozyme or a recognition site for a ribozyme.

A HCV-RNA construct is produced according to Example 1 or Example 3, where an antibiotic resistance gene is linked to the HCV-RNA sequence through a ribozyme or a recognition sequence for a ribozyme. These constructs are illustrated in a diagram in Fig. 7. Huh 7 cells are transfected with

this HCV-RNA construct as described in Example 2. A selection with the appropriate antibiotic follows the transfection into the cells. The inserted ribozyme is activated in the cell clones obtained in the procedure or, in the case of a construct, which carries a recognition sequence for a ribozyme, the ribozyme is transfected into the cell (for example by means of transfection of a ribozyme construct or infection with a viral expression vector, into which the respective ribozyme has been inserted). In both cases the resistance gene is separated from the HCV-RNA sequence by the ribozyme-dependent cleavage. The result in the case of the HCV genome is an authentic HCV genome without a resistance gene, which can form authentic infectious virus particles. A HCV replicon without resistance gene is created in the case of the HCV subgenomic constructs.

Example 5: Co-transfection of a HCV-RNA construct with a separate luciferase transfection construct

A HCV-RNA construct is produced according to Example 1 (A) or Example 3 or Example 4. At the same time a transfection construct is produced, which comprises the luciferase gene, whereby this luciferase gene is linked to a first nucleotide sequence, which encodes a HCV protease (for example NS3 protease) cleavage site, to a second nucleotide sequence, which encodes for another protein or a part of another protein. HCV-RNA construct and transfection construct are transfected into any host cells, preferably hepatoma cells, most preferably Huh 7 cells. This can be realised as described in Example 2. The product of the modified luciferase gene is a luciferase fusion protein, where the luciferase is inactivated due to the fusion with the foreign part. The fusion protein, which contains a recognition sequence for a HCV protease, is cleaved in transfected cells with high HCV replication, and

consequently the active form of the luciferase, which can be identified through luminometric measurement, is released. If the replication of the HCV-RNA construct is inhibited the fusion protein will not be cleaved and no active luciferase will be released. The quantitative determination of the luciferase is therefore a measure for the replication of the HCV construct. Instead of the luciferase gene, another reporter gene can just as easily be used, which is modified in the same way, so that its expression depends on the viral replication, although this reporter gene is not part of the HCV construct. A cellular protein, which is deactivated or activated by the HCV proteins or nucleic acid, can also be used as a so called surrogate marker. The expression or activity of this surrogate marker is in this case a measure for the replication of the viral DNA.

20 **Example 6: Production of HCV subgenomic constructs with integrated foreign genes to be used as liver cell specific vector in gene therapy**

25 These recombinant and selectable HCV subgenomic constructs are transfected in transcomplementing helper cell lines, which means in cell lines, which express the missing functions (for example the structural proteins) in an inducible or constitutive way. Cell clones containing a functional HCV subgenomic construct can be established through appropriate selection. The viral structural 30 proteins expressed from the host cell allow the formation of virus particles, into which the RNA of the HCV subgenomic constructs will be transfected. The results are therefore virus-like particles, which contain a HCV subgenomic construct according to the invention including 35 the inserted foreign gene and which can transmit this to other cells by means of infection. An example for this construct is illustrated in Fig. 8.

It is also possible to use the HCV subgenomic construct with integrated foreign gene directly as an expression vector. This involves the same method as mentioned previously except that cell lines, which do not express transcomplementing factors, are transfected. In this case the HCV construct is only used as an expression vector.

10 **Example 7: Production of cell culture adapted HCV-RNA constructs**

(A) **Method of isolation**

15 The following method was used to determine adaptive mutations and to produce cell culture adapted HCV-RNA constructs: cells were transfected with a HCV-RNA construct as described in Examples 1 and 2 and G418-resistant cell clone produced. For the determination of ability to 20 replicate (understood in this context to be the number of G418 resistant cell clones obtained per microgram of transfected HCV-RNA or HCV-RNA construct), the total RNA from one of the cell clones, [the 9-13 clone (Fig. 1 B, lane 11)], was isolated and the quantity of HCV-RNA contained within it was determined by Northern Blot as described in Fig. 2 B. Ten micrograms of the total RNA, containing approx. 10^9 molecules of HCV-RNA, was then 25 transfected into naive Huh-7 cells using electroporation (Fig. 9). In parallel, 10^9 in vitro transcripts of the analogous neo-HCV-RNA, which had been adjusted with isolated total RNA from naive Huh-7 cells to a total RNA quantity of 10 μ g, were transfected in naive Huh-7 cells. After selection with G418, the number of cell colonies, 30 expressed as 'colony forming units (cfu) per microgram RNA', was determined in both these cultures. At a concentration of 500 μ g/ml G418 in the selection medium, the number of colonies obtained with the HCV-RNA contained

in isolated total RNA from clone 9-13, was approx. 100,000 cfu per microgram HCV-RNA. In contrast, only 30 - 50 colonies were obtained with the same quantity of in vitro transcribed HCV-RNA. This result confirms that the specific infectivity of the HCV-RNA isolated from the cell clones is approx. 1,000 - 10,000 times higher than the infectivity of the analogous in vitro transcripts. The experimental approach is shown in Fig. 9.

10 With the aid of 'long-distance RT-PCR', the HCV-RNA was amplified from the total RNA of the 9-13 cells, the PCR amplificate was cloned and numerous clones were sequenced. A comparison of the sequences of these recloned RNAs with the sequence of the RNA originally transfected into the 15 naive Huh-7 cells, showed that the recloned RNAs possessed numerous amino acid exchanges distributed over the whole HCV sequence (Fig. 10). *Sfi*I fragments of these recloned mutants were used to replace the analogous *Sfi*I fragment of the original replicon construct, and RNAs of the 20 respective mutants were transfected in naive Huh-7 cells. After selection with G418 the number of colonies created was determined for each HCV-RNA mutant. While only 30 - 50 colonies per microgram RNA were obtained with the parental RNA the number of colonies was noticeably higher for two of the 25 recloned variants (Fig. 10). In the case of the HCV-RNA constructs 9-13I and 9-13C the specific infectivity was increased to 100 - 1,000 cfu per microgram RNA and for 9-13F replicon it was 1,000 - 10,000 cfu per microgram RNA. These results show that the amino acid exchanges in the 30 analysed NS3-5B regions of the mutants 9-13I, 9-13C and particularly of 9-13F, led to a considerable increase in ability to replicate. In contrast all the other HCV-RNA constructs (9-13 A, B, G, H und K) were no longer able to replicate, they thus contained lethal mutations.

35

In order to answer the question which of the amino acid exchanges in the 9-13F construct led to an increase in

replication, the exchanges were introduced separately or in combination into the parental HCV-RNA construct, and the corresponding RNAs transfected in naive Huh-7 cells. The result of the transfection with these RNAs is summarised in 5 Table 1. From this it is evident that in the present example the high ability to replicate is determined by several mutations. The amino acid exchanges in the HCV-RNA regions NS5A and NS4B make the greatest contribution. The single exchanges in the NS3-Region also make a contribution 10 and perhaps they are synergistic.

These results confirm that it was through the G418 selection of the cells transfected with the neo-HCV-RNA construct that there was enrichment of those HCV-RNAs 15 having noticeably higher ability to replicate. HCV-RNA constructs with greatly differing replication efficiencies can be selected using the experimental approach described here. The higher the concentration of the antibiotic in the selection medium, in/on which the HCV-RNA construct containing cells are cultivated for selection, the higher 20 must be the extent of adaptive mutations and hence replication efficiency of the relevant HCV-RNA constructs, to allow the cells to grow under these conditions. If the selections are carried out using lower antibiotic 25 concentrations, cells can survive and multiply, but the HCV-RNA construct shows a comparatively lower replication efficiency and fewer adaptive mutations.

As has been shown, the 9-13F HCV-RNA construct described so 30 far, which contains several adaptive mutations, had a higher replication efficiency than the parental HCV-RNA. In order to obtain HCV-RNAs with even higher replication in cell culture, the HCV-RNA contained in the total RNA of a selected cell clone was passaged several times in naive 35 Huh-7 cells. The selected 5-15 cell clone, was obtained by transfection with the HCV-RNA construct I₃₈₉/NS3-3' (Fig. 1). It largely corresponds to the cell clone 9-13, produced

by transfection with a HCV-RNA construct, having a HCV-IRES shorter by 22 nucleotides ($I_{377}/NS3-3'$; Fig. 1). Ten micrograms of total RNA, isolated from cell clone 5-15, were transfected into naïve Huh-7 cells using electroporation and the cells subjected to a selection with 1 mg/ml G418. The total RNA from one of the cell clones thus produced was again isolated, transfected into naïve Huh-7 cells and selected in the same way. This process was repeated a total of four times. After the fourth passage 10 the total RNA was isolated from a cell clone and the neo-HCV-RNA amplified with the aid of the 'long-distance RT-PCR'. The amplified DNA fragment was digested with the restriction enzyme *Sfi*I and inserted into the *Sfi*I-restricted parental construct $I_{389}/NS3-3'$. Over 100 DNA 15 clones were obtained altogether and then analysed by means of restriction digestion. In vitro transcribed RNA of about 80 of these clones was each transfected into naïve Huh-7 cells and subjected to a selection with 500mg/ml G418. Of the 80 neo-HCV-RNA variants examined, the great majority 20 proved to be replication defective. However, the specific infectivity, expressed as 'colony forming units' per microgram RNA, was noticeably increased in the case of two mutants, 5.1 and 19 (Table 2). Through several passages of the RNA in cell culture it is clear that HCV-RNAs are 25 produced whose replication efficiency due to mutations ("adaptive mutations") is several orders of magnitude higher than the original RNA cloned from patients.

(B) Modified method

30

Adaptive mutations produced and identified according to (A) can be transferred into a HCV-RNA construct with low ability to replicate. This leads to a huge increase in the replication of this construct. The increase is so great it can be demonstrated that HCV-RNAs transfected into cell culture can replicate even in the absence of selection pressure. Fig. 12 shows a comparison of the replication 35

efficiency of HCV-RNAs, which corresponded either to the starting sequence or to the adaptive sequences 9-13F or 5.1. For the purposes of simple measurement, the neo-gene was removed and replaced by the gene for luciferase. The negative control used was again a HCV-RNA construct that was replication defective due to a deactivating mutation in the NS5B RNA polymerase. Already 24 hours after transfection a noticeable difference is evident in luciferase activity between the defective RNA and the 9-13F or 5.1 constructs, while hardly any difference could be seen between the defective RNA (318 DN) and the parental RNA construct (wt) that possessed no adaptive mutations. During the whole period of observation, the highest luciferase activity, and thus highest replication, was obtained with the 5.1-RNA. These results not only confirm the high replication efficiency of this RNA, but also show that it is possible to create a cell culture system with adapted HCV-RNA constructs for which the presence of a selectable gene is no longer necessary. A summary of the nucleotide and amino acid differences between the starting construct and the mutants 9-13F, 5.1 and 19 is presented in Table 3.

25 **Example 8: Production of cell culture adapted HCV-RNA full-length genome**

In the examples 1 to 7 a subgenomic HCV-RNA was used which lacked the whole structural protein region from core up to 30 p7 or even NS2. It will be shown in this example that it is possible to make a HCV full-length genome replicate in cell culture with the aid of an adapted NS3-5B sequence. For this purpose the *Sfi*I fragment of the highly adapted HCV-RNA 5.1 produced according to Example 7 is first transferred into a selectable HCV full-length genome (Fig. 35 12). This HCV genome was transfected into naive Huh-7 cells and subjected to selection with various G418

concentrations. Depending on the strength of selection (the G418 concentration), a varying large number of cell clones was obtained (Fig. 12 B). By contrast no colonies were obtained with the parental HCV full-length genome containing no adaptive mutations, as was the case for the negative control, which was replication defective due to a deactivating mutation in the NS5B RNA polymerase. To confirm that the thus resulting cell clones really contained an autonomously replicating HCV full-length construct, total RNA from several cell clones was isolated and analysed by means of the Northern Blot method. The full-length HCV-RNA was clearly detectable in all cell clones (Fig. 12). It is thus clearly confirmed, that with the aid of cell culture adapted HCV sequences it is possible to produce a HCV full-length genome, which replicates highly efficiently and autonomously in a cell line, i.e. adapted HCV full-length genomes can also be produced with the system of the invention. Furthermore, as this clone possesses the complete HCV sequence, i.e. it also possesses the structural proteins necessary for virus particle formation, it is possible to produce large quantities of infectious virus particles in cell cultures with this system. As a confirmation of these viruses, cell-free cell supernatants carrying a replicating HCV full-length genome, are added to naive Huh-7 cells and the thus infected cells subjected to selection with G418. Each cell clone growing under these conditions originates from an infected cell. The viruses in the cell culture supernatant of cells possessing a replicating HCV full-length genome can be enriched and purified using various known state of the art methods such as ultracentrifugation or microdialysis. They can then be used for the infection of naive cells. Using this method it is clearly demonstrated that cell culture adapted full-length genomes can be produced with the HCV cell culture system of the invention. These genomes replicate with high efficiency in cells and produce infectious viruses. The latter can be detected by

infection of an experimental animal, preferably a chimpanzee.

5 **Example 9: Production of HCV full-length constructs and HCV subgenomic constructs with reporter genes**

A HCV-RNA construct is produced in which a reporter gene is inserted in place of the antibiotic resistance gene (Fig. 13). Replication can thereby be determined through the quantity or activity of the reporter gene or reporter gene product. The reporter gene is preferably a gene from the group of the luciferase genes, the CAT gene (chloramphenicol acetyl transferase gene), the lacZ gene (beta galactosidase gene), the GFP gene (green fluorescence protein gene), the GUS gene (glucuronidase gene) or the SEAP gene (secreted alkaline phosphatase gene). This reporter gene and its products, namely the relevant reporter proteins, can be detected for example using fluorescence, chemiluminescence, colorimetrically or by means of immunological methods (for example, enzyme-linked immunosorbent assay, ELISA).

The reporter gene can be expressed either from a separate IRES or in the form of a fusion protein, which is active either as such or fused with a HCV protein via a proteolytically cleavable amino acid sequence in such a way that the reporter is separated from the HCV protein by cleavage of a cellular or viral (HCV) protease.

30

Example 10: Production of HCV full-length constructs with integrated foreign genes used as liver cell specific vectors for gene therapy or as expression vectors

35

The construct (Fig. 14) is transfected in cells and leads to the formation of HCV virus particles that can be used

for the infection of further cells. Since the virus particles have encapsidated RNA with a foreign gene, it can be used in the infected cells for the production of the protein coded by this foreign gene. Cells transfected with 5 the construct also express the foreign gene.

10 **Example 11: Production of monocistronic HCV-RNA constructs**
in which the resistance gene product is
expressed as a fusion protein with the HCV
portion.

15 It is an advantage for some tests if the HCV-RNA construct does not possess a heterologous IRES element. Tests of this type are, for example, the determination of interferon resistance. If a cell possessing a HCV-RNA construct is incubated with interferon alpha or beta, a reduction in replication of the HCV-RNA results. In order to explain the mechanism of this effect it is necessary for the HCV-RNA
20 construct not to possess any heterologous IRES, as otherwise it is not possible to determine whether the interferon mediated inhibition is via inhibition of the HCV replication or inhibition of the heterologous IRES. For this reason constructs are produced for which the
25 resistance gene is fused with a HCV protein (Fig. 15). Either the fusion protein is active as such or the resistance gene product is linked to a HCV protein via a proteolytically cleavable amino acid sequence in such a way that it is separated from the HCV protein by a cellular or
30 viral (HCV) protease.

Table 1: Specific infectivities (cfu/µg RNA) of HCV RNA constructs with adaptive mutations found with the 9-13F mutant introduced into the parental construct I₃₈₉/NS3-3'/wt

| amino acid exchange ¹ | HCV protein | cfu/µg RNA ² |
|---|-------------|-------------------------|
| none | | 30 - 60 |
| 1283 arg -> gly | NS3 | 200 - 250 |
| 1383 glu -> ala | NS3 | 30 - 60 |
| 1577 lys -> arg | NS3 | 30 - 60 |
| 1609 lys -> glu | NS3 | 160 - 300 |
| (1283 arg -> gly + 1383 glu -> ala + 1577 lys -> arg + 1609 lys -> glu) | NS3 | 360 - 420 |
| 1936 pro -> ser | NS4B | 1000-5000 |
| 2163 glu -> gly | NS5A | 1000-5000 |
| 2330 lys -> glu | NS5A | 30 - 60 |
| 2442 ile -> val | NS5A | 30 - 60 |
| all together | | 5000 |

¹ amino acid change in the polyprotein of the HCV isolate con 1 (EMBL-gene bank No. AJ238799); amino acids are given in single letter code.

² Colony forming units (number of cell clones) obtained with a selection of 500 µg/ml G418.

Table 2: Specific infectivities (cfu/µg RNA) of the parental HCV RNA construct I₃₈₉/NS3-3'/wt and the variants 9-13I, 9-13F, 5.1 and 19.

| Transfected RNA variant | cfu/µg RNA ¹ |
|-------------------------|-------------------------|
| wild type | 30 - 50 |
| 9-13 I | 100 - 1.000 |
| 9-13 F | 1.000 - 10.000 |
| 5.1 | 50.000 - 100.000 |
| 19 | 50.000 - 100.000 |

¹ Colony forming units (number of cell clones) obtained with a selection of 500µg/ml G418.

Table 3: Nucleotide and amino acid sequence differences between the parental HCV RNA construct I₃₈₉/NS3-3'/wt and the mutants 9-13I, 9-13F, 5.1 und 19

| Clone | nt-position | nt-exchange | aa-exchange |
|--------|-------------|-------------|-------------|
| 9-13 I | 3685 | C > T | P > L |
| | 4933 | C > T | T > M |
| | 5249 | T > C | - |
| | 8486 | C > T | - |
| | 8821 | G > A | W > stop |
| | 8991 | C > G | R > G |
| | 9203 | A > G | - |
| | 9313 | T > C | F > S |
| | 9346 | T > C | V > A |
| 9-13 F | 3866 | C > T | - |
| | 4188 | A > G | R > G |
| | 4489 | A > C | E > A |
| | 4562 | G > A | - |
| | 4983 | T > C | - |
| | 5071 | A > G | K > R |
| | 5166 | A > G | K > E |
| | 6147 | C > T | P > S |
| | 6829 | A > G | E > G |
| | 7329 | A > G | K > E |
| | 7664 | A > G | I > V |
| NK5.1 | 8486 | C > T | - |
| | 8991 | C > G | R > G |
| | 4180 | C > T | T > I |
| | 4679 | C > T | - |
| | 4682 | T > C | - |
| | 5610 | C > A | L > I |
| | 6437 | A > G | - |
| | 6666 | A > G | N > D |

| | | | |
|------|------|-------|-------|
| | 6842 | C > T | - |
| | 6926 | C > T | - |
| | 6930 | T > C | S > P |
| | 7320 | C > T | P > S |
| | 7389 | A > G | K > E |
| NK19 | 3946 | A > G | E > G |
| | 4078 | C > G | A > G |
| | 4180 | C > T | T > I |
| | 4682 | T > C | - |
| | 5610 | C > A | L > I |
| | 5958 | A > T | M > L |
| | 6170 | T > A | - |
| | 6596 | G > A | - |
| | 6598 | C > G | A > G |
| | 6833 | C > T | - |
| | 6842 | C > T | - |
| | 6930 | T > C | S > P |
| | 7141 | A > G | E > G |
| | 7320 | C > T | P > S |
| | 7389 | A > G | K > E |
| | 7735 | G > A | S > N |

Given are the differences between the nucleotide and amino acid sequences of the parental HCV RNA sequence con 1 (EMBL-gene bank No. AJ238799) and those of the cell culture adapted HCV RNAs. Numbers refer to the nucleotide and amino acid positions of the con 1 isolate. nt, nucleotide; aa, amino acid.

SEQUENCE LISTING

<110> Bartenschläger, Ralf
<120> Hepatitis C Virus cell culture system
<130> ba-1
<140> 199 15 178.4
<141> 1999-04-03
<160> 11
<170> PatentIn Ver. 2.1
<210> 1
<211> 11076
<212> DNA
<213> Hepatitis C Virus
<400> 1
ggcagccccc gattggggc gacactccac catagatcac tccctgtga ggaactactg 60
tcttcacgca gaagcgtct agccatggcg ttagtatgag tgcgtgcag cttccaggac 120
ccccccccc gggagagcca tagtggctcg cggAACCGT gatgacaccg gaattgccag 180
gacgaccggg tcccttcgtt gatcaaccgg ctcacatgcct ggagatttgg gctgtcccc 240
gctgagactgc tagccgatg gtgtgggtc gcgaaaggcg ttgtgtact gctgtatagg 300
gtgtgtcga gtgcggggg aggtctcgta gaccgtgcac catgagcaccg aatctaaac 360
ctcaaaagaaa aaccaaaacgt aacaccaacg ggcgcggcat gatgaaaca gatggattgc 420
acgcagggtc tccggccgtc tgggtggaga ggctattcgg ctatgactgg gcacaaacaga 480
caatcggtcg ctctgtatgcc gcccgttcc ggctgtcgc gcaggggcgc cgggttctt 540
ttgtcaagac cgacccgtcc ggtgcctcg atgaactgca ggacgaggca gcgccgctat 600
cgtggctggc cacgacgggc gtcccttgcg cagctgtct cgacgttgc actgaagcgg 660
gaagggactg gctgttattt ggcgaagtgc cggggcagga tctctgtca ttcacccctt 720
ctctgtccga gaaagtatcc atcatggct atgcaatgcg ggggtgcgat acgcttgcatt 780
cggttaccccg cccatcgac cacaaggca aacatcgcat cgacgagca cgtactccgga 840
tggaaaggccg tcttgcgtat caggatgatc tggacgaaaga gcatcagggg ctcgcggccag 900
ccgaactgtt cgccaggctc aaggcgcgcga tgccgcggcggat cggatgttc gtcgtgaccgc 960
atggcgatgc ctgttgcgcg aatatcatgg tggaaaatgg cccgtttctt gatttcatgc 1020
actgtggccg gctgggtgtg gggggccgt atcaggacat agcgttggct acccggtgata 1080
ttgtgtgaaga gcttggccg gaatggctg accgttccct cgtgttttac ggtatcgccg 1140
ctcccgatttgc acggccatc gccttctatc gccttcttgc cagtttctt tgagttaaa 1200
cagaccacaa cgggttccctt ctatgcggat caattccggc cctctcccttcc cccccccctt 1260
aacgttactg ggcgaagccg ctggaaataa ggccgggtgtg cgtttgcata tatgttattt 1320
tccacccatattgtccgttcc tggcaatgtg agggccggc aacctggccc tgcgttcttgc 1380
acgaggatcc ctagggtctt tttccctctc gccaaggaa tgcacgttct gttgaatgtc 1440
tgcaggaaag cagtttcttgc ggaagcttct tggaaagacaaa caacgttcttgc acgcacccctt 1500
tgcaggcagc ggaacccccc acctggcgac aggtgcctct gggccaaaa gccacgtgtt 1560
taagatacac ctgcacccggc ggcacacccca cagtgccacg ttgtgagtt gatagttgt 1620
gaaagagtca aatggcttcc ctcaaggcgtt ttcaacaagg ggctgtaaagg tgcccgaaag 1680
gtatccccatttgc tgcgttccatc tgcgttccatc catgttttac atgtgtttag 1740
tgcagggtttaa aaaaacgttca ggcccccccgaa accacggggc cgtgttttgc ctttggaaaa 1800
cacgatataa ccatggccac gaatcttataa cctcaaaagaa aaacccaaacg taacaccaac 1860
cgccggccac aggacgttca gttcccgccg ggtgggtcga tcgtcggtgg agtttacccgt 1920
ttggccgcga gggggcccgat gttgggtgtg cgcgcgacta ggaagacttc cgacgggtcg 1980
aaacccctgtt gggccggaca acctatcccc aaggtcgcc agcccgagggg tagggcctgg 2040
gtcgcccttgc ggtaccccttgc gccccttcat ggcacatggg gttttgggttgc gggaggatgg 2100
ttctgtcac cccgtggctc tccgttctatg tggggcccca cggacccccc gctgttgc 2160
cgcaatttgg gtaaggctatc cgtatccctc acgttgcggct tcggccatct catgggttac 2220
tttccgtctcg tccgttccatc ctagggggc gtcgcaggc ccctggcgca tggcgccgg 2280
tttctggagg acggcgatc ctatgcacca gggaaatctc cgggttgc cttttctatc 2340
ttccctttgg tttgtgttgc ctgttttgc accccatgtt cggcttatgtt agtgcgcac 2400
tgcgttccatgt tgcgttccatc cccgggttgc tgcgttccatc ctagggagaa caactctcc 2460
cgccgttccatgt tgcgttccatc tccacgttgc gggccggaggatc acgttgcgttcc cccactacg 2520
cgatgtatc gccatgttgc ttgtgttgc gggccgggttgc tccgttgc cgtatgtac 2580
ttgggagatc tctgtccatc ttttttccatc gtcggccacgc ttttttccatc ttcgttccatc 2640
gggcacggaga cgttacagggc ctgtcaatttgc tcaatatac cggccacgtt gacaggttac 2700
gggcacggaga cgttacagggc ctgtcaatttgc tcaatatac cggccacgtt gacaggttac 2760

cgtatggctt gggatatgat gatgaactgg tcacctacag cagccctagt ggtatcgag 2820
 ttactccgga tcccacaagc tgcgtggat atggggcgg gggcccatg gggagtccta 2880
 gcgggccttg cctactattc catggtggg aactggcta aggttctgat tgtatgcta 2940
 ctctttgccc gcgttgcgg gggacccatgt gacacgggg ggacatggc caaaaacacc 3000
 ctcgggatta cgtcccttctt ttcacccggg tcatccaga aatccagct tgtaaacacc 3060
 aacggcagct ggacatcaa caggactgca ctgaactgca atgactccct caacactggg 3120
 ttcccttgctg cgctgttcta cgtgcacaag ttcaactcat ctggatgccc agagcgcatt 3180
 gcccacgtca gcccacatgca cgcgttcgtc caggggtggg gggccatcac ttacaatgag 3240
 tcacacagct cgacccaggag gccttattgt tggcactacg caccggggcc gtgcgttac 3300
 gtaccgcgg cgcaagggtgt tggccatgt tactgttca ccccaagccc tgctgttgg 3360
 gggacgaccg accgggttcgg cgccctactg tacagggtgg gggagaatga gacggacgtg 3420
 ctgcttcta acaacacgcg gcccggcaaa ggcaactgtt ttggctgtac atggatgaaat 3480
 agcaactgggt tcaccaagac gtgcggggc ccccggtgtt aatcggggg gatcggaat 3540
 aaaaacccatgaa cctgccccac gcgtgttcc cggaaacacc cccggggccat ttacaccaag 3600
 tggtgttccgg ggccttggtt gacacccaga tgcttggcc actacccatata caggcttgg 3660
 cactacccct gcactgtca ctttaccatc ttcaaggta ggtatgtacgt ggggggagtg 3720
 gagcacaggc tcgaagccgc atgcaattgg actcgaggag agcgttggtaa cctggaggac 3780
 agggacagat cagagcttag cccgctgtg ctgttctacaa cggagtgcc ggtattgccc 3840
 tgttccctca ccacccctacc ggctctgtcc actgggttga tccatctcca tcagaacgtc 3900
 gtggacgtac aatacctgtt cggataggg tcggccgttg tctcccttgc aatcaaattgg 3960
 gagatgttcc tggtgttctt ccttcttgc gggacacgcg gcgtctgtgc ctgttgg 4020
 atgtatgtc tgataactca agctgaggcc gcccataagc actctgggtt cctcaacgcg 4080
 gcatccgtgg cccggggcga tggcatttc tcccttctgc tggttcttgc tgctgcctgg 4140
 tacatcaagg gcaggttgcg cccctggggcg gcatatgccc tctacggcgt atggccgtt 4200
 ctccctgtcc tgctggcggtt accaccacgca gcatacgcca tggacccggg gatggcagca 4260
 tcgtgcggag gcgcgggttt cgttaggttg atactcttgc cttgttccacc gcactataag 4320
 ctgttccctcg cttagtctcat atgggtgttca caatattttt tcaccaggcgc cgaggcacac 4380
 ttgcaagtgt ggatcccccc cctcaacgtt cggggggggcc gcatgtccgtt catcctcc 4440
 acgtgcgcga tccacccaga gctaattttt accatcacca aaatcttgcg cggccataactc 4500
 ggttccactca tggtgttccca ggttggata accaaatgtc ctgtacttgcg ggcgcacac 4560
 gggcttattc tgcatgtcat gttggcggg aaggttgcgtt ggggttcatca tgccaatag 4620
 gctctcatga agtggccgc actgacaggt acgtacgtt atgaccatcat cacccttgc 4680
 cgggacttggg cccacgcggg cctacgagac cttgcgttgc cagttgagcc cgtcgttcc 4740
 tctgtatgg agaccaaggat tatcacctgg gggcagacca cggcggcgtg tggggacatc 4800
 atcttggcc tggccgttcc cggccgcagg gggaggggaga tacatctgg accggcagac 4860
 agccttgcgaa ggcgggggtt ggcacttccgc ggccttattt cggcttactc ccaacagac 4920
 cggggcttac ttggctgtcat catcaactgc ctcacaggcc gggacaggaa ccaggctcag 4980
 ggggggttcc aagtggctc caccccaaca caatattttt tggcgttgcgtt cgtcaatggc 5040
 gtgtgttggg ctgttcatca tggtgttccggg tcaaagaccc ttggccggccaa aaggggccca 5100
 atcacccaaa tgacacccaa tggtggaccat gacctctgc gttggcaagc gccccccccc 5160
 ggcgttctt tgacaccatg cacctcgccg agtgcgtacc ttacttggt caccaggcat 5220
 ggcgttca tttccgttgcg cggccggggc gacagcaggg ggagcctact ctccccccagg 5280
 cccgttctt acttgcaggg ctttccgttgc ggttccactgc tctcccttgc ggggcacatc 5340
 gtgggcattt ttcggctgc ctgtgttgcacc cgggggttgc cgaaggccgtt ggactttgt 5400
 cccgtcgttact ctatggaaac cactatgtgg tcccccgttct tcacggacaa ctcgttccct 5460
 cccggccatc cgcagacattt cccgggttgc catctacacg cccctactgg tagcggcaag 5520
 agacttaagg tggccgttgc gtatgcgtcc caagggttgc aggtgttgcgtt cctgaaccccg 5580
 tccgtgcggg ccacccctagg tttccggggc tataatgttca aggacatgg tattgcaccc 5640
 aacatcagaa cccgggttgc gaccatcacc acgggttgc cccatcacgtt ctccacatcat 5700
 ggcaagtttcc ttggccgttgc tggtgttgc tggggccctt atgacatcat aatatgttgc 5760
 gagtgcctact caactgtact gaccatcatc ctggccatgc gcacagtccct ggaccaagcg 5820
 gagacggctg gacgcgttgc ctttccgttgc gacccgttca cggccctccggg atcggtcacc 5880
 gtggccacatc caaactatgttca ggttgggttgc ctgtccacgtt ctggagaaat ccccttttat 5940
 ggcaaaaggca tcccccatttca gaccatcaag gggggggaggc accttattttt ctggcatttcc 6000
 aagaagaatgttgcgttgc cccggccgttgc tggttgc tggactcaat tgctgttgc 6060
 tattaccggg gccttgcgttgc tttccgttgc ccaactatgttca gacgttgcgtt tgctgttgc 6120
 acggacgttgc taatgttgc gtttccgttgc gatgttgcact ctttccgttgc tgcaataata 6180
 tggtgttgcacc acgttgcgttgc ctttccgttgc gacccgttgc ttccatgttgc gacgttgcacc 6240
 gtggccacaaac acgttgcgttgc acgttgcgttgc cccggccgttgc ggttggtagt gggcaggatg 6300
 ggcattttaca ggtttgttgc tccaggagaa cccggccctccgg gcatgttgc ttccttgcgtt 6360
 ctgtgttgcgttgc gtttgcgttgc ggttggtagt tggttgcgttgc ttccttgcgtt cggacacccatc 6420
 gtttaggttgc gggcttgcgttgc aacacccatc ggttggtagt tttccgttgc ggttggtagt ccatctggag 6480
 ttcttggggat ggttggtagt cccggccgttgc tccaggagaa cccggccctccgg gcatgttgc ttccttgcgtt 6540
 aaggcaggccatc gagacaaactt cccggccgttgc tttccgttgc ggttggtagt ggttggtagt ggttggtagt 6600
 gtcaggccgttgc cccggccgttgc tttccgttgc ggttggtagt ggttggtagt ggttggtagt ggttggtagt 6660
 acgttgcgttgc gggccacccatc ggttggtagt ggttggtagt ggttggtagt ggttggtagt ggttggtagt 6720
 accacacacccatc ccataacccatc atacatcatgt gcatgttgcgtt ggttggtagt ggttggtagt 6780

ctactttctg taggggttagg catctatcta ctccccaacc gatgaacggg gagctaaaca 10860
ctccaggcca atagggccatc ctgtttttt ccctttttt ttttctttt tttttttttt 10920
ttttttttt ttttttttc tcctttttt ttccctttt ttccctttc ttccctttgg 10980
tggctccatc ttagccctag tca^cggctag ctgtgaaagg tccgtgagcc gcttgactgc 11040
agagagtgc gatactggcc tctctgcaga tcaagt 11076

<210> 2
 <211> 8637
 <212> DNA
 <213> Hepatitis C Virus

<400> 2
 gccagccccc gattggggc gacactccac catagatcac tcccctgtga ggaactactg 60
 ttttcacgc gaaagcgtct agccatggcg ttgtatgag tgcgtgcag cctccagac 120
 ccccccctcc gggagagcca tagtggctctg cggAACCGT gagtacaccg gaattgcac 180
 gacgaccggg tccttcttgc gatcaacccg ctaatgcct ggagatggc gcgtgcccc 240
 gcgagactgc tagccgatg gtgtgggtc gcgaaaggcc ttgtgtact gcctgatagg 300
 gtgcttgcg gtcggccgg aggttcgtca gaccgtgcac catgagcacg aatcctaaac 360
 ctcaaaagaaa aaccaaaggc cgccgcatga ttgaacaaga tggattgcac gcaggttctc 420
 cggccgctt ggtggagagg ctatccggct atgactggc acaacagaca atccgctgtc 480
 ctgatggcg cgtttccgg ctgtcagcgc agggcgccc gtttctttt gtcaagacgg 540
 acctgtccgg tgcctgtaaat gaaactgcagg acgaggcgc gggctatcg tggctggca 600
 cgacggcggt tccttgcgca gctgtctcg acgttgcac tgaagcggg 660
 tgcttattgg cgaagtgcgg gggcaggatc tcctgtatc tcaccttgc 720
 aagtatccat catgctgtat gcaatgcggc ggctgcatac gttgtatccg 780
 cattcgcac ccaagcgaaa cattgcacatc acgcgacgcg tactcggtc 840
 ttgtcgtatca ggtatgtctg gacgaagagc atcagggtct cggccagcc 900
 ccaggcttca ggcgcgcatg cccgacggcg aggttcgtc cgtgacccat 960
 gcttgcggaa tattatgtgt gaaaatggcc gctttctgg attcatgcac tggccggc 1020
 tgggtgtgc ggaccgctat caggacatac cgttgcatac cgtgatatt gtcgaagac 1080
 ttggccggca atggctgac cgttctctcg tgcttacgg tattgcgcgt cccgattcgc 1140
 agcgcacatgc cttctatcgc cttcttgacg agttcttctg agtttaaaca gaccacaacg 1200
 gtttccctct agccggatcatc tttccggccccc tttccctcccccctaa cgttactggc 1260
 cgaaggcgt tggataaagg cgggtgtgcg ttgttataat ttttc cccatatttgc 1320
 cccgttttgc gcaatgttag gggccggaaa cctggccctg tttttgcac gaggatccct 1380
 aggggtctt cccctctcgc caaaggatg caaggctctgt tgaatgtcgt gaaaggac 1440
 gttcctctgg aagttcttg aagacaaaca acgtctgtac cggcccttgc 1500
 aaccccccac ctggcgacag gtgcctctgc ggcggaaagc cactgtata agataacacct 1560
 gcaaggcg gcaacccca gtgccacgtt gtgagttgg tagttgtgg aagagtcaaa 1620
 tggctctctt caagcgattt caacaagggg ctgaaggatg cccagaaggat 1680
 atgggatctg atctggggcc tgggtgcaca tgcttacat gtttttagtc gaggttaaaa 1740
 aacgtctagg ccccccgaac caccggggac tggtttctt ttgaaaaaca cgataatacc 1800
 atggaccggg agatggcgc atcgtgcgg ggcgggttt tcgttagttt gataactctt 1860
 accttgcac cgcactataa gctgttccctc gctaggctca tattttgtt acaatatttt 1920
 atcaccaggc ccgaggcaca ttgcacatgt tggatcccccc cctcaacgt tcggggggc 1980
 cgcgttgcgc tcatcttgc cactgtgcgc atccacccag agtaatctt taccatcacc 2040
 aaaatcttgc tgcctataact cggtccactc atggcttcc aggtgttat aaccaaagt 2100
 ccgtacttcg tgcgcgcaca cgggctcatt cgtgcacgc tgctggcgc gaaagggttgc 2160
 gggggtcat atgtccaaat ggctctcatg aagttggccg cactgacagg tacgtacgtt 2220
 tatgaccatc tcacccact gggggactgg gcccacgcg gcctacgaga ctttgcgtt 2280
 gcagttgacg cctgtctt ctgtatatg gagaccaagg ttatcacatc gggggcagac 2340
 accggccgtt gtggggatcatcttggc cttccctctt cccggccgcg gggggaggag 2400
 atacatctgg gacccgcaga cagcccttga gggcagggtt ggcactctt cgcgttattt 2460
 acggcctact cccacacac ggcggccata cttggctgc tcatcactag cttcacaggc 2520
 cgggacacca accaggtcga gggggaggtc caagtgtct ccacccgac acaatctt 2580
 ctggcgaccc gctcaatgg cgtgttttgc actgtctatc atgtgcggc tccaaagacc 2640
 cttggccggcc caaaggggccc aatcacccaa atgtacacca atgtggacca ggacctcgtc 2700
 ggctggcaag cggcccccgg ggcgggttcc ttgacccat gcacctgcgg cagctcgac 2760
 cttaacttgc tcaacggggc tggcgtatgc atccgggtc gcccgggggg cgtacgcagg 2820
 gggggcttac tctccccccat gggcgatctc tacttgcagg gctttccggg cggtccactg 2880
 ctctggccctt cggggcgcgc tggggatcatc tttccgggtc cctgtgcac cggagggtt 2940
 gcaaggcgg tggactttgt accccgtcgat tctatggaaa ccactatgc gttccggc 3000
 ttcacggaca actcgcccc tccggccgtt cccggacat tccagggtgc ccatctacac 3060
 gcccctactg gtatggccaa gacactaag gtggccgtc cgtatgcac ccaagggtat 3120
 aagggtcttgc ttctgaaccc gtcgtgcgc gacccctatc gtttccgggc gtatatgtct 3180
 aaggcacaatg gtatcgaccc taacatcaga accggggtaa ggacccatcac cacgggtgc 3240
 cccatcatgt actccacca tggcaagttt cttggccgtc gttgttgc tggggggc 3300
 tatgacatca taatatgtga tgatgtccat tcaactgtact cggccactat cttggggcatc 3360
 ggcacatgtt tggaccaagg ggacccggct ggacccgcac tcgtgtgcgc cggccaccgt 3420
 acgcctccgg gatcgatccac cttggccacat ccaacatcg agggagggtgc tctgtccac 3480
 actggagaaa tcccccttta tggcaagcc atccccatcg agacccatcaa gggggggagg 3540
 cacctcattt tctggccatcc caagaagaaa tggatgtac gtcggccgaa gctgtccggc 3600

ctcggactca atgtgttagc atattaccgg ggcctgtat tatccgtcat accaactagc 3660
 ggagacgtca ttgtcgtagc aacggacgtc ctaatgacgg gcttaccgg cgatttcgac 3720
 tcagtgtatc actgcaatac atgtgtcacc cagacagtgc acttcagcct ggacccgacc 3780
 ttcaaccattt agacgacgac cgtgcaccaa gacgcgggtg caccgtcgca gcggcgaggc 3840
 aggactgtt gggcaggat gggcattttc aggttgttga cttcaggaga acggccctcg 3900
 ggcgtatgtcg attctctgtt tctgtcgtag tgctatgtac cgggtgtgc ttgttacgag 3960
 ctcacgccc cggagacccc agtttagttt cgggttacc taaacacacc aagggttggcc 4020
 gtctgcagg accatcttga gttctggggag agcgttta caggcctcacc ccacatac 4080
 gcccatttct tgcctccagac taagcaggca ggagacaact tcccttaccc ggttagcatac 4140
 caggctacgg tgcgtccag ggctcaggctt ccacccat cgtgggacca aatgtggaa 4200
 tgcgttccatc ggctaaagcc tgcgtgcac gggcaacgc ccctgtgtt taggctggg 4260
 gccgttccaa acgagggttac taccacacac cccataacca aatacatcat ggcgtatc 4320
 tcggctgacc tggagggtcg tgcggacacc tgggtgtgg taggcggagt cctagcact 4380
 ctggcccggtt attgttgcac aacaggcgcgt gtgttgcattt tggcggaggat catcttgc 4440
 ggaaaggccgg cccatccatcc cgcacgggaa gtccttacc gggagttcgat tgatggaa 4500
 gagggtccctt cccatccatcc tccatcgaa caggaaatgc agctcgccgaa acaattccaa 4560
 cagaaggca tcgggttgc gcaaacagcc accaagcaag cgaggctgc tgctccctg 4620
 gtggaaatcca agtggcgac ctcgaagcc ttctggcga agcatatgtg gaatttcatc 4680
 agcgggatac aatattttagc aggttgtcc actctgcctt gcaacccccc gatagcatca 4740
 ctgtatggcat tcacagcctc tattaccaggc cccgttccatcca cccaaacatac cctctgttt 4800
 aacatcttgg gggatgggt gggccggccaa cttgttccctt ccacgcgtgc ttctgtttc 4860
 ttagggccggc gcatcgcttgg agcgggtgtt ggcagcatg gcttggggaa ggtgttgg 4920
 gatattttgg cagggtatgg agcgggggtt gcaaggccgc tctgtggctt taaggctatg 4980
 agcggcgaga tgccctccac cggaggcttgc tttaatcttac tccctgttat cctctccct 5040
 ggcgccttag tcgttgggggt cgtgtcgca gcgataactgc gtcggcacgt gggcccaagg 5100
 gagggggctg tgcaatggat gaaacggctg atagcgttgc ttctggggggtaaaccacgc 5160
 tccccccacgc actatgtgcc ttagagcgcac gtcgcacac gtgtcactca gatctctct 5220
 agtcttacca tcaactcagct gtcgaagagg cttcaccatg ggtatcaacga ggactgtcc 5280
 acgcatatgc cccgttccatc gtcgaagagat gtttgggatt ggatatgcac ggtgttgc 5340
 gatttcaaga cctgttccca gtcgaatgc ctgcggcatg tggggggatggc ttcttttc 5400
 tcatgttcaac tggtgttccaa gggagtctgg cggggccgc gcatatgc tggggccct 5460
 ccatgtggag cagatcacc cggacatgtt aaaaacgggtt ccatgaggat cgtggggccct 5520
 aggacctgtt gtaacacgtt gcatggaaaca ttccccatca acgcgtacac cacggccccc 5580
 tgcacggccct cccggccgc aattatttttctt agggcgctgtt ggggggtggc tgctgaggag 5640
 tacgtggagg ttacgggtt gggggatttc cactacgttgc cgggcgttgc aaccacgtc 5700
 gtaaaatgtcc cgtgtcaggat tccggccccc gaattttca cagaagtggc tgggggtccgg 5760
 ttgcacaggat acgctccacgc gtcgaacacc ctcctacggg aggagggtcac attcttgc 5820
 gggctcaatc aatacctgtt tgggttccacag cttccatgcg agcccgaaacc ggacgtagca 5880
 gtgttcaatc ccatgttccac cggcccttc caccatcgat cggagacggc taagcgtagg 5940
 ctggccaggat gatctccccc ctctttggcc gatctatcgat ctggccatgc tctgtccct 6000
 tcccttggagg caacatgcac taccatgttcat gactccccc acgcttgcattt catcgagcc 6060
 aaccttctgtt ggcggcagga gatggggggg aacatccacc ggtggagtc agaaaataag 6120
 gtagtaattt tggactctt cggccgttcc caagcgaggagg aggtatggag ggaagtatcc 6180
 ttcccgccgg agatctgtt ggggtccagg aaattccctc gagcgatgcc catatggca 6240
 cggccggatt acaacccttcc actgtttagag tccctggaaagg accccggacta cgtcccttcca 6300
 gtgttacacgc ggtgttccat ggcgcctgc aaggcccttc gcataccacc tccacggagg 6360
 aaggaggacgg ttgttctgtt agaatctacc gtgttcttgc ctttggggat gtcggccaca 6420
 aagacccttcg gcaatcccgat cttgttggcc gtcgcacgcg gcaacggcaac ggccttcttcc 6480
 gaccggccctt cggacgacgg cgacgcgggat tccgcacgtt agtgcgtactc ctccatgc 6540
 ccccttggagg gggagccggg ggttcccgat tccacgcgcg ggttcttgc taccgttacgc 6600
 gaggaggctt gtcggggatgt ctgttgcgtc tcgtatgttca acacatggatc aggccctctg 6660
 atcacggccat gtcgttgcggat gggaaaccaatg ctggccatca atgcactgtt caactcttt 6720
 ctccgttccat acaacttggat ctatgttacatc acatctgcac ggcgttgcctt gcccggaaag 6780
 aagggttccat ttcgtatgttgc gcaatgttgc gacgaccact accccggactt gctcaaggag 6840
 atgttgcgttccatc aggttgcgttccat aacacttccat ctcgttgcggat gtcgttgc gtcctgttacgc 6900
 ctgttgcgttccatc cccatcgatc cccatcgatc tttggatgtt gggcaaaaggatc gtcggggaaac 6960
 ctatccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc gcaagacact 7020
 gagacccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc ccaaccacgg 7080
 aaggggggccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc tcgttgcgttccatc 7140
 gagaaaaatgg cccttttacgtt gtttttttgc accctccctc aggccgttgc gggcttccatc 7200
 tacggatttttccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc ctggaaagcg 7260
 aagaaatgtccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc ggttactgag 7320
 aatgttgcgttccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc cgaagccaga 7380
 caggccatcaggatccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc taatttcaaa 7440
 gggcagaacttccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc cagctgcgg 7500
 aatacccttcatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc gtccttgc 7560
 tgcacgttccatcaggatccatcaggatccatc tttggatgtt gggcaaaaggatc gtccttgc 7620

gaggacgagg cgagcctacg ggccttcacg gaggctatga ctagatactc tgccccccct 7680
ggggaccgc ccaaaccaga atacgactg gagttgataa catcatgctc ctccaaatgtg 7740
tcagtcgcgc acgatgcate tggcaaaagg gtgtactata tcacccgtga ccccaccacc 7800
ccccttgcgc gggtgcgtg ggagacagct agacacactc cagtcaattc ctggcttagc 7860
aacatcatca tgtatgcgc caccctgtgg gcaaggatga tcctgtatgc tcatttcttc 7920
tccatccttc tagtcagga acaacttggaa aaaggccctag attgtcagat ctacggggcc 7980
tgttactcca ttgagccact tgacctaccc cagatcatc aacgactcca tggccttagc 8040
gcatttcac tecatagttt ctctccaggt gagatcaata ggtggcttc atgcctcagg 8100
aaacttgggg taccgcctt gcgagtctgg agacatcggg ccagaagtgt ccgcgctagg 8160
ctactgtccc agggggggag ggctgcccact tggcaagt acctcttcaa ctgggcagta 8220
aggaccaagc tcaaactcac tccaaatccc gctgcgtccc agttggattt atccagctgg 8280
ttcgttgcgt gttacagcg gggagacata tatcagccctg tgcgtgc cggacccgc 8340
tggttcatgt ggtgcctact cttactttct gtgggttag gcatctatct actcccaac 8400
cgatgaacgg ggagctaaac actccaggcc aataggccat cctgtttttt tccctttttt 8460
tttttctttt tttttttttt tttttttttt tttttttttt ctccctttttt ttccctctttt 8520
ttttccctttt ctccctttt gggctccat cttagcccta gtcacggcta gctgtgaag 8580
gtccgtgagc cgcttgactg cagagagtgc tgatactggc ctctctgcag atcaagt 8637

<210> 3
<211> 8001
<212> DNA
<213> Hepatitis C Virus

<400> 3

gcccccccccc gattgggggc gacactccac catagatcac tccccctgtga ggaactactg 60
tcttcacgca gaaacgtct agccatggcg ttatgtatgag ttcgtgcag cctccaggac 120
ccccccctccc gggagagcca tagtggctcg cggaaagggt gatcacccg gatgtttgg gctgtcccc 180
gacgaccggg tccttcttg gatcaacccg ctcacatgcct ggagattttgg gctgtcccc 240
gcgagactgc tagccgatgta gtgttgggtc gcaaaaggcc ttgtggtaact gctgtatagg 300
gtgcttgcga gtgcggccggg aggtctcgta gaccgtgcac catgagcacg aatcctaaac 360
ctcaaaagaaa aaccaaacgt aaccaacg ggcgcgcct gatgtttgg gatggatgtc 420
acgcagggtc tccggccgt tgggtggaga gcttattcgat ctatgactgg gacaacaga 480
caatcggtcg ctctgtatgc ggcgttccc gctgtcagc gcaaggggcgc 540
ttgtcaagac cgaccgttcc ggtgcctgtg atgaaactgtca ggacaggca gcaacacaga 600
cgtggcttgc cacgacgggc gttccttgcg cagctgtgtc cgacgttgc 660
gaagggactg gctgttattg ggcgaagtgc cggggcagga ttcctgtca ttcacccctt 720
ctccgtccga gaaagtatcc atcatggctg atgcaatgcg gcccgtcat acgcttgatc 780
cggttacccg cccattcgac caccaagcga aacatcgat cgacgcagca cgtactcgga 840
tggaaaggccg tcttgcgtat caggatgtatc tggacgaaaga gcatcaggggg ctcgcgcag 900
ccgaaactgtt cgcagggtc aaggcgcgcg tggccgcgg cgaggatctc gtcgtacccc 960
atggcgatgc ctgttgcgg aatatcatgtt tgaaaatgg cgcgttcttgc gattcatcg 1020
actgtggccg tgggtgtg gggacggct atcaggacat acgttggct accecgatata 1080
ttgtctgaaga gcttggcgcc gaatgggtgt accgttccct cgtgttttac ggtatcgccg 1140
ctcccgattc gcagcgatc gccttctatc gccttcttgc ctagttcttc tgatgtttaaa 1200
cagaccacaa cggttccctt ctagcggtat caattccggcc ccttccctc cccccccctt 1260
aacgttactg gccgaagccg ctggaaataa ggccgtgtg ctgttgcata tattgttattt 1320
tccaccatat tgccgtctt tggcaatgtg agggcccgaa aacctggccc tgcttctt 1380
acgagccatc ctagggttct ttcccctctc gccaaaggaa tgcaagggtt gttgaatgtc 1440
gtgaaggaag cagtctctt ggaaggttct tgaagacaaa caacgtctgt agcgaccctt 1500
tgcaggcgc gaaacccccc acctggcgac aggtgtctt gggccaaaa gccacgtgtt 1560
taagatcac ctgcaaaaggc ggcacaaaccg ctagcggac gttgtggatg gatagttgt 1620
gaaagagtca aatgctctc ctcaagcgta ttcaacaagg ggtgtggaa tgcccaag 1680
gtacccctt gtatggatc tgatctgggg ctcgggtcata catgttttac atgttttag 1740
tcgagggttaaaa acgtcttgc gcccccccgaa accacggggg cgtgtttttc ctttggaaaa 1800
cacgataata ccatggcgcc tattacggcc tactcccaac agacgcgagg cctacttggc 1860
tgcatacatca ctggctcac aggccgggac aggaaccagg tcgaggggga ggtccaagtg 1920
gtctccacccg caacacaaatc ttccctggcg acctcgctca atggctgtg ttggactgtc 1980
tatcatgggt cccgtcaaa gacccttgc ggcacaaagg gcccaatcac cc当地atgtac 2040
accataatgttgg accaggacat cgtcggtcg caacgcggcc cccggggcgcc ttcccttgaca 2100
ccatgcaccc tggccgacgtc gacccatttc tggtcaca ggcacccgtt gttcattcg 2160
gtgcggccg gggccgacag cagggggagc ctactctcc caaggcccgat cccctacttg 2220
aagggtctt cggccgttcc actgtctctgc ccctcgggcc acgtgttgg catcttccg 2280
gtgcgggtgt gcaccccgagg gtttgcgaag ggggtgtact ttgtacccgt cgagtctatg 2340
gaaaccacta tgcggtcccc ggttctcagc gacaactcgat ccgttccggc cgtaccgcac 2400
acattccagg tggcccatct acacgcccct actgttagcg gcaagacac taagggtccg 2460
gtgcgtatg cagcccaagg gataaagggtt cttgtcttgc acccgccgtt cggccgcacc 2520
cttaggtttcg gggcgatataat gtctaaaggca catgttatcg accctaatacat cagaaccggg 2580
gttagggatca tcacccacggg tggcccttccat acgtacttca cctatggcaaa gtttcttggcc 2640
acggcggtt gcttggggg cccatgtac atcataatat gtgtatgtg ccactcaact 2700
gactcgacca ctatccgtgg categggaca gtccttgacc aaggcgagac cggctggagcg 2760
cgactcgctg tgctcgccac cgtacgcttccat gtcgttgc gatgtatccat 2820
atcgaggagg tggctctgtc cagcacttggaa gaaatccctt tttatggcaaa acatccaaac 2880
atcgagacca tcaagggggg gaggcacctc atttctgca atttcaagaa gacccatcccc 2940
gagctcgccg cgaaagtgtc cggccctcgaa ctcaatgtg tagcatatta gggggccctt 3000
gatgtatccg tcataccaaac tagcggtggac gtcattgtcg tagcaacggaa cgctctaatt 3060
acgggttttca cggcgatattt cgtactcgatg atcgactgca atacatgtt caccctggaca 3120
gtcgacttca gcttggaccc gaccccttccat attgagacga cgaccgtgc acaagacgcg 3180
gtgtcgacgt cggccggcc agcgaggact ggttagggca ggtatggcat ttacagggtt 3240
gtgactccag gagaacggcc ctcggccatg ttgcattctt cgggttctgtg cgagtctat 3300
gacgggggtt gtgttggta cgtacgttccat cccggccaga ctcaggatgat gttgggggtt 3360
tacctaaaca caccagggtt gcccgtctgc caggaccatc tggatgttgc gggagacgtc 3420
tttacaggcc tcacccacat agacgcccatt ttcttgcata agactaagca ggcaggagac 3480
aacttccctt acctgttagc ataccagggtt acgggtgtcg ccagggtctca ggctccaccc 3540

ccatcggtgg accaaatgtg gaagtgtctc atacggctaa agcctacgct gcacgggcca 3600
 acggccctgc tgtataggct gggagccgtt caaaacgagg ttactaccac acacccata 3660
 accaaataca tcatggcatg catgtcggt gacctggagg tcgtcacgag cacctgggt 3720
 ctggtaggcg gagtcttagc agctctggcc gcgtattgcc tgcacaacagg cagcgtgtc 3780
 attgtggca ggatcatctt gtccggaaag cccggccatc ttcccgacag ggaagtccct 3840
 taccgggagt tcgatgagat ggaagagtgc gcctcacacc tcccttacat cgaacaggaa 3900
 atgagctcg cggaaacaat caaaacgagg gcaatcggt tgctgaaac agccaccaag 3960
 caaggcgagg ctgctgctcc cgtgggtggaa tccaaatggc ggacccctcg agccttcgg 4020
 gcaagcata tggatattt catcaacggg atacaatatt tagcaggctt gtccactctg 4080
 cctggcaacc cccgatagc atcactgatg gcattcacag cctctatcac cagccgctc 4140
 accacccaaac ataccctctt gtttaacatc ctggggggat ggtggccgc ccaacttgct 4200
 cctcccaacg cgtggctctgc ttctcgtaggc gccggatcg ctggagcg 4260
 ataggccctg ggaagggtgct tggatattt tggcagggtt atggaggagg ggtggcaggc 4320
 ggcgtctgg ctttaagggtt catgacggc gagatggccct ccacccggaga cctggtaac 4380
 ctactccctg ctatctctc cccctggccct ctgtcggt ggtgtgtg cgcagcgata 4440
 ctgcgtggc acgtggggccc aggggagggg gctgtcgat ggtgaaccg gctgatacg 4500
 ttgcgttccg ggggttaacca cgtctccccc acgcactatg tgccctgagag cgacgctgca 4560
 gcacgtgtca ctcagatctt ctctagttt accatactc agctgtgaa gaggcttcac 4620
 cagtggatca acgaggactg cccacacgcca tgcgtccggc cgtggctaaag agatgtttgg 4680
 gatggatat gcacgggtt gactgattt aagacccggc tccagttccaa gtcctgtcc 4740
 cgattggccgg gaggccctt ctctctatgt caacgtgggtaa acaaggaggat ctggggggc 4800
 gacggcatca tgcaaaaccac ctgcccattt ggacacaga tcacccgaca tggaaaac 4860
 ggttccatgtt ggtatggggc gcttagggacc tggatgttca cttccactac 4920
 attaacgcgtt acacccacggg cccctgcaccc cccctcccg cggccaaatata ttcttagggcg 4980
 ctgtggccgg tggctgttca gggatgttca gggatgttccggc ggttgggggta tttccactac 5040
 gtgacgggca tgaccactga caacgtaaatg tgccctgtc aggttccggc ccccgaaattc 5100
 ttcacagaatg tggatggggc gctgggtgcac aggtacgtc cagcgtgtca accccctcta 5160
 cggggaggagg tcacatttcc ggtcggttcc aatcaatcc tggatggggc acagctccca 5220
 tgcagcccg aaccggacgt agcgtgtcc acttccatgc tcaacggaccc ctggccacatt 5280
 acggccggaga cggctaaacg taggtgtggc agggatgtcc cccctccctt tcatgactcc 5340
 tcagctatcc agctgtctgc gcttccatgtt aaggcaatc gcacatcccg cggacgtcg 5400
 cccggacgtt acctctatgc ggcacccatc ctgtggccggc agggatgtgg gctcaagatc 5460
 accccgtgg agtcagaaaa taaggttagt attttggact tttccagggc gtcggatgtt 5520
 gaggaggatg agggaaatgt atccgttccg gctggatgtcc tgcggatgtt caggaaattc 5580
 cctcgagcg tggccatatg ggcaccccg gattacaacc ctccactgtt agatccctgg 5640
 aaggaccgg actacgtccc tccagttgtt cacgggtgtc cattggccgc tgccaaaggc 5700
 cctccgatatac caccatccacg gggatgtggc acgggtgtcc tggatgttcc taccgtgtt 5760
 tctggcttgg cggatgtcg cacaaggaccc ttcggatgtt cggatgtcg ggcgtcgac 5820
 agccggacgg cggatgtcg tccgtggacc ccctccggc acggatgtcg gggatccgac 5880
 gttgaatgtt actctccat gggccctt gggatgtggc cggatgttcc cggatgtcg cgtatctc 5940
 gacgggttcc ggttaccgtt aaggcggggg gcttaggtgg acgtcgatgtt ctgctcgatg 6000
 tcctacacat ggacaggccg cctgtatccacg ccgtcgatgtt cggaggaaac caagctgccc 6060
 atcaatgcac tgaccaactc ttgtctccgtt caccacaaat tggatgttcc tacaacatct 6120
 cgcagcgaa gcctggccgca gaaagggtc acctttgaca gactgcagggtt cctggacac 6180
 cactaccggg acgtgtctaa ggagatgttca gggatgttcc gcaacgtttaa ggctaaactt 6240
 ctatccgtgg aggaaggctt taaggtgttcc ccccccattt cggccatgtt taaatggc 6300
 tatggggcaaa aggacgttcc gaaacctatcc agcaaggccg taaaccatcat cccgtccgt 6360
 tggaggact tggatggaaatc cactgttccatc ccaatttgcac caccatcatc gcaaaaaat 6420
 gagggtttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc ttcgttcc ttcgttcc 6480
 cctcaggccg tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 6540
 ttccctggta atgctgttccaa gggatgttcc tttccatactt ctccgttcc gcccgttcc tccgttcc 6600
 tggatgggttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 6660
 tggatgggttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccgttcc 6720
 tggatgggttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 6780
 gggggccccc tgacttaccatc taaaggccatc aactgtggcc atggccgtt cccgtccgt 6840
 ggtgtactgtt gggatgttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 6900
 tggatgggttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 6960
 atctgttccaa gggatgttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7020
 atgacttagat actctccccc ccctggggac ccggccaaatc cggatgttcc tttccatactt ctccgttcc 7080
 ataacatcat gtcctccaa tggatgttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc 7140
 tatctccatcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7200
 actccatgttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7260
 atgatccatcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7320
 ttaggttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7380
 attcaacatcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7440
 aatagggtgg tttccatactt ctccgttcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc 7500
 cggggccatcc tggatgggttcc ttcataccgg tttccatactt ctccgttcc gcccgttcc tccacccttc 7560

aagtacctct tcaactgggc agtaaggac^c aagctcaa^ac tcactccaa^t cccggctgc^g 7620
tcccagt^tgg atttatcc^ag ctgg^ttcgtt gctgg^ttaca g^cggggggaga catata^tcac 7680
a^gc^ctgt^ttc^t gtggccgacc ccgctgg^ttc atgtgg^tg^cc tactcctact ttctgt^tagg^g 7740
gtaggcatct atctactccc caaccgat^ga acggggagct aaacactcc^a g^gccaa^tagg^t 7800
ccatcc^tgtt ttttcc^ttt tttttttt^tcc tttttttt^ttt tttttttt^ttt tttttttt^ttt 7860
ttttcc^ttt ttttttcc^ttt tttttttt^tcc tttttttt^tcc ttgg^tgg^tct ccatcttagc^t 7920
cttagt^tcac^t g^tctag^tgt^tg aaagg^tccgt^t gagc^tcgct^tg actgc^tagaga^t gtgct^tatac^t 7980
tggcctctct^t g^cagat^tcaag^t 8001

<210> 4
 <211> 7989
 <212> DNA
 <213> Hepatitis C Virus

<400> 4
 gccaaggcccc gatttggggc gacaactccac cataagatcac tccccctgtga ggaactactg 60
 ttttcacgca gaaacgcgtct agccatggcg ttagttaga tgcgtgcag cctccaggac 120
 cccccctccc gggagagcca taatggctcg cggaaaccgt gagtacaccg gaattggccag 180
 gacgaccggg tccttcttgc gatcaacccg ctcaatgcct ggagatttg gctgtcccc 240
 gogagactgc tagccgagta gtgttgggtc gctgaaaggcc ttgtgtact gctgtatagg 300
 gtgttgcga gtgtccccc aggtctcgta gaccgtgcac catggacacg aatcctaacc 360
 ctcaaaagaaa aaccaaaaggc cgcgcctatg ttaaacaaga tgattgtcac gcaaggtttc 420
 cggccgcttgc ggtggagagg ctattcggt atgactgggc acaacagaca atcggctgtc 480
 ctgatggccg cgtgtccgg ctgtcagcgc agggggcccc gtttctttt gtaaagaccc 540
 acctgtccgg tgcctctgaa gaaactgcagg acgaggcgc gcccgtatcg tggctggcca 600
 cgacggccgt tccttgcga gctgtctcg acgttgtcac tgaagcggga agggactggc 660
 tgctattggg cgaatgtccg gggcaggatc tcctgtcata tcaccttgc cctggccaga 720
 aagtatccat catggctgtat gcaatgcggc ggctgcatac gtttgcattc gctacgtcc 780
 cattcggcca ccaagcgaaa catcgccatcg acgcggcgc tgcgtggatg gaagccggtc 840
 ttgtcgatca ggtatgtcg gacgaaagagc acgtgggtc cgcgcgcagg gaaactgttc 900
 ccaggctca ggcgcgcatg cccgacggcc aggtatctcg ctgtgaccat ggcgtatgc 960
 gcttgcggaa tatcatgttg gaaaatggcc gtttttctgg attcatcgac tggccggc 1020
 tgggtgtggc ggaccgctat caggacatag ctgtgctac ctgtgatatt gctgaagagc 1080
 ttggccggca atgggtcgac ctgttctcg tgcttacgg tatggccgtc cccgatttcg 1140
 agcgcatcgc ttcttacgc ttcttgcacg agttcttcg agtttaaaca gaccacaaacg 1200
 gtttccctct agcgggatca attccggcccc tctccctccc ccccccctaa ctgtactggc 1260
 cgaagccgt tggaaataagg cccgtgtgc tttgttata tggatattt caccatattg 1320
 ccgttcttgc gcaatgtgag gggccggaaa cctggccctg ttttttttgc gacgttcc 1380
 aggggtcttt cccttctcg caaaggaaatg caaggctcg tgaatgtcg gaaggaagca 1440
 gttctctgg aagcttcttg aagacaaaca acgtctgtag cgaccctttg caggcaggcg 1500
 aaccccccac ctggcgacag gtgcctctgc ggccaaagc cactgttata agatacacc 1560
 gcaaaaggcc cacaacccca gtgccacgtt gtgagttga tagttgttga aagagtcaaa 1620
 tggctctctt caagctgtt caacaagggg ctgaaggatg cccagaaggat acccattgt 1680
 atgggatctg atctggggcc tcgggtgcaca tgctttatcg tggtttagtc gaggtaaaaa 1740
 aacgtctagg ccccccgaac cacggggacg tggttttctt ttgaaaacaatcgatc 1800
 atggcgctta ttacggctta ctcccaacacg acgcggaggcc tactttgtcg catcatact 1860
 agcctacacg gcccggacag gaaccggcgtt gaggggagg tccaaatgttgc 1920
 acacaatctt tcctggcgac ctgcgtcaat ggcgtgtgtt ggactgtcta tcatgggtgc 1980
 ggctcaaaga cccttgcgg cccaaaggcc ccaatcaccc aaatgtacac caatgtggac 2040
 caggacctcg tcgggtggca agcgcggcccc gggcgcgtt cttgacacc atgcacccgtc 2100
 ggcagctcg acctttactt gtcacgagg catgcgcgtt tcattccgtt ggcgttcc 2160
 ggcgcacagca gggggaggct actctccccc agggccgtt cctacttgaa tgccgttcc 2220
 ggcgttccac tgctctggcc ctgggggcac gctgtggca ttttccggc tgccgtgtgc 2280
 acccgagggg ttgcgaaggc ggtggactt gtaccctcg agtctatgg aaccactatg 2340
 cgggtccccc ttcttacggca caactctcg cttccggccg taccgcagac attccagtg 2400
 gccccatctta acgcctctac ttgttgcggc aagacacta aggtggccgc tgctatgc 2460
 gccccaaagggt ataagggtct tgctctgaaac cctgcgtcg cccgcaccctt aggtttccgg 2520
 gctgtatatgt ctaaggcaca ttgtatcgac cctaacatca gaaccgggggt aaggaccatc 2580
 accacgggtt cccccatcac gtactccacc tatggcaagt ttcttgcga cgggtgttc 2640
 tctggggccg cctatgacat cataatatgt gatggatgtc actcaactga ctcgaccact 2700
 atcctggggca tcggcacagt cctggaccaa gcgaggacgg ctggagcgcg actcgctgt 2760
 ctgcgcaccc ctacgcctcc gggatcggtc accgtgcac atccaaacat cgaggaggtg 2820
 gctctgtcca gcaactggaga aatcccccgtt tttggccaaatg ccatcccccc cgagaccatc 2880
 aaggggggggg ggcacctcat ttctgtccat tccaagaaga aatgtatgatg gctcgcccg 2940
 aagctgtccg gctcgactt caatgtgtat gcatattacc gggcccttgc tgatccgt 3000
 ataccaacta gcgaggacgtt cattgtcgta gcaacggacg ctctaatgac gggcttacc 3060
 ggcgttcccg actcaatgtc cgtactgcatac acatgtgtca cccagacagt cgacttcgc 3120
 ctggaccggc ctttccat tggacgcacg accgtgcac aagacgcgtt gtcacgtcg 3180
 cagcggccgag gcaaggactgg tagggccagg atggccattt acagggttgc gactccagg 3240
 gaacggccctt cgggcattttt cgttcttgcg agtctatgac cgccggctgt 3300
 gcttggatcg agctcaccgc cggccggaccc tcgtttaggt tgccgggtt cctaaacaca 3360
 ccaagggttgc cctgttgcga ggaccatctg gatggccggg agacgttcc tacaggccctc 3420
 accccatcatg acggccatcc ttgttcccg actaaggcagg caggagacaa ttcccttac 3480
 ctggtagcat accaggctac ggtgtgcgc agggtctcagg ctccacccatc atcgtgggac 3540
 caaatgttga agtgcgtatc acggctaaag cctacgcgtc acggccaaac gcccctgtcg 3600

tataaggctgg gagccgttca aaacgagggtt actaccacac accccataac caaataacatc 3660
 atggcatgca tgcggctga cctggaggc gtcacagca cctgggtgct gtagggcga 3720
 gtcctagcag ctctggccgc gtattgcctg acaacaggca gctgggtcat tggggcagg 3780
 atcatcttgt cccgaaagcc gcgcattt cccgcaggaa aactgccttta cccggaggtc 3840
 gatgagatgg aagagtgcgc ctcacaccc ctttacatcg aacaggaaat gcaagtcgc 3900
 gaiaacattca aacagaaggc aatcggttgc ctgcacaaac ccacaggca aacggaggct 3960
 gctgctcccg tggtaatcc caagtggcgg acccttcaag cttctggc 4020
 tggaaatttca tcagcggat acaatattt gcaggctgtt ccactctgca tggcaacccc 4080
 gcgatagcat caetgtatgc attcagcc tctatccca gcccgcac caccacat 4140
 acccttctgt ttaacatctt gggggatgg gtggccccc aacttgcctc tcccagcgt 4200
 gcttctgtt tcgtaggcgc cggcattgc gtagggctg ttggcagcat aggccctggg 4260
 aagggtctt tggatattt ggcaggatgg gtagcagggg tggcaggcgc gctcgtggcc 4320
 tttaaaggta tgacggcga gatgcctcc accggaggc tggtaaccc tccctctgt 4380
 atcccttccc ctggccccc agtctgggg gtcgtgtcg cagcataat gctggcccg 4440
 gtagggcccg gggggggggc tggcagttt atgacccgc tgataacgtt 4500
 ggttaacccacg tctcccccac gcaactatgtt ctttgcggc acgtgtcgc 4560
 cagatcttct ctatcttac catcaactcg ctgttgcaga ggcttcacca gtaggtgtt 4620
 gaggactgtt ccacgcctatg ctccggctcg tggctaaagag atgtttggg 4680
 acgggtgttga ctgatttca gacctggcgc cagtcacacg tccctggccg 4740
 gttttttttt ttcattgtca acgtgggtac aagggtctt ggcggggcga cggcatcatg 4800
 caaaacccatg gcccattgtt agcacaatgg accggacatg tggaaaaacgg tttccatgagg 4860
 atcggtggggc cttaggaccc tagtaacacg tggcatggaa cattccccc taaacgcgtac 4920
 accacggggc cctgcacggc cttcccccggc ccaattttt ttcattgttgc 4980
 gctgctgagg agtacgttga gtttacggcgtt gtttttttatttccatgttgc 5040
 accactgaca acgtttaatgg cccgtgtcag tttccggccca ccaatttttccatgttgc 5100
 gatgggggtc ggttgcacag gtacgttca gctgttcaac cccttcttacg ggaggaggtc 5160
 acatttcttgc tcgggttca tcaataccctt gtttttttccatgttgc 5220
 ccggacgtt cttccatgttgc ttcattgttcc accggacccctt ccacattac gtaggtgttgc 5280
 gctaaggcgtt ggttgcggcgg gggatcttcc cttccatgttgc cttccatgttgc 5340
 ctgttgcgc ctccatgttgc tttccatgttgc actacccttcc atgacttccatgttgc 5400
 ctcatcgagg ccacatcttgc tttccatgttgc gtaggtgttgc gtaggtgttgc 5460
 tcagaaaaata agttagtaat tttggactt ttcggatccatgttgc tccaaacccatgttgc 5520
 agggaaatgtt ccgttccggc gggatccatgttgc cttccatgttgc tccaaacccatgttgc 5580
 cccatatggg cacggccggc ttacaaccctt ccactgttgc tttccatgttgc 5640
 tacgttccctc cttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 5700
 cttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 5760
 gagctcgcca caaaacccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 5820
 acggcccttc ctggccatggc tttccatgttgc tttccatgttgc tttccatgttgc 5880
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 5940
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6000
 acaggccccc tgatccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6060
 agcaacttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6120
 ctgcggcaga agaagggttca tttccatgttgc tttccatgttgc tttccatgttgc 6180
 gtgtcaagg agatgaaaggc gtaggtgttca tttccatgttgc tttccatgttgc tttccatgttgc 6240
 gaaggctgttca tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6300
 gacgttccggc accttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6360
 ctggaaagca ctggacaccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6420
 gtccaaaccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6480
 gtttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6540
 atgggtcttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6600
 gcttggaaatg cttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6660
 acggtacttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6720
 cccgaaggca gacggccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6780
 actaatttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6840
 accatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6900
 aagctccagg actgcacatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 6960
 gcccgggaccc aagaggacca gtttccatgttgc tttccatgttgc tttccatgttgc 7020
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7080
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7140
 gaccccccacca cttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7200
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7260
 actcattttt tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7320
 atctacgggg cttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7380
 ctggccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7440
 tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7500
 gtttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7560
 aactggccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc tttccatgttgc 7620

ttatccagct ggttcgttgc tggttacagc gggggagaca tataatcacag cctgtcttgt 7680
gcccggcccc gctgggttcat gtgggtcccta ctcctacttt ctgtagggtt aggcatctat 7740
ctactcccca accgatgaac ggggagctaa acactccagg ccaataggcc atccctgtttt 7800
tttccctttt tttttttctt tttttttttt tttttttttt ttctccctttt 7860
tttttcctct ttttttcctt ttctttccctt tggtggctcc atcttagcc tagtcacggc 7920
tagctgtgaa aggtccgtga gccgcttgcac tgcagagagt gctgatactg gcctctctgc 7980
agatcaagt 7989

<210> 5
 <211> 8649
 <212> DNA
 <213> Hepatitis C Virus

<400> 5
 gccagcccc gattggggc gacactccac catagatcac tccccctgtga ggaactactg 60
 tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgcgtgcag cctccaggac 120
 cccccctccc gggagagcca tagtggctcg cggaaacggg gagtacaccg gaattggccag 180
 gacgaccggg tccttcttg gatcaacccg ctcacgtcc ggagatttg gggtgcccc 240
 gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtaact gctgtatagg 300
 gtgcttgcgatgtggccggg aggtctcgat gaccgtgcac catgagcacc aatcctaaac 360
 ctcaaagaaa aaccaaactg aacaccaacg ggcgcgccc gatggacaaa gatggattgc 420
 acgcaagggtc tccggccgt tgggtggaga ggcttacgat ctatgactgg gcacaacaga 480
 caatcgctg ctctgtatcc gccgtgttcc ggctgtcage gcaaggggcgc cgggttctt 540
 ttgtcaagac cgacactgtcc ggtgccttga atgaactgca ggacgaggca ggcggctat 600
 cgtggctggc cacgacgggc gttcccttgcg cagctgtctc cgacgttgc actgaaagcgg 660
 gaagggactg gctgtatgg ggcgaagttc cggggcagga tctccgttca tctcaccctt 720
 ctccctgcgc gaaatgtatcc atcatggct atgcaatgcg ggggtgtcat acgcttgc 780
 cggctactg cccatcgac cacaagcga aacatcgcat cgacgcgagca cgtactcgga 840
 tggaaaggccg ttttgcgtatgg caggatgtc tggacaaaga gcatcaggggg ctcgcggcc 900
 cggaaactgtt cgccaggctc aaggcgcgcg tggccgcggg cggatgtctc gtcgtgaccc 960
 atggcgatgc ctgttgcgc aatatcatgg tggaaatgg cccgttttctt ggattcatcg 1020
 actgtggccg gctgggtgtg gcgaccgtc atcaggacat acgcttgc 1080
 ttgtgaaga gcttggccgc gaatgggtcg accgttctt cgtgtttac ggtatcgccg 1140
 ctcccgattt cgcagcgcattt gccttctatc gccttcttgc cagtttctc tgagtttaaa 1200
 cagaccacaa cgggttccctt ctacgggat caattccgc cctctccctc cccccccctt 1260
 aacgttactg gccaaaggccg cttggataaa gggccgtgtg cttttgttca tatgttattt 1320
 tccaccatatt tggccatgtt gggccgggg aaccgttgc 1380
 acgagcattc ctagggtctt tttccctctc gccaaggaa tgcaagggtt gttgaatgtc 1440
 gtgaaggaaag cagtttctt ggaagctt tgaagacaaa caacgtctgt 1500
 tgcaggcgc ggaacccccc acctggcgc acgttgcctt gcccggccaaa 1560
 taagatacac ctgcaaaaggc ggcacaaccc cagtggccacg ttgtgatgtt 1620
 gaaagagtc aatggctctc ctcaagcgtt tcaacaagg ggctgaagga 1680
 gtacccatt gtatggatc tgatctgggg ctcgggtca catgttttac atgtgtttag 1740
 tcgaggtaaa aaaacgtcta ggcccccccgca accacggggg ctttgcgtttc ctttgcgtt 1800
 cacgataata ccatggaccc gggatggca gcatcgatcg gggccgggtt tttcgttaggt 1860
 ctgatactt tgacttgc accgcattat aagcttgc tgcgttagct catatgggg 1920
 ttacaatatt ttatcaccag ggcggaggca cacttgcag tttggatccc cccccctcaac 1980
 gttccccccggg gccgcgtatgc cgtcatccctc ctcacgtgc cgtatccaccc agagctaattc 2040
 tttaccatca ccaaaatctt gtcgcata ctcggccac tcatgtgttcc ctagctgtt 2100
 ataaccaaaatg tggctactt cgtgcgcgc cacgggttca ttcgtgcgtt 2160
 cggaaagggtt ctgggggtca ttatgtccaa atggcttca tgaagttggc cgcactgaca 2220
 ggtacgtacg tttatgtacca ttcgcacccca ctggggact gggcccaaccc 2280
 gaccttgcgg tggcgttgc gcccgtgtc ttctctgtata tggagaccaa ggttatcacc 2340
 tggggggcag acacccgcgc gtgtggggac atcatctgg gcttgcggcc 2400
 aggggggggg agatacatct gggacggca gacagcctt aaggccagggtt gttggactc 2460
 ctgcgccta ttacggccta ctcccaacag acgcggaggcc tacttggctg catcatact 2520
 agcctcacag gccgggacag gaaccaggcc gggggggagg tccaagtgtt ctccaccgca 2580
 acacaatctt tccttgcgcac ctgcgtcaat ggcgtgtt ggtactgtcta tcatgtgttcc 2640
 ggctcaaaaga cccttgcggg cccaaaggcc ccaatcacc aatgtacac caatgtggac 2700
 caggacgtcg tggctggca acgcggccccc gggccgggtt ctttgcacacc atgcacctgc 2760
 ggcagctgg accttactt gtcacgggg catgcgtatgc tcatctggg ggcggccggg 2820
 ggcgcacacg gggggggactt acttccccc agggccgtt ctttgcgtt gggcttccg 2880
 ggccgttccac tgcctgtccc ctcggggcac gctgtggca ttttgcggc tggcgtgttgc 2940
 acccgagggg ttgcgaaggc gttggactt ttttgcgtt ggtactatgg aaccactatg 3000
 cggtccccgg tcttcacggc caactcgtcc cttccggccg taccggagac attccagggtt 3060
 gccccatctac acgcggccatc tggtagggcc aagagcacta aggtggccggc tgcgtatgca 3120
 gccccaaagggtt ataaagggtt ttttgcgtt gggccaccctt ggtttccggg 3180
 gctgtatgtt ctaaggcaca tggatgtcgc ctttgcgtt gggccaccctt aaggaccatc 3240
 accacggggg ccccaatccat gttttggccat ttttgcgtt ggtttccggc ctttgcgtt 3300
 tttttggggcc ctttgcgtt gggccaccctt ggtttccggc ctttgcgtt 3360
 atccctggccatc tggccacactt ctttgcgtt gggccaccctt ggtttccggc ctttgcgtt 3420
 ctgcgcaccc ctacggccatc gggatggccg accgttgcac atccaaacat gttttccggc ctttgcgtt 3480
 gttttccggc gttttccggc ctttgcgtt gggccaccctt ggtttccggc ctttgcgtt 3540
 aagggggggg ggcacccatc ttttgcgtt gggccaccctt ggtttccggc ctttgcgtt 3600

gcggggaccc aagaggacga ggcgagccta cgggccttca cgaggactat gactagatac 7680
tctgcccccc ctggggaccc gcccaaacca gaatacactg tggagttgat aacatcatgc 7740
tcctccaaatg tgcgtcgacgcacatgc tctggcaaaa ggggtgacta tctcacccgt 7800
gaccggcacca ccccccttgc gcgggctgctg tggagacag cttagacacac tccagtcata 7860
tcctggctag gcaacatcatcatgtatgc cccaccttgc gggcaaggat gatcctgtatg 7920
actcatttct tctccatctct tagctcaag gaacaacttg aaaaaggccct agattgtcag 7980
atctacgggg cctgttactc cattgagccta cttgacccatc ctcagatcat tcaacgactc 8040
catggccta ggcattttc actccatgt tactctccag ttgagatcaa tagggggct 8100
tcatgcctca ggaaaacttgg ggtaccgccttgcgttgcgactcg ggccagaagt 8160
gtccgcgcta ggctactgtc ccaggggggg agggtgccttgcgttgcgaa gtacctcttc 8220
aactgggcag taaggaccaa gctcaaactc actccaaatcc cggtgcgtc ccagttggat 8280
ttatccagct ggttgcgttgc tggttacagc gggggagaca tatatcacag cctgtctcg 8340
gcccggaccc gctgggtcat gtggtgcttca ctcctacttt ctgttaggggt aggcatctat 8400
ctactccca accgatgaac ggggagctaa acactccagg ccaataggcc atccctttttt 8460
ttttccctttt tttttttttt tttttttttt tttttttttt ttccctttttt 8520
tttttccctct ttttttctt ttctttccctt tggtgctcc atcttagccct tagtcacggc 8580
tagctgtgaa aggtccgtga gccgcttgac tgcagagatg gctgatactg gctctctgc 8640
agatcaagt 8649

<210> 6
 <211> 8001
 <212> DNA
 <213> Hepatitis C Virus

<400> 6

gccagcccc gattggggc gacactccac catagatcac tcccctgtga ggaactactg 60
 tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgcgtgcag cctccaggac 120
 cccccctccc gggagagcca tagggctcg cggAACCGT gagtacaccg gaattggcc 180
 gacgaccggg tccttcttg gatcaacccg ctcacgtcc ggagatttg gggtggcc 240
 gcgagactgc tagccga gtttgggtc gcgaaaggcc ttgtgtact gcctgatagg 300
 gtgcttgcga gtgcggccgg aggtctcgta gaccgtgcac catgagcacg aatcctaaac 360
 ctcggaa aaccaaacgt aacaccaacg ggcgcgc catgagcacg aatcctaaac 420
 acgcgggttcccgccgt tggtggaga ggcttccat ctagactgg gacaaacaga 480
 caatcggtcg ctctgtgcc gccgttcc ggctgtcagc gcaaggggcgc cgggttctt 540
 ttgtcaagac cgaacctgtcc ggtgcctgtatgactgca ggacgaggca ggcggctat 600
 cgtggcttgc cacgacgggc gttccttgcg cagctgtgt cgacgttgc actgaagcgg 660
 gaagggactg gctgttattg ggcaagtgc cggggcaggat ttcctgtca ttcacccctt 720
 ctccctgcga gaaagtatcc atcatggctg atgcaatgcg gccgtgtcat acgcttgc 780
 cggctaccctg cccatttcgac caccaagcga aacatcgcat cgacgagca cgtactcg 840
 tggaaagccgg tcttgcgtat caggatgtc tggacaaga gcatcaagggg ctcgcggc 900
 ccgaaactgtt cgcagggtc aaggcgcgcg tggccgcgg cggaggatctc gtcgtgaccc 960
 atggcgatgc ctgttgcgtt aatatcatgg tggaaatgg ccgtttttt 9gattcatcg 1020
 actgtggccg gtcgggtgtg gcgaccgtt atcaggacat acgcttgc 1080
 ttgtcaagaa gcttggccgc gaatgggtg accgttccct cgtgtttac ggtatcgccg 1140
 ctcccgatcc gcaaggcgttccgcgttccatc gccttcttgcg cagtttccatc ttaggtttaaa 1200
 cagaccacaa cgggttccctt ctggggat caattccgc cctctccctc cccccccctt 1260
 aacgttactg gccgaagccg ctggaaatgg ggcgggtgtg cgtttgtcta tatgttattt 1320
 tccaccatattt tggcaatgtg agggccggaa aacctggccctt tggcttttgc 1380
 acgacgttcccttgcgttccatc gccaaggaa tgcaggatgtc gttgaatgtc 1440
 gtgaaggaaag cgttccatc ggaaggatgtt tggaaatggaa caacgttgcgtt 1500
 tgcaggccggc ggaacccccc acctggcgtc aggtgcctt gcccggccaaa gccacgtgt 1560
 taagatacac ctgcaaaaggc ggcacaaaccc cgttgcacg ttgtgatgtg gatagtgt 1620
 gaaagatgtca aatggcttcc tcaagcgttca ttcaacaagg ggctgaaggaa tgcccagaag 1680
 gtacccattt gtagggatc tggatctgggg cctcgtgtca catgttttac atgtgttttag 1740
 tcgagggttaaaa aacgttca gggcccccggaa accacggggc cgtgggtttc ctttggaaaa 1800
 cacgataataa ccattggccgca tattacggcc tactcccaac agacgcggg cctacttggc 1860
 tgcattcatca ctggccatc agggccgggac aggaacccagg tgggggggaa ggtccaaatgt 1920
 gtctccaccggc caacaaatcc tggccatc accgtcgtca atggcggtgtt tggactgtc 1980
 tatcatgtgttccggcttcaacc gacccttgcg gggccaaagg gccaatcac ccaaattgtac 2040
 accaatgtgg accaggaccc tgcggcgtgg caagcggccccc cccggggcgcg ttccttgaca 2100
 ccatgcaccc tggccagctc ggaccttac ttggtcacga ggcattccgcg tgcattccg 2160
 gtgcggccggc gggccgacag cagggggagc ctacttccc ccaggccctt ctcctactt 2220
 aagggtctttt cggccgggtcc actgtcttgc ccctccgggc atgtgtggg catcttccg 2280
 gtcggcgtgt gcaaccgggg ggttgcgaaq ggggtggact ttgttccctt ctagtctatg 2340
 gaaaccataa tgcggccccc ggttccatc gacaactgtt cccctccggc cgtaccggc 2400
 acattccagg tggccatc acacggccctt acgttgcgtt gcaaggacac taagggtccg 2460
 gtcgtatgttccatc cagcccaagg gtaggttccatc tggccatc acccttaacat cggccggcacc 2520
 cttaggttccatc gggccgtatcatc gtcataaggca catgttgcgtt acccttaacat cagaaccggg 2580
 gtagggacca tcaccacggg tggcccccattt acgttgcgtt cctatggca gtttcttgcc 2640
 gacgggtgtt gtcgttgggg cggccatgtac atcataatat gtgtatgtg ccactcaact 2700
 gactcgacca ctatccctggg catcggttccac gtcattggacc aacggggagc ggctggagcg 2760
 cgactcgatcg tgcgtccac ccgttccatc ccggatcg tccatgtcc acatccaaac 2820
 atcgaggagg tggccatcgtc cagactgttca gaaatccctt ttatggca ggcattccccc 2880
 atcgccacca tcaagggggg gggccatccatc ttttgcatttca gaaatgttgc gaaatgttgc 2940
 gagctccggc cgaatgttccatc cggccatggca ctcaatgttgc tagcatat cccggccctt 3000
 gatgtatccg tcataccaaatc tagggggatc gtcattgttgc tggcaacggc cgctctaatt 3060
 acgggttta cggccgatcc cgttccatc gacgttgcgtt atcataatgtt caccctacaca 3120
 gtcgttccatc gcttggaccg gacccatccatc attggatgttgc cggccatccac 3180
 gtgttccatc cgcaggccggc aggccggact ggttggggca ggttggccat ttacagggtt 3240
 gtgttccatc gagaacggcc ctcggccatc ttcgttccatc cggccatccatc 3300
 gacgggggtt gtcgttgggtt cggccatccatc cccggccatc ctcgttccatc 3360
 tacctaaaca caccagggtt cccgttccatc cggccatccatc tggatggggca gggaggccgtc 3420
 ttatccatc gtcaccatc agacggccatc ttcttgcgttccatc agatggca ggcaggccatc 3480
 aactccctt acctggatgttccatc acgggttccatc cccggccatc ggcgttccatc 3540
 ccatcggtttt accaaatgttccatc ggttggatgttccatc acggccatccatc gacggccatc 3600

acgccccctgc tgtataaggct gggagccgtt caaaacgagg ttactaccac acaccccaata 3660
 accaaataca tcatggcatg catgtcggtc gacctggagg tcgtcacgag caccctgggt 3720
 ctggtaggcg gagtccttagc agctctggcc gcttattggc tgacaacagg cagcgtggc 3780
 attgtggca ggatcatctt gtcggaaag cggccatca ttcccgacag ggaagtcctt 3840
 taccgggagt tcgatgagat ggaagagtgc gcctcacacc tccttacat cgaacaggaa 3900
 atgcagctcg ccgaacaatt caaacagaag gcaatcggt tgctgcaaa agccaccaag 3960
 caageggagg ctgctgtcc ctgtgggaa tccaatggc ggacccctga agccttcgg 4020
 gcaagcata tggatatt catcagcggt atacaat tagcaggctt gtccactctg 4080
 cctggcaacc ccgcatacg atcaactgatg gcattcacag cctctatcac cagccgctc 4140
 accacccaaac ataccctctt gtttacatc ctgggggat gggtggccgc ccaacttgct 4200
 cctcccaagcg ctgcttcgtc ttctgttaggc gccggcatcg ctggagcg 4260
 ataggccctt ggaagggtgt tggatatt ttgcagggtt atggagcagg ggtggcaggc 4320
 gcgctcg 4380
 cctttaaggat catgagcg 4440
 ctactccctg ctatccctc 4500
 ctgcgtccgc acgtggccc 4560
 ttcgttgcg 4620
 gacatgtca ctcagatctt ctctagttt accatcaactc agctgtctaa 4680
 cagtgatca acgaggactg ctccacgcca tgctccggct cgtggctaa 4740
 gattggatat gcacgggtt gactgattt aagacctggc tccagttcaa 4800
 cgttgcgg 4860
 gatggatattt ctctcatgt caacgtgggt acacactatg tggtagag 4920
 gacggcatca tgcaaccac ctgcccattt ggagcacaga tcacccgaca 4980
 ggttccatga ggatcg 5040
 attaacgcgt acaccacggg 5100
 ctgtggccgg 5160
 ttcacagaag tggatgggtt ggggttgac aggtacg 5220
 cgggaggagg tcacatttctt ggtgggctc 5280
 tgccggcccg aacggacgt 5340
 acggcgagaa cggctaagcg 5400
 tcaactgaccccg 5460
 cgggacgtg acctcatcg 5520
 aaccggctgg 5580
 gaggaggatg agagggaaat 5640
 cctcgagcg 5700
 aaggaccctt 5760
 cctccgatcc 5820
 tctgccttgg 5880
 acgggcacgg 5940
 gttgagtcgt 5980
 accttcatcat gggccctt 6000
 gacgggtt 6060
 tccatcacat 6120
 gtcaatgcac 6180
 tgagcaactt 6240
 cgcacgc 6300
 cactaccggg 6360
 ctatccgtgg 6420
 tggggccaa 6480
 tggggact 6540
 ggggtttt 6600
 cctcaggccg 6660
 ttccctggta 6720
 tggacttgg 6780
 gggggccccc 6840
 tgactaattt 6900
 ggtgactga 6960
 atctcgatc 7020
 atgactatg 7080
 ataacatcat 7140
 tatctcaccc 7200
 actccagtca 7260
 atgatccctga 7320
 cttagattgtc 7380
 attcaacgac 7440
 aatagggtgg 7500
 cgggcccggaa 7560
 aagtacctt 7620

tcccagtgg atttatccag ctgggtcggt gctgggtaca gcgggggaga catatatcac 7680
agcctgtctc gtgcccggacc ccgctgggtc atgtggtgcc tactcctact ttctgttaggg 7740
gtaggcatct atctactccc caaccgatga acggggagct aacactcca ggccaatagg 7800
ccatccgtt tttttccctt ttttttttc tttttttttt tttttttttt tttttttttt 7860
ttttctcctt tttttttctt cttttttcc ttttctttcc tttggtggtc ccatcttagc 7920
cctagtcacg gctagctgtg aaaggccgt gagccgctt actgcagaga gtgctgatac 7980
tggccctctctt gcagatcaag t 8001

<210> 7
 <211> 11076
 <212> DNA
 <213> Hepatitis C Virus

<400> 7

gcccggcccc gattgggggc gacactccac catagatcac tcccctgtga ggaactactg 60
 tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgcgtgcag cctccaggac 120
 ccccccctccc gggagagcca tagtggctcg cggAACCGGT gaggatcaccc gaattgccag 180
 gacgaccggg tccttcttg gatcaacccg ctcaatgcct ggagatggc gctgtcccc 240
 gcgagactgc tagccgagta gtgtgggtc gcgaaaggcc ttgtggtaact gctgtatagg 300
 gtgcttgcgat gtccccccggg aggtctcgta gaccgtgcac catgagcacg aatcctaaac 360
 ctcAAAGAAA aaccaaacgt aaccaacacg ggccgcacat gattgaacaa gatggattgc 420
 acgcaggatcc tccggccatc tgggtggaga ggtatccgg ctatgactgc gcacaacaga 480
 caatcgctg ctctgtatcc gcccgttcc ggtgtcagc gcaaggccgc cgggttttt 540
 ttgtcaagac cgacccgtcc ggtgcctcgta atgaaatgcg ggacggaggca ggcgcgtat 600
 cgtggcttgc cacgacgggc gttccctgcg cagctgtgcg ctagctgtgc actgaagccg 660
 gaagggactg gctgtattt ggcgaagtgc cggggcaggaa tccctgtca ttcacccctt 720
 ctccctggcga gaaagatatac atcatggctg atgaaatgcg gcccgtgcac acgcttgc 780
 cggctacccg cccattcgac caccacggc aacatcgat ctagccgcac cgtactcg 840
 tggaaaggccg tcttgcgtat caggatgtatc tggacaaga gcatcagggg ctcgcggcc 900
 ccgaactgtt cgccaggcgc aaggccgcac tgccgcacgg cggaggatctc gtcgtgaccc 960
 atggcgatgc ctggccgcg aataatcatgg tggaaatgg ccgtttttt ggttcatcg 1020
 actgtggccg gctgggtgtg gggggccgtc atcaggacat acgcttgcg acccggtata 1080
 ttgtcaaga gcttggccgc gaatgggtcg accgtttcc cgtgttttac ggtatcgccg 1140
 ctcccgatcc gcagcgcatac gccttctatc gccttcttgc ctagtttcc ttaggtttaaa 1200
 cagaccacaa cgggttccctt ctagccggat caattccgc cctctccctc cccccccccc 1260
 aacgttactg gccgaaggccg cttggataaa ggccgtgtg cgtttgtcta tatgttattt 1320
 tccaccatat tggcgatcc tggcaatgtg agggcccgaa aacctggcc tggcttctt 1380
 acgagccatc ctggggatc ttccccccttc gccaaaggaa tgcgaaggatc gttgaatgtc 1440
 gtgaaggaa gcttggatc tggatctgggg cctcggtca catgttttac ggtatgttgc 1500
 tgcaggccgc gggaaaaaaa acctggcgac aggtgttctc gggccaaaaa gcaacgtgt 1560
 taagatacac ctggccaaaggc ggcacaaccc ctagccac cttgtgttgc gatagtgt 1620
 gaaagatgtc aatggcttcc tcaagcgatc ttcaacaagg ggctgtggaa tgcccagaag 1680
 gtacccattt gtagggatc tggatctgggg cctcggtca catgttttac atgtgtttag 1740
 tgcaggatataa aaaacgttca ggcggccggaa accacggggc cttgtgtttc cttgtggaaa 1800
 cacgataataa ccatggccac gaatccataa cctcaaaagaa aaaccaaaacg taacaccaac 1860
 cgccggccac aggacgtcaa gttccgggc ggtggtcaga tgcgtggcgg 1920
 ttggccgcga gggggccccc gttgggtgtg cgcgcgacta ggaagacttc cgagccgtcg 1980
 caacccgtg gaaggccgcac acatcccccc aaggccgtcc acccccgagg tagggccctgg 2040
 gtcagcccg ggtaccccttgc gccccttcat ggcatttgc gttgggggtg ggcaggatgg 2100
 ctccgttgcac cccgtggcgc tccggcttagt tggggccca cggccccccg gctgtgttgc 2160
 cgcaatttgg gtaaggatc ctagatccctc acgtggggct tcggccatct catgggttac 2220
 attccgtcg tcggccggcc cctagggggc gtcggccaggcc cctggccgc tggcgccgg 2280
 gttctggagg acggcgtgaa ctatgcacca gggaaatctgc cccgttgc ttttctatc 2340
 ttccctttgg ctgtgttgc ctgtttgcacc atcccaatgtt cccgttatgc agtgcgcac 2400
 gtatccggag tggatccatgt cagccggc tgcgtccaaacg caagcattgt gtagggcgg 2460
 gcccggatcg tcatcatac ccccccgggtgc gtcggccatcg ttcggggagaa caactccctcc 2520
 cgcgtgggg tagcgttccat tccacccgtcc gggccggagg acgttagcgt ccccaactacg 2580
 acgatccgtac gccatgtcga tttgtcgat gggccgggtg ctctccgtc cgtatgtac 2640
 gtggggatgc tctggggatc tggatccctc gtcggccatcg tggccatctt ctcggccctgg 2700
 cggcacggaa cgtacaggaa ctgcacccatgc tcaatataatc cccggccacgt gacaggttac 2760
 cgtatggctt gggatccatgt gatgttgc tccatccatcg cagccctatgt ggtatcgac 2820
 ttactccggaa tccacccaaacg tggatccatgt atggatccgtt gggccatccatgtt gggaggatc 2880
 gcccggcccttgc cctactatccatgttgggg aactgggtca aggttctgtatgt tggatccatgt 2940
 ctcccttggc gctgtgttgc gggaaatccatgt gtcggccatcg gggccatccatgtt gggaggatc 3000
 ctccggatcg cgtcccttgc tccacccgggtccatccatgttgc gggccatccatgtt gggaggatc 3060
 aacccggatcg ggcacccatcg cccggccatccatgttgc gggccatccatgtt gggaggatc 3120
 ttcccttgc tccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3180
 gcccggcccttgc cctactatccatgttgggg aactgggtca aggttctgtatgt tggatccatgt 3240
 tcacacatgttgc gggccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3300
 gtacccggccg cgcggatcg tggatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3360
 gggacggccg accgggttgcg cccggccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3420
 ctgtgttgc tccatccatgttgc gggccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3480
 agcactgggttgc tccatccatgttgc gggccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3540
 aacccatccatgttgc gggccatccatgttgc gggccatccatgttgc gggccatccatgtt gggaggatc 3600

<210> 8
 <211> 8001
 <212> DNA
 <213> Hepatitis C Virus

<400> 8
 gccagcccc gättggggc gacactccac catacatcac tcccctgtga ggaactactg 60
 tttcacgca gaaagcgtct aäccätggc ttagtatgag tgcgtgcag cctccaggac 120
 cccccctccc gggäagcc aatgggtctg cggaaaccgt gatgacaccg gaattgcac 180
 gacgaccggg tccttctt gatcaacccg ctcaatgcct ggagatttg gctgcccc 240
 gcgagactgc tagccgagta gtgtgggc gcgaaaggcc ttgtgtäct gctgataagg 300
 gtgcttgcga gtgcggccgg aggtctcgta gaccgtgcac catgagcaccg aatcctaacc 360
 ctcaaäaaa aaccaaacgt aacaccaacg ggcgcgcatt gattgacaaa gatggattgc 420
 acgcaggatc tccggccgt tggtggaga ggctattcg ctatgactgg gcacaaacaga 480
 caatcggtg tcctgtatcc ggcgttcc ggctgcacg gcaaggggcgc cgggttctt 540
 ttgtcaagac cgaccgttcc ggtgccttga atgaactgca ggacgaggca ggcggcgtat 600
 cgtggcttgc cacgacgggc gttcttgcg cagctgtct cagctgttgc actgaaggcg 660
 gaaggactg gctgtattg ggcgäagtgc cggggcaggat tctctgtca tctcaccctt 720
 ctccctggca gaaagtatcc atcatggctg atgcaatgcg gggctgcatt acgcttgcatt 780
 cggctaccctg cccattcgac cacaaggcga aacatcgatc cgacgcgac 840
 tggaaäccgg tcttgcgtat caggatgatc tggacgaa gcatcagggg 900
 cggactgtt cggcaggctc aaggccgcga tgccgcacgg cgaggatctc 960
 atggcgatgc ctgttgcgg aatatcatgg tgaaaatgg cccgttctt 1020
 actgtggccg gctgggtgtg gggggccgt atcaggatc acgcttggat 1080
 ttgtgaaga gcttggggc gaatgggctg accgcttctt cgtgttttac 1140
 ctcccgattt ccaacgcgttcc gcttcttgcg cagtttcttgc 1200
 cagaccacaa cgttccctt ctacggggat caattccgc cctctccctc 1260
 aacgttactg gccgaaäccgg cttgaaataa ggccgtgtg cgttgcata 1320
 tccaccat tggccgttcc tggcaatgtg agggccggaa aacccgtggcc 1380
 acgacattt ctggggctt tcccttcttcc gccaaäggaa tgcäagggtct 1440
 gtgaaggaaag cagtcttgc tgaagatcttca caacgttgc 1500
 tgcaggcaggc ggaacccccc acctggcgcac aggtgttctt cggcccaaaa 1560
 taagatacac ctgcaaaaggc ggcacaaaccc cagtgcacg ttgtgatgt 1620
 gaaagatc aatggcttcc ctcaagcgta ttcaacaagg ggctgaagga tggccagaäg 1680
 gtacccatt gtatggatc tgatctgggg cctcggtca catgttttac atgtgtttag 1740
 tcgagggtta aaaacgtcta ggcccccccgaa accacggggat cgtgttttcc 1800
 cacgataata ccatggcgcc tattacggcc tactccaaac agacgcgagg cctacttggc 1860
 tgcatcatca ctagecctac agggccggcagg aggäaccagg tcgaggggga ggtccaagt 1920
 gtctccaccg caacaaatc ttccctggcg acctgcgtca atgcgtgtg ttggactgtc 1980
 tatcatgggt cggctcaaa gacccttgcg gggccaaagg gccaatcac 2040
 accaatgtgg accaggacat cgtcggtcttca caagcccccc cggggcgcgc 2100
 ccatgcaccc gggcagctc gacccatttac ttgtcacaatc ggcacatggca tgcatttccg 2160
 gtgcggccgc gggccgacag cagggggacat ctaacttccc ccaggccctt 2220
 aagggtctt cggccggatcc actgctctgc ccctcgccg acgtgtggg catcttccg 2280
 gctgcccgtt gcaaccggagg ggttgcgaag ggggtggact ttgtacccgtt cgagtctatg 2340
 gaaäccacta tgcggtcccc ggttcttgcg gacaactgtt ccctccggc cgtaccgcag 2400
 acattccagg tggcccatat acacggccctt actgttgcgt gcaagacac taagggtccg 2460
 gtcgtatgc cagcccaagg gtataagggtt cttgtcttgc accctgttccgtt cggccgcacc 2520
 ctatgtttccg gggcgatataat gtcataaggca catgttatgc accctaaatc cagaatcggg 2580
 gtaaggacca tcaccacggg tgccccccatc acgtacttcca cctatggca gtttcttggc 2640
 gacgggtggtt gctctggggg cgcctatgc acatataat gtgtatgtgtt ccactcaact 2700
 gactcgacca ctatctggg catcgccaca gtcctggacc aaggggagac ggctggaggcg 2760
 cgaactcgatc tgctccaccc cgtctacgcctt ccgggatcg tcaccgtgc acatccaaac 2820
 atcgaggagg tggctctgtc cagcaacttgc gaaatccctt ttatggcaaa agccatcccc 2880
 atcgagacca tcaagggggg gaggcacccatc attttctgc attccaagaa gaaatgtgt 2940
 gagctcgccg cgaagctgc cggcccttgcg ctcaatgttgc tagcatat ccggggccctt 3000
 gtgtatccg tcatccaaatc tagcgaggac gtcattgtcg tggcaacggca cgtctataatg 3060
 acggccatcc cccgttgcattt cgaactcgatc atcgacttgc atacatgtgtt cacccttgc 3120
 gtcgacttca gcttgcaccc gacccatccatc attgagacca cggccgtgc accaaacgcgc 3180
 gtgtcacttca cggccgttgcg aggccaggact ggttagggca ggatggcat ttacaggat 3240
 gtgactccatc gagaacggcc ctcggccatc ttgcatttcc cgggttctgtg cggatgttat 3300
 gacggggctt gtcgttgcg cggatctcactt cccggccgaga cctcaggat tggatgttgc 3360
 tacctaaaca caccagggtt gcccgttgc caggaccatc tggatgttgc gggagacgcgc 3420
 ttacaggcc tcaccacatc agacggccat ttcttgcggcc agactaagca ggcaggagac 3480
 aacttccctt acctgttgcg ataccaggatc acgggttgcg ccagggtca ggttccacat 3540
 ccatcggttcc accaaatgtt gaaatgttgc atacggctaa agcctacgcg caccggccca 3600

tcccagtgg atttatccag ctgggtcggt gctggttaca gcgggggaga catatatcac 7680
agcctgtctc gtggcccgacc cccgctgggttc atgtgggtgcc tactcctact ttctgttaggg 7740
gtaggcatct atctactccc caaccgatga acggggagct aaacactcca ggccaatagg 7800
ccatccgtt tttttccctt ttttttttcc tttttttttt tttttttttt 7860
ttttctccctt ttttttccctt ttttttttcc ttttttttcc ttgggtggct ccacatcttagc 7920
ccttagtcacg gctägctgtg aäaggccgt gagccgttg actgcagäga gtgctgatac 7980
tggccctctc gcagatcaag t 8001

<210> 9
<211> 11076
<212> DNA
<213> Hepatitis C Virus

<400> 9
gccagcccc gatggggggc gacactccac catagatcac tccccgtgta ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgctgtcgag cctccagac 120
ccccctccccc gggagagcca tagtggctctg cggAACCGGT gatgacaccg gaattgccag 180
gacgaccggg tccttcttg gatcaaccgg ctcaatgcct ggagatttgg gctgtcccc 240
gctgagactgc tagccgagta gtgttgggtc gctaaaggcc ttgtggtaact gcctgtatagg 300
gtgtccgtga gtccccggg aggtctcgta gaccgtgcac catgagcaccg aatcctaaac 360
ctcaaaagaaa aaccaaaacgt aacaccAACGGC ggcgcgcccc gattgaaaca gatggattgc 420
acgcagggtc tccggccgct tgggtggaga ggctatttcgg ctatgactgg gcacaaciaga 480
caatcggtc ctctgatgcc gccgttcc ggctgtcagc gcaggggcgc cgggttctt 540
ttgtcaagac cgacgttgc ggtccctgta atgaactgcg ggacgaggca gcggggctat 600
cgtggcttgc cacgacgggc gttccctgctc cagctgtgct cgacgttgc actgaagcgg 660
gaagggactg gctgttattg ggcaagggtc cggggcaggaa tctctgtca tcteacattt 720
ctcctgccc gaaagtatcc atcatggctg atgcaatgcg gctgtcgcg acgcttgcatt 780
cggttaccc cccatcgac caccacggaa aacatcgcat cgagcgagca cgtactcgga 840
tggaaaggccg ttttgcgtat caggatgatc tggacgaaaga gatcaggggg ctccgcacag 900
ccgaatgtt cggcaggctc aaggcgcgc gtcggcaggcg cggatctc gtcgtgaccc 960
atggcgatgc ctgttgcgg aatatcatgg tggaaaatgg cccgttttttgc gatgtatcatc 1020
actgtggccg gctgggtgtg gctggaccgc atcaggacat acgcttggct cgtcttttac acccgtgata 1080
ttgctgaaga gtttggggc gaatgggctg accgcttccct cgtcttttac ggtatcgccg 1140
ctcccgattt gcagcgcattc gccttctatc gccttctgaa cgatcttcc ttagttaaaa 1200
cagaccacaa cgggttccctt ctagcggat caattccggcc cctctccctc cccccccctt 1260
aacgttactg gccgaaggccg ctggataaa ggccgggtgtg cgtttgtcta tatgttattt 1320
tccaccatatt tgccgttctt tggcaatgtg agggccggaa aactctggccc tgcgttcttgc 1380
acgacattt ctagggttctt ttccctctc gccaaggaa tgcaggatctc gttgaatgtc 1440
gtgaaggaaag cagttctctt ggaagcttct tgaagacaaa caacatgttgc acgcaccctt 1500
tgcaggcaggc ggaacccccc acctggcgcac aggtgcctt gctggccaaaa gccacgtgt 1560
taagataacac ctgcaaaaggc ggcacaaccc cagtgccacg ttgtgagttt gatagttgt 1620
gaaagagtc aatggcttc ctcacggcgtat ttcaacaagg ggctgaagga tgcctcagaag 1680
gtaccccttatt gtatggatc ttagtctgggg cctcggtgca catgttttac atgtttag 1740
tcgagggtttaaaa aacatgttca ggcggccggaa accacggggg cgtgggttttcc ttttggaaaa 1800
cagcataataa ccatggcgcac gaatctttaaa cctcaagaa aaaccaaaacg taacaccaac 1860
ccggcccccac aggacgttca gttccccggc ggtggtcaga tgcgtgggttcc agtttaccc 1920
ttggccgcga gggcccccag gtgggtgtg cgcgcgacta ggaagacttc cgcagggtc 1980
caacctctgtt ggtacccctt gcccctctat ggcaatgagg gcttgggtgtt ggcaggatgg 2040
gctcagcccg ggtacccctt gcccctctat ggcaatgagg gcttgggtgtt ggcaggatgg 2100
ctctctgttca cccgtggctc tggccttagt tggggcccca cggacccccc gctgtgggtc 2160
cgcaattttt gtaagggtcat cgataccctc acgtgcggct tcggcgtatc catgggttac 2220
attccgttc tcggccccc cctagggggc gctgcccagg ccctggcgc tggcgtccgg 2280
tttctggagg acggcgatgaa ctatgcacca gggaaatctc cgggttgc ttttcttata 2340
tcttcttttttgg ctttgcgttctt ctttttttttgc atcccaggat cccgttata gatgtcgcaac 2400
gtatccggat gtttccatgtt caccacggac tgcgttccaaacg caacatgttgc ttagtggggca 2460
cgccgacatgtatc tcatgcatac ccccggttgc gtggccctgc ttggggagaa caactcttcc 2520
cgctgttggg tagcgttccatc tcccacgtt gggggccaggaa acgttagtgc ccccaactac 2580
acgatacgtac gccatgttca ttgtctctt gggggccggc ctctctgttgc cgctatgtac 2640
tggggatgtc tctgtggatc ttttttccctt gtcggccaggc tggcccttgc tccgcctcgc 2700
gggcacggaga cagttacggc ctgcaatttgc tcaatataatc cccggccacgt gacaggtcac 2760
gttatggctt gggatatgtat gatgtactgg tcacccatcg cagcccttagt ggtatcgca 2820
tactccggaa tcccaaaacgc tgcgttggat atggtggggg gggcccttgc gggaggcccta 2880
cgccggctt cctactatcg ttttttttttgc aactgggttgc aggttctgtat ttttttttttgc 2940
tctttggcc gctgttgcgg gggaaacctat gtcgggatttgc tccatcccaaaatccatgt tggcaggggg 3000
acggcgatgtt ggcacatcaa caggactggc tcatcccaaaatccatgt tggcaggggg 3060
tcttctgttgc cgctgttca cgtgcacaaatcgttgc tcaactctatc tggatggccc agagcgttgc 3120
ccagctgtca gccccatcgaa cgggttgcgttgc tcaactctatc tggatggccc agagcgttgc 3180
cacacagatc cggaccaggag gcttttattgt tggactacag caccggccgc gtcgggtatc 3300
taccacgggg cgcagggtgt tggccctgttgc tggactacag ccccaagccgc tggcgtgggt 3360
ggacgaccgc acgggttccgg cgtggccatcg tggactacag ccccaagccgc tggcgtgggt 3420
tgcgttccatc acaacacccgc gccggccggc gcaactgttgc tggactacag ccccaagccgc tggcgtgggt 3480
gcacttgggt tcaccaagac gtcggggggc ccccggttgc acatccggggg gatcggtatc 3540
aaaccttgc cctggcccccac ggactgttgc tggactacag ccccaagccgc tggcgtgggt 3600

tgggttcgg ggcttgggtt gacacccaga tgcttggtcc actacccata caggcttgg 3660
 cactacccct gcactgtcaa ctttaccatc ttcaaggtta ggatgtacgt ggggggagtg 3720
 gaacacaggc tcgaagccgc atgcaattgg actcgaggag agcgttgtaa cctggaggac 3780
 agggacaaat cagagcttag cccgctgtc ctgtctacaa cggagtgcc ggtattgccc 3840
 tgttcttca ccacccatc ggctgttcc actgggttga tccatctcca tcagaacgtc 3900
 gtggacgtac aatactgtt cggataggg tggcggttgc tctcccttgc aatcaaattgg 3960
 gagttgtcc tggttctt ctttcttgc gggacggcgc gctgttgc aatcaaattgg 4020
 atgatgtgc tgatagctca agctgagggc gcccata gaga acctgggttgc ctcacaaacgc 4080
 gcacccgtgg cggggcgca tggatttcc tcccttcttgc tggttcttgc tgctgcctgg 4140
 tacatcaagg gcaggctggt ccctggggcg gcatatgccc tctacggcgt atggccgcta 4200
 ctccgtctcc tgctggcgtt accaccacga gcatacgcca tgaacccggga gatggcagca 4260
 tgggtggag gggcggtttt ctttgcgttgc atactcttgc ctttgcacc gcactataag 4320
 ctgttccctcg cttaggtctcat atgggtgttca caatatttttca caccaggggc cgaggcacac 4380
 ttgcgttgcgtt ggatcccccc ctcacacgtt cggggggggcc gcatatgttgc ctcacaaacgc 4440
 acgtgcgcga tccacccagaa gtaatctt accatccaca aatattgttgc cgcataactc 4500
 ggtccactca tgggtgttca ggctggatata accaaaatgtc cgtacttcgtt ggcgcacac 4560
 gggcttcatc gtgtatgtcat gctgtgtcgaa aaggttgcgtt ggggttcatc tgccaaatgt 4620
 gctctatgtt gttggccgc actgacaggt acgtacgtt atgaccatctt caccacactg 4680
 cgggacttggg cccacccggc cttacggac tttggcggttgc cagttgagcc cgtcgttcc 4740
 tctgtatgtt agaccaaggat ttttacccgttgc ggggcagaca cccggccgtt ggggacatc 4800
 atcttggcc tggccgttcc cggccggcagg gggagggaga tacatcttgc accggcagac 4860
 agccttgaagg ggcagggttgc ggcacttcc ggccttatttcc cggccacttcc ccaacagac 4920
 cggggcttac ttgggtgtcat catactatgc ctcacaggcc gggacaggaa cgggttgcgtt 4980
 ggggggttcc aatgggttcc caccggcaaca caatcttcc tggccgttgc cgtcaatggc 5040
 gtgtgttggta ctgttctatca tgggtgttgc tccaaagaccc ttggccggccc aaggggccca 5100
 atcaccctaaa tggatccaa tggggaccat gacccgttgc gttggcaagg gccccccccc 5160
 ggcgcgttcc tggatccatg cacccgttgc gacccgttgc tttacttgc caccggcat 5220
 ggcgcgttcc tttccgttgc cccggccggc gacccgttgc gggccctactt ctcccccagg 5280
 cccgttccctt acttggatggg ctcttccggcc ggttccacttgc tctggcccttc ggggacatc 5340
 gtggccatc tttgggttgc ctgtgttgc cgggggttgc cggaggccgtt ggactttgttgc 5400
 cccgttgcgtt cttatggaaac cactatgttgc gttccgttgc tccatccggccat ctcgtccct 5460
 cccggccgttac ctcacccatc ctcacccgttgc catatccatc cccctacttgc tagccggcaag 5520
 agcactaagg tggccgttgc gtatgttgc cccggccgtt gggccctacttgc cctgaaccc 5580
 tccgttgcgtt ccacccatc tttccggccgtt tttatgttgc tttatccatc tttatccatc 5640
 aacatccatc tccgggttgc gacccatccac acgggttgc cccatccatc tttatccatc 5700
 ggcacccatc ttggccgttgc tttatccatc gggggccctt atgacatcat aatatgttgc 5760
 ggtggccatc caatccatc gacccatccatc tttatccatc gggggccctt gggccatccatc 5820
 gagacccgttgc gacccatccatc tttatccatc gggggccctt gggccatccatc atccgttgc 5880
 gtggccatc caatccatc gggggccctt tttatccatc tttatccatc tttatccatc 5940
 ggcacccatc tccgggttgc gacccatccatc tttatccatc gggggccctt tttatccatc 6000
 aagaagaaat gtgtatgttgc cccggccgtt tttatccatc tttatccatc tttatccatc 6060
 tattaccggg gcttccatc tttatccatc tttatccatc tttatccatc tttatccatc 6120
 acggacgttgc taatgttgc tttatccatc tttatccatc tttatccatc tttatccatc 6180
 tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6240
 gtggccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6300
 ggcacccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6360
 ctgtgttgcgtt gttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6420
 gttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6480
 ttctggggaga gcttccatc tttatccatc tttatccatc tttatccatc tttatccatc 6540
 aagcaggccatc gagacaaatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6600
 gtcaggccatc cccatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6660
 acggacgttgc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6720
 accacacaccc cccatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6780
 acggacgttgc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6840
 acggacgttgc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6900
 gagacccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 6960
 tacatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7020
 caaaacccatc cccatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7080
 atcggacgttgc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7140
 gggccatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7200
 atcggacgttgc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7260
 gggccatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7320
 gggccatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7380
 gggccatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7440
 gggccatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7500
 gtgtgttgcgtt gttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7560
 aaccggccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 7620

gagagcgcacg ctgcacgcacg tgcactctacg atccctctcta gtcttaccat cactcagctg 7680
 ctgaagaggc ttccaccaatg gatcaacgag gactgctcca cgccatgcctc cggctcggtg 7740
 ctaagagatg tttggattt gatatgcacg gtgttactg atttcaagac ctggctccag 7800
 tccaagctcc tgccgcattt gcccggatgc cccttcttctt catgtcaacg tgggtacaag 7860
 ggagtctggc ggggcacgg catcatcaaa accacctgcc catgtggggc acagatcacc 7920
 ggacatgtga aaaacggttc catgaggatc gtggggctta ggacctgttag taacacgtgg 7980
 catggacat tccccattaa cgcgtacacc acggggccct gcacgcctcc cccggcgcca 8040
 aattatctca gggcgctgtg ggggggtggct gctgaggagt acgtggagggt tacgcgggtg 8100
 ggggatttcc actacgtac gggcatgacc actgacgacg taatgggtccc gtgtcagggt 8160
 cccggcccccg aattttcac aagaatggat ggggtgggt tgacacaggta cgctccacg 8220
 tgcaaaaaacc tcctacggga ggaggtcaca ttccctggctg ggctcaatca atacctgggt 8280
 gggtcacagc tcccatgcga gccccaaacccg gatgtacgcg tgcacttcc catgtctacc 8340
 gacccctccc acattacggc ggagacggct aagcttaggc tggccagggg atctcctccc 8400
 cccttggcca gctcatcagc tagccagotg tctgcgcctt ccttgaaggc aacatgcact 8460
 acccgctatg actdcccggc cgctgacccctc atcgaggccaa acctcttgcg gggcaggag 8520
 atggggggga acatcaccgg cgtggagtc gaaaataagg tagtaatttt ggactctttc 8580
 gagccgtcc aagcgaggaa ggatgagagg gaagtatccg ttccggcgga gatctcggt 8640
 aggtccagga aatttccctcg agcgatgcctt atatggcaac gcccggattaa caaccctcca 8700
 ctgttagagt ccttggaaaggc cccggactac gtccctccag tggtagacacgg gtgtccattg 8760
 ccgcctgcca aggccccctc gataccaccc tcacggagga agaggacggg tgcctctgtca 8820
 gaatcttaccg tgctttctgc ttggcgag ctcgcacccg agacccctgg cagctccgaa 8880
 tcgtcgccg tcgacagcgcc cacggcaacg gcctcttgc accagccctc cgacgacggc 8940
 gacgcggat ccgacgttgc gtctgtactcc tccatggccc cccttgagggg ggagccgggg 9000
 gatccgatc tcagcgacgg gtcttggctt accgtaacgc aggaggctag tgaggacgtc 9060
 gtctgtctc ctatgttccat cacatggacca ggcgccttc tcaacgcctg cgctgcggag 9120
 gaaaccaacg tgcccatcaa tgactgacg aactcttgc tccgttccatca caacttggtc 9180
 tatgttacaa catctcgacg cgcaaggctc cggcagaaga aggttccatcc tgacagactg 9240
 caggctctgg aecgaccacta cccggacgtg ctcaggaga tgaaggcgaa ggcgtccaca 9300
 gtttaaggcta aacttctatc cgtggaggaa gcctgttacg tgaacggccccc acattcgcc 9360
 agatctaaat ttggctatgg gcaaaaggac gtccggaaacc tatccagcaa ggccgttaac 9420
 cacatccgct ccgtgtggaa ggacttgcg gaagacactg agacccaaat tgacaccacc 9480
 atcatggcaa aaaatggatg tttctgcgtc caaccagaga agggggggccg caagccagct 9540
 cgccttatcg tattttccaga ttgggggggtt cgtgtgtcg agaaaatggcc cctttacat 9600
 gtggcttcca cccttccctca gggcgatgtt ggcttccat acggattccca atactcttct 9660
 ggacagcgccg tcgagttctt ggtgaatgcc tggaaagcg agaaaatggcc tatgggtttc 9720
 gcatatgaca cccgctgttt tgcactcaacg gtcaactgaga atgacatccg tggtagaggag 9780
 tcaatctacc aatgttgcgtt ttggcccccc gaaaggccacg aggccataag gtgcctcaca 9840
 gagccggctt acatcggggg cccctgtact aattctaaag ggccagaactg cggctatcgc 9900
 cgggtcccgcc cgagcggtgt actgacgacc agtgcggta ataccctcac atgttacttg 9960
 aaggccctgtg cggctgtcg agtgcgaaag ctccaggact gcacgatgtc cgatgcgg 10020
 gacgacccctt tcgttatctcg tggaaagcg gggacccaaag aggacggagc gagectacgg 10080
 gccttcacgg aggtatgac tagatactctt gccccccctgg gggacccggc caaaccagaa 10140
 tacgacttgg agttgataac atcatgttccatccatgttgcgca cgatgcacat 10200
 ggcaaaaaggg tgcactatctt caccgtgac cccaccaccc cccttgcgctt ggctgcgtgg 10260
 gagacagacta gacacactcc agtcaattcc tggctaggca acatcatcat gtatgcgcc 10320
 accttgggg caaggatgtt cctgtatgact cattttcttccatccatgttgcgca agtgcaggaa 10380
 caacttggaaa aagcccttaga ttgtcagatc tacggggctt gttactccat tgagccactt 10440
 gacctaccc agatcattca acgactccat ggccttagcg cattttactt ccatagttac 10500
 tctccagggtt agatcaatag ggtggcttca tggctcaggaa aacttggggt accggcccttg 10560
 cgagtctgtg gacatcgggc cagaatgttc cggcgatggc tactgtccca gggggggagg 10620
 gctgcccactt gtggcaagta ccttcttcaac tggcgatggaa ggaccaagct caaactcact 10680
 ccaatccccg ctgcgtccca gttggattta tccagctgtt tggctgtgg ttacaacggg 10740
 ggagacatata ttcacacccgtt gtctcggtcc cgaccccgctt ggttcatgtg gtgcctactc 10800
 ctactttctg tagggtagg catctatcta ctcccaacc gatgaacggg gagctaaaca 10860
 ctccaggccca ataggccatc ctgtttttt ccctttttt tttttttttt tttttttttt 10920
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 10980
 tggctccatc ttacggccatc ttagcccttag tcaacggctag ctgtgaaagg tccgtgagcc gcttgcactc 11040
 agagagtgtt gatactggcc tctctgtcaga tcaagt 11076

<210> 10
 <211> 8001
 <212> DNA
 <213> Hepatitis C Virus

<400> 10
 gccagcccc gattggggc gacactccac catagatcac tccccgtgaa ggaactactg 60
 tcttcacgca gaaagctct agccatggcg ttagtatgag tgcgtgcag cctccaggac 120
 ccccccctccc gggagagcca tagtggctcg cggaaacggg gaggatcacccg gaattggccag 180
 gacgaccggg tccttcttg gatcaacccg ctcacatgcct ggagatttgg gctgtcccc 240
 gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtgttact gcctgtatagg 300
 gtgttgcga gtggccccc aggtctcgac gaccgtgcac catgagcacg aatcttaaac 360
 ctcaaaagaaa aaccaaaccgt aacaccaacg ggcgcgccc gatggatttgc 420
 acgcagggtc tccggccgt tgggtggaga ggcttattcgatcatgatggc 480
 caatcgctg ctctgtatcc gccgtgttcc ggctgtcagc gcaacacaga 540
 ttgtcaagac cgacactgtcc ggtgcctgaa atgaaactgca ggacgaggca ggcggctat 600
 cgtggctggc cacgacgggc gttccttgcg cagctgtct cgacgttgc actgaagcgg 660
 gaagggactg gctgttattg ggcgaagttc cggggcagga ttcctgtca ttcacccctt 720
 ctccctggcga gaaatgtcc atcatggctg atgaaatgtcc gccgtgtcat acgcttgatc 780
 cggtactctg cccatcgat caccacggaa aacatcgatc cgacgagca cgtactcgaa 840
 tggaaaggccg tcttgcgtat cggatgtatc tggacaaaga gcatcgggg ctcgcggccag 900
 ccgaactgtt cgccaggctc aaggcgcga tgccgcggg cggatgttc gtcgtgaccc 960
 atggcgatgc ctgcgttgcg aatatcatgg tggaaaatgg ccgcctttctt ggttcatcg 1020
 actgtggccg gtcgggtgtg gcgacccgtt atcaggacat agcgttgcgtt acccggtata 1080
 ttgtcaagaa gcttggcgcc gaatgggtctt accgcttctt cgtgttttac ggtatcgccg 1140
 ctcccgatcc gcacgcgtatc gccttctatc gccttcttgcg cagtttctt ctagtttaaa 1200
 cagaccacaa cgggttccctt ctagcgggtat caatccgc cctctccctc cccccccctt 1260
 aacgttactg gccgaagccg cttggaaataa ggcgggtgtg cttttgtcta tatgttattt 1320
 tccacccat tggccatctt tggcaatgtt aaggccggaa aacccgttcccg ttttttttgc 1380
 acgagcatcc ctgggggtctt tttccctctt gccaaggaa tcaaggcttctt gttgaatgtc 1440
 gtgaaggaaag cagtttctt ggaagcttctt tgaagacaaa caacgtctgt akgacccctt 1500
 tgcaggcagc ggaacccccc acctggcgac aggtgcctctt gcccggccaaa gccacgtgt 1560
 taagatcac ac tgcggaaaggc ggcacaaccc cagtgccacg ttgtgatgtt gatgttgc 1620
 gaaaggtca aatggctctc ctcaagcgta ttcaacaagg ggctgtaaagg tggccagaag 1680
 gtatcccatt gtatggatc tcatctgggg cctcggtgca catgttttac atgtttag 1740
 tgcaggatccaa aaaaatgttca gggcccccggc accacggggc ctttttttgc 1800
 cacgataataa ccatggccgatc tattacggcc tactcccaac agacgcgggg cttacttggc 1860
 tgcacatcatca ctggccatcc acggccggggc aggaacccggc tggagggggg ggtccaaatgt 1920
 gtctccaccc caacacaatc tttctggcg acctgcgtca atggcgatgtt ttggactgtc 1980
 tatcatgggtt ccggctcaaa gacccttgcg gggccaaagg gcccacatcac ccaatgtac 2040
 accaatgtgg accaggaccc ctgcggctgg caagccccc cggggccggc ttcccttgc 2100
 ccatgcacctt gggcggccatcc gggatgttac ttgttgcacca ggcacatggcg tgcatttcc 2160
 gtgcggccggc gggccggccatcc gggatgttac ttgttgcacca ggcacatggcg tgcatttcc 2220
 aagggttccctt ccggccgggtcc actgtctgtc ccctcggtgg acgtgttggg catcttccg 2280
 gtcggcgatcc gacccggggc gtttgcgtt gggatgttgg ttttgc 2340
 ggaaacccatca tgcggatccatcc ggttgcgtt gacaactgtt cccctccggc cgtacccggc 2400
 acatccatcc gggccatccatcc acacggccatcc actggatgtt gcaacacggc taagggttccg 2460
 gtcgtatcc gggccatccatcc gtttgcgtt gcaacacggc gggatgttgg gggatgttgg 2520
 cttagtttccatcc gggccatccatcc gtttgcgtt gcaacacggc gggatgttgg gggatgttgg 2580
 gtaaggacca tcaccacggg tggcccccaccc acgtacttca cctatggca gtttgc 2640
 gacgggtgtt gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 2700
 gactcgacca ctatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 2760
 cgactcgatcc tgcgttgggg cgcctatgtac atcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 2820
 atcgaggagg tggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 2880
 atcgaggacca tcaagggggg gaggccatccatcc attcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 2940
 gagctcgccg cggatgttccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3000
 gatgtatccatcc tcaaccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3060
 acgggttccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3120
 gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3180
 gtgtatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3240
 gtgtatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3300
 gacggccatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3360
 tacctaaacca caccagggtt gggccatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3420
 ttacaggccc tcaaccatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3480
 aacttccctt acctgttgcg ataccaggatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3540
 ccatcgatccatcc gggccatccatcc gtcgttgggg cgcctatgtac atcataatat gtgtatgtt gcaactcaact 3600

acgcgcctgc tgtataggct gggagccgtt caaaacgagg ttactaccac acaccccat 3660
accaaataca tcatggcgtg catgtcgct gacctggagg tcgtcacgag caccctgggt 3720
ctggtaggcg gagtccttagc agctctgccc gcttattgcc tgacaacagg cagcgtggc 3780
attgtggcga gatcatctt gtccggaaag cccgcata ttcccgacag ggaagtcctt 3840
taccggagt tcgtgagat ggaagatgc gcctcacacc tcccttatcat cgaacaggga 3900
atgcagctcg cccaaacatt caaacagaag gcaatcggt tgctgaaac agccaccaag 3960
caaggcggg ctgtctgc cgtgtggaa tccaagtggc gacccatcg agccttctgg 4020
gcaagcata tggtaatcatc catcagcggg atacaatatt ttagcggctt gtccactctg 4080
cctggcaacc cccgcata ggtttaaatc atactgtg gcatcatacg cctctatcatc cagcccgctc 4140
accacccaac ataccctctt gtttacatc ctggggggat ggttggccgc ccaactgtct 4200
cctccagcg ctgtctctgc tttcgtaatc gcccgcatacg ctggagccgc tggtggcagc 4260
ataggcctt ggaaggtgt tttcgatatt ttggcagggtt atggagcagg ggtggcaggc 4320
gctgtctgg cctttaaatc catgagcggc gagggtccct ccaccggaga cctggtaac 4380
ctactccctg ctatcccttc cctggcgcc ctatgtcg ggtgtgtg cgcagcgata 4440
ctgcgtcgcc acgtggggccca ttcgcttcgc gggtaacca gcaagcgtca ctcagatct 4500
cgtctccccc acgactatg tgcctgagag cgcacgtc 4560
ctctagttt accatcactg acgtgtgaa gaggtcttc 4620
ctccacggca tgcctccggc tgcggtaaag agatgtttg 4680
gattggatat gcaagggttt gactgattt aagacctggc tccagtccaa gctcttcgg 4740
cgattgcccgg gaggcccctt cttctcatgt caacgtgggt acaagggat ctggcggggc 4800
gacggcatca tgcaaaaccac ctgcccattt ggagcacaga tcaaccggaca tggtaaaaac 4860
ggttccatgtt ggatcgtggg gcttaggacc tggtagtaaca cgtggcatgg aacatttttt 4920
attaacccgtt acacccacggg cccctgcacg ccctcccccgg cgccaaattt ttctaggcg 4980
ctgtggcgccg taggtgctga ggagtacgtg gagggtacgc ggttggggga ttccactac 5040
gtgacggccg tgaccatgtt caacgtaaag tgccctgtc aggttccggc ccccgattt 5100
ttcacagaag tggatggggt ggggttgcac aggtacgtc cagcgtgcaaa cccctctta 5160
cgggaggagg tccatccctt tgccatgtt aatcaatacc tggttgggtt acagctccca 5220
tgcggccctg aaccggatgtt acggcgaga cggctaagcg taggctggc agggatctc ccccccctt 5280
tcagctagcc agctgtctgc gcttccctt aaggcaacat gcaactaccgg tcatgactcc 5340
ccggacgctg acctcatcg gggcaacccctc ctgtggcgcc agagatggg cgggaaacatc 5400
accccgctgg agtcagaaaa taaggtagt attttggact ttcccgagcc gctcaagcg 5520
gaggaggatg agggggagt atccgttccg gcgagatcc tgccggaggtc caggaaattt 5580
cctcgagcg tgcccatatg ggcacggcc gattacaacc ttccactgtt agagtcctgg 5640
aaggacccgg actacgttcc tccatgtt gacgggtgc cattggccgc tgccaaaggcc 5700
cctccgatatac cacttcacg gggaaagagg acgggtgtc tgtagaaatc taccgtgtt 5760
tctgccttgg cggagctcg cacagagacc ttcccgacgtt ccaatcgcc gggctcgac 5820
agcggcacgg caacggccctc tcctgaccag ccctccgacg acggcgacgc gggatccgg 5880
gttgagtcgtt actccctccat gccccccctt gggggggatc cgggggatcc cgtatctc 5940
gacgggtt ggttaccgtt aagcgaggag gctagtggg acgtcgtctg ctgtctcgat 6000
tccatcacat ggcaggcgcc cctgatcagc ccatgcgtg cgagggaaac caagctggcc 6060
ataatcgac tgaccaactt tttgtccctt caccacaact tggctatgc tacaacatct 6120
cgacgcggaa acctgcccga gaagaaggcc accttgcata gactcgagg tctggacac 6180
caactccggg acgtgtctaa ggatgtgaa gcaaggcgtt ccacagttaa ggctaaactt 6240
ctatccgtgg aggaaggctgt taagctgacg cccccatcc cggccatgg taaatggc 6300
tatggggcaa aggacgtccg gaaacctatcc agcaaggccg ttaaccacat cgcgtcc 6360
tggaggact tgctggaaaga cactgagaca ccaattgtaca ccacccatcat ggcaaaaaat 6420
gaggttttctt ggttccaaacc agagaagggg ggcggcaagc cagctcgctt tatacgattt 6480
ccagatttgg ggggtcggtt gtgcgagaaa atggccctt acgtgtggg tccaccctc 6540
cctcaggccg tgatgggctc ttccatcgga ttccaaatact ctctggaca ggggtcgag 6600
ttccctggta atgcctggaa agcgaagaaa tggccctatgg gcttcgatata tacaacatgt 6660
tgggtttactt caacggtcac tgagaatgtac atccgtgtt aggagtcaat ctaccaatgt 6720
tgtgacttgg cccccgaagc cagacaggcc ataaggctgc tcacagagcc gctttacatc 6780
ggggggccccc tgactaattt taaggggcag aactgggtt atccgggtt cgcgtcc 6840
gggtgactga cgaccagctg cggtaatacc ctcacatgtt acttggaggc cgtcgcc 6900
tgtcgagctg cgaagctcca gactgacg atgctcgat tgggagacgc ctttgcgtt 6960
atctgtgaa ggcggggac ccaagaggac gaggcgagcc taccggccctt cacggaggtt 7020
atgacttagat actctggccc ccctggggac ccggccaaac cagaatacga tttggagtt 7080
ataacatcat gtcctccaa tggatcgatc ggcacatgtt catctggca aagggtgtac 7140
tatctccatcc gtcggccctt caccggccatc ggcggccgtg cgtggagac agctagacac 7200
actccagtc attcctggctt gggcaacatc atcatgtat cgcggccatctt gtgggcaagg 7260
atgatcttgc tgactcattt ttctccatc tttctatc aggaacaact tggtaaaaaggc 7320
cttagattgtc agatctacgg ggcctgttac tccatggc acgttgcattt acctcgatc 7380
attcaacgac tccatggcct tagcgatc tcaactccata ttactctcc aggtgagatc 7440
aatagggtgg ctcatgtc caggaaactt ggggtaccgc ctttgcgttgc ctggagacat 7500
cgggccagaa gtgtccgc ctaggtactg tcccgagggg ggagggtgtc cacttgcgtc 7560
aagtacctt tcaactggc agtaaggacc aagctcaaac tcaactccat cccggctgcg 7620

tcccagtgg atttatccag ctggttcggt gctgggtaca gcgggggaga catatatcac 7680
a~~g~~ccgtctc gtgcccggacc ccgcgtggtc atgtggtgcc tactcctact ttctgttaggg 7740
gtaggcatct atctactccc caaccgtatga acggggagct aaacactccaa g~~g~~ccaatagg 7800
ccatccgtt tttttccctt ttttttttc tttttttttt tttttttttt 7860
ttttctccctt tttttttctt tttttttcc tttttttcc tttgggtggct ccatcttagc 7920
cctagtcacg gctagctgtg aaaggccgt gagccgcttg actgcagaga gtgctgatac 7980
tggccctctt gcagatcaag t 8001

<210> 11
 <211> 11076
 <212> DNA
 <213> Hepatitis C Virus

<400> 11
 gccaagcccc gáttggggc gacactcac cátatgatcac tcccctgtgá ggaactactg 60
 ttttcacgca gaaágcgtct agccatggc tagtggctg cggaccggt gatgacaccg gattggca 120
 cccccctccc gggagagcca tagtggctg cggaccggt gatgacaccg gattggca 180
 gacgacccgg gatcaaccg ctaatgcct gatggatttg gctgtcccc 240
 gcgagactgc tagccgaga gtgtggtc gcgaaaggcc ttgtggact gctgtatagg 300
 gtgtggcga gtgccccggg aggtctcgta gaccgtcac catgagcacg aátcctaaac 360
 ctcaaagaaa aaccaaacgt aacaccacg ggcgcgcat gatggatttg gatggatttc 420
 acgcaggatc tccggccgt tgggtggaga ggtatcccg ctatgactgg gcaacaacaga 480
 caatcgctg ctctgtatcc gccgttcc ggtgtcagc gcaaggccg cccgttctt 540
 ttgtcaagac cgacctgtcc ggtgcctgta atgaaatgc ggcaggccg gccggat 600
 cgtggctggc caccacggcc gttcctgtcg cagctgtctc cgacgttgc actgaagcgg 660
 gaaggactg gctgtattt ggcgaagtgc cggggcagga tccctgtca ttcacccctt 720
 ctccctggca gaaagtatcc atcatggctg atgcaatgc gggctgcatt aégttgc 780
 cggctacccg cccatccgac caccacggc aacatcgat cggccgagca cgtactccg 840
 tggaaacccgg tcttgcgt caggatgtc tggaccaaga gcatcaacggg ctcgcggcc 900
 ccgaactgtt cgcaggatc aaggccgca tggccacgg cggaggatctc gtcgtgaccc 960
 atggcgatgc ctgttgcgt aatatcátgg tggaaatgg cccgttctt ggattcatcg 1020
 actgtggccg gctgggtgtg gccggaccgt atcaggacat agcgttggc accecgatata 1080
 ttgtcaaga gcttggccg gatggggctg accgttctc cgtgttctt ggtatcgcc 1140
 ctcccgattc gcagcgatc gccttctatc gccttcttgc caggttctt tgagttttaa 1200
 cagaccacaa cgggttccct ctacgggat caatccgc cctctccctc cccccccct 1260
 aacgttactg gccgaagccg cttggataa ggccgtgtg cgttgcata tatgttattt 1320
 tccacccat tgcgttccctt tggcaatgtt agggccggaa aacctggccc tgcgttctt 1380
 acgagcattc ctggggctt tccctctc gccaaaggaa tgcacggatc gttgaatgtc 1440
 gtgaaggaaag cagttcttctt ggaagcttctt tgaagacaaa caacgtctgt agcgaccctt 1500
 tgcaggccgc ggaacccccc acctggcgc acgttcttgc gggccaaaa gccacgtgt 1560
 taagatacac ctgcaaaaggc ggcacaaccc cagtgccacg ttgtggatgg gatgttgc 1620
 gaaagactca aatggcttc ctcaacgcgtt ttcaacaagg ggtgtaaagg tgcccagaag 1680
 gtacccattt gtatggatc tgatctgggg cctcgggtca catgctttac atgtgttag 1740
 tgcagggtttaa aaaacgtcta ggcccccccg accacggggc cgtggtttc ctttggaaaa 1800
 caccataataa ccatggcacc gatcttcaaa cctcaaaagaa aaacccaaacg taacaccaac 1860
 cggcccccac aggacgtcaa gtggccggc ggtgtgtca tgcgtgggtt agtttaccc 1920
 ttggccgcga ggcccccccg gtgggtgtg cggccgacta ggaagacttc cgagcggtc 1980
 caacctctg gaaggccgaca acctatcccc aaggctcgcc agcccgagg tagggccctt 2040
 gtcagcccg ggtacccctt gcccctctat ggcaatggg cgtgggggtt ggcaggatgg 2100
 ctccctgtcac cccgtggctc tggccctagt tggggccca cggacccccc gctgtggc 2160
 cgcaatttgg gtaaggatcat cgataccctc acgtgggtc tgcgtccatc catgggttac 2220
 atccctctg tggccggccc cctagggggc gtcgtccagg ccctggcga tggcgtccgg 2280
 gttctggagg acggcgtgaa ctatgcaaca gggaaatctgc cgggttgc ttttctatc 2340
 ttccctttgg ttttgcgtc tgggtggatccatccatgtt cccgttatgaa agtgcgcáac 2400
 gtatccggag tggatcatgtt caccgacgac tgcgtccacgg cäggatgtt gttgaggca 2460
 gcccacatga tcatgcatac ccccggtgc gtcgtcccg ttccggagaa caactccctt 2520
 cgctgttgg tagcgttccat tccacgtcc gcccacggc acgttgcgtt ccccaactacg 2580
 acgatacgc gccatgtcgtt tgggtgtt gggggcgtt ctctgtctc cgttatgtac 2640
 gtgggagatc tctgggtatc tgggttccctc gtcgtccacgg tggatgtt ctcgtcccg 2700
 cggcacgaga cgtacagga ctgcaattgc tcaatatac cccggccacgt gacaggtcac 2760
 cgtatggctt gggatatgtt gatgactgg tccatctac cäggccctact ggtatcgca 2820
 ttactccggta tcccaacaagg tgcgtggat atgggtgggg gggcccttgg gggagtccta 2880
 gcccccttgc cctactatc catggggggg aactgggtt gatgttgc tggatgttca 2940
 ctctttggcgg gctgtggcgg gggaaatctt gtcgtccacgg gacggatggc caaaaacacc 3000
 ctccggatata cgtcccttcc ttcacccggg tccatccacgg aaatccatgt tggatgttca 3060
 aacggcactt ggcacatcaa caggactgc ctgaaatgc atgactccctt caacactggg 3120
 ttccctgtctg cgtgttcttgc cgtgcacaag ttcaactcat ctggatgtccc agagcgatc 3180
 gcccacatgc gccccatgc cgggttgcgtt cagggggtgg gggccatcac ttacaatgt 3240
 tcacacatgtt cggacccgg gcttattgt tggactacg ccccccggcc gtcgtccatc 3300
 gtacccggcgg cgcacggatc tgggtggat tggccatgt tactgttca ccccaagccccc tggatgttca 3360
 gggacggccg accgggttgc cgtccctactc tacagttggg gggagaatgt gacggacgtg 3420
 ctgttcttgc tccacacacgc gcccggccaa ggcaactgtt tggatgttca atggatgtat 3480
 agcactgggt tccaccaagac gtcgtccacgg ccccccgttca acatggggg gatcgccat 3540
 aaaaccttgc cctggcccccac ggactgttcc cggacggccac ttacaccaag 3600

gagagcgcacg ctgcagcacg agtcaactcg atccctctca gtcttaccat cactcaagt 7680
ctgaagaggc ttaccatgt gatcaacagag gactgctcca cgccatgctc cggctcg 7740
ctaagatgt tttggattt gatatgcacg gtgtgactg atttcaagac ctggctccag 7800
tccaagctcc tgccgcattt gcccggagtc cccttcttct catgtcaacg tgggtacaag 7860
ggagttctggc ggggcacgg gacatgtga aaaacggttc catggacat tccctttaa cttcatgcaaa accacctgcc catgtggagc acagatcacc 7920
catgaggatc gtggggccta gacactgttag taacacgtgg 7980
cgctacacc acggggccct gcacgcctcc cccggcgcca 8040
gccccgttagt gctgaggagt acgtggaggt tacgcgggtg 8100
ggggatgtcc actacgtgac gggcgatgg actacaaacg taaagtgcce gtgtcagggt 8160
ccggcccccg aattttcac aagaatggat ggggtgcggg tgcacaggta cgctccagcg 8220
tgcaaaacccc tccatcggga ggaggtcaca ttccctggcg ggctcaatca atacctgggtt 8280
gggtcacage tccatgcga gcctgaaccc gatgtacgag tgctcaactt catgtctacc 8340
gacccctccc acattacggc ggagacggct aagcttaggc tggccagggg atctcccccc 8400
cccttggcca gtcatcagc tagccagctg tctgcgcctt ccttgaaggc aacatgact 8460
accctgtatg actccccggg atggggcggg aacatcaccgg cgctgacccctt atcggggcca acctccgtg gggcaggag 8520
atggggcggg aacatcaccgg cggtggatca gaaaataagg tagtaatttt ggactcttc 8580
gagatggagg ggatgatccg ttccggcgg gatctcgcc 8640
aggtccagga aatttccctcg cgatgtggcc atatgggcac gcccggattt caaccccttca 8700
ctgttagagt ccttggagga cccggactac gtccctccag tggatcacgg gtgtccattt 8760
ccgcctgcca agggccctcc gataccaccc tcacgaggg aagggacggg tgcgtctgtc 8820
gaatctaccg tgcgtctgc cttggggag ctgcggccacg agacccctgg cagotccgaa 8880
tcgtcggccg tgcacagcgg cacggcaacg gctctccctg accagccctc cgacgacggc 8940
gacgcgggat ccgacgttga gtcgtactcc tccatgcccc ccttggaggg ggagccgggg 9000
gatcccggat tcaacggccg gtcttggctt accgtaaagcg aggaggctag tgaggacgtc 9060
gtctgtctgtc cgatgtccca cacatggaca ggccgcttga tcaacggccatg cgctgcggag 9120
gaaaccaaggc tggccatcaa tgcactgagc aactcttgc tccgtccacca caacttggtc 9180
tatgtaccaa catctcgacg cgaaacccctg cggcagaaga agtccaccc tgacagactg 9240
caggtccctgg acgaccacta cggggacgtg ctcaggaga tgaaggcgaa ggcgtcccaa 9300
gttaaggcta aacttctatc cgtggggggaa gcctgtaaacg tgcggccccc acattcgccc 9360
agatctaaat ttggctatgg ggcaaggac gtccggaaacc tatccagcaa ggccgttaac 9420
cacatccgct ccgtgtggaa ggacttgcg gaagacactg agacaccaat tgacaccacc 9480
atcatggcaaaaatggat tttctgcgtc caaccagaga agggggggccg caagccagct 9540
cccttatacg tattcccaaga tttgggggtt cgtgtgtcg agaaaatggc cctttacat 9600
gtggcttcca ccctccctca ggccgttgcg ggcttccat acggatccca atactctct 9660
ggacagcggg tgcgttccctt ggtgaatgcc tggaaacgca agaaaatggcc tatgggttc 9720
gcatatgaca cccgtgttt tgcactcaacg gtcactgaga atgacatccg tggtagggag 9780
tcaatctacc aatgttgcg cttggccccc gaagccagac aggccataag gtcgtccaca 9840
gagcggcttt acatcggggg cccctgact aattctaaag ggcagaactg cggctatccg 9900
cggtcccgcc cgacgggtgt actgacgacc agtgcggta ataccctcac atgttactt 9960
aaggccgctg cggccctgtcg agtgcgaaag ctccaggact gcacgatgtc cgtatcgccg 10020
gacgacccctt tgcgttatctg tgaaagcgcg gggacccaaag aggacgaggc gggctacgg 10080
gccttacgg aggctatgac tagatactct gccccccctg gggacccggcc caaaccagaa 10140
tacgacttgg agttgataac atcatgtcc tccaatgtgt cagtcgcga cgatgcacat 10200
ggcaaaagggg tgcgttatctt caccctgtac cccacccacc cccttgcgcg ggtgcgtgg 10260
gagacacta gacacactcc agtcaattcc tggtagggca acatcatcc tgcgtccgg 10320
accttgggg caaggatgat cctgtatgact cattttctt ccattcttct acgtcaggaa 10380
caacttggaaa aagccctaga ttgtcagatc tacggggctt gttaactccat tgagccactt 10440
gacctaccc agatcattca acgactccat ggccttagcg cattttcaact ccatagttac 10500
tctccaggtg agatcaatag ggtggcttca tgcctcaggaa aacttgggtt accggccctt 10560
cgagttctgg gacatcgggc cagaagtgac cgctgtggc tactgtccca gggggggagg 10620
gctgcacccat gtggcaagta ccttcttcaac tggcgttacaa ggaccaagct caaactcaact 10680
ccaatccccc ctgcgtccca ttggggatcc tccaggtgt tcgttgcgtt ttacagcg 10740
ggagacatatac acacagctt gtctcggtc cgaccccgctt ggtcatgtt gtcgtactc 10800
ctactttctg tagggtagg catctatcta cttcccaacc gatgaacccgg gacactaaac 10860
ctccaggcca ataggccatc ctgtttttt ccctttttt tttttttt tttttttt tttcccttgg 10920
ttttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttcccttgg 10980
tggctccatc ttagccctag tcaacggctag ctgtgaaagg tccgtgagcc gcttactgc 11040
agagactgtgt gatactggcc tctctgcaga tcaagt 11076

Vainberg, Irina

From: Fehlner, Paul
Sent: Tuesday, September 30, 2003 8:06 AM
To: 'Michael Sasaki, Esq. (msasaki@anadyspharma.com)'
Cc: Vainberg, Irina
Subject: Hepatitis C Virus Constructs ... (PCT/US01/46350; our file 00342/200h395-W00)

Michael:

In the absence of instructions to the contrary, as requested in our email of September 26, we have instructed the Authorized Office to go ahead with issuing an International Preliminary Examination Report. We will forward the report to you in due course.

Best regards, Paul

Paul F. Fehlner, Ph.D.
Darby & Darby P.C.
805 Third Avenue
New York, NY 10022

(212) 527-7665 | direct
(212) 753-6237 | fax

<http://www.darbylaw.com>

